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INTRODUCTION 
Bladder cancer is the fifth most common malignancy in the Western world 
after prostate, breast, lung and colorectal cancer. Its incidence directly increases 
with age reaching a maximum between 60 and 70 years. Bladder cancer is 2.5 
times more common in men than in women. The most common bladder 
carcinogens are aromatic amines. A number of etiological factors are tied to the 
development of bladder tumors (examples: chronic infections, radiation & 
chemotherapy, occupational exposure to aromatic amines). However, cigarette 
smoking is by far the most important risk factor nowadays. More than 90% of 
bladder cancers are urothelial cell carcinomas (UCC). The other histological 
types concern squamous cell carcinoma (6-8%) and adenocarcinoma (1-2%). In 
Egypt and other countries with endemic spread of schistosomiasis, squamous 
cell carcinoma used to be the most frequent histological subtype. The majority of 
UCCs is found in the bladder. UCCs of the renal pelvis, ureter and urethra 
together account for less than 10% of the carcinomas.  
The most important symptom that raises suspicion for a bladder tumor is 
micro- or macroscopic hematuria. The hematuria is mostly painless and often 
intermittent which frequently causes a delay in the diagnosis. Behind irritative 
bladder symptoms such as frequency, urgency or pain, a bladder tumor or flat 
carcinoma in situ may hide out. The diagnosis of UCC is made endoscopically by 
urethro-cystoscopy (UCS) and urine cytology (UC). An intravenous urogram 
and/or CT-scan or ultrasound is needed to visualize the upper urinary tract (renal 
pelvis and ureters) and the kidneys. UCS allows direct visualization of an 
exophytic lesion in the bladder. UC particularly aids in the diagnosis of high-
grade, flat carcinoma, i.e. carcinoma in situ (CIS). In case of suspicion for UCC in 
the bladder, a trans-urethral resection (TUR) or biopsy is planned to obtain a 
histo-pathological diagnosis. Figure 1 shows an example of a UCS before TUR.   
 
Figure 1 
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Treatment strategies and follow-up mostly rely on the histological Stage 
(TNM-classification)1 and Grade (WHO-grading systems)2,3 of the tumor(s). 
Figure 2 shows the current TNM-classification for UCC.  
 
Figure 2 
TNM 1997 classification for UCC.1  
 
 
 
 
 
 
 
 
 
 
 
CIS: carcinoma in situ. Ta: Non-invasive papillary carcinoma. T1: Tumor invades subepithelial 
stroma. T2a: Tumor invades superficial muscle. T2b: Tumor invades deep muscle. T3a: Tumor 
invades perivesical tissue microscopically. T3b: Tumor invades perivesical tissue macroscopically. 
T4a: Tumor invades prostate, uterus or vagina. T4b: Tumor invades pelvic or abdominal wall.  
N0: No regional lymph node metastasis. N1: Metastasis in a single lymph node ≤ 2 cm. N2: 
Metastasis in a single lymph node >2 cm and ≤ 5 cm, or multiple lymph nodes ≤ 5 cm. N3: 
Metastasis in a lymph node >5 cm. 
M0: No distant metastasis. M1: Distant metastasis. 
 
In approximately 75% of patients, UCC is superficial (i.e. Stages; pTa-pT1, CIS) 
at first presentation. After TUR, these patients are intensively monitored by 
cystoscopy because of frequent recurrences and a 10 to 15% chance for 
progression to invasive, potentially lethal UCC. Patients with intermediate or high 
risk superficial UCC (multifocal and >pTaG2 disease) usually receive adjuvant 
intravesical instillations with, in most cases, bacillus Calmette Guérin (BCG) to try 
to delay recurrence and prevent progression. Patients with persistent high risk 
(G3) superficial lesions are candidates for a cystectomy. More information on the 
follow-up of superficial UCC is given in the next paragraph of this chapter. 
Cystectomy, radiation- or systemic chemotherapy are the preferred treatment 
options in case of invasive (i.e. ≥pT2) disease depending on presence of 
metastasis, patients co-morbidity and life expectation. The treatments for 
invasive UCC have the aim to reduce disease specific mortality. Besides other 
clinical and pathological parameters, particularly tumor-stage and grade are 
important for prognosis. Table 1 gives an overall overview of UCC prognosis at 
first diagnosis. This table also shows that bladder cancer is a heterogeneous 
disease with an unpredictable clinical course, especially for an individual patient. 
Nevertheless, patients with superficial UCC have a relatively good prognosis and 
the greatest concern in these patients is not to reduce mortality but to lower and 
Mucosa 
 
Stroma 
Muscle (inner half) 
 
Muscle (outer half) 
 
 
Perivesical tissue 
 
 
(Organ) invasion 
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postpone recurrent UCCs and to prevent progression to invasive (≥pT2) UCC. 
On the other hand, many patients diagnosed with invasive UCC and those who 
progressed to invasive UCC will not survive their disease despite the above 
mentioned treatment options. 
 
Table 1 
Prognosis of Urothelial Cell Carcinoma. Correlation with Tumor-Stage and Grade. 
 
Tumor Stage/Grade Recurrence Progression/ 
Metastasis 
5 years 
Survival 
Superficial pTa-pT1 G1-2 N0 M0 40-60% 0-5% 90% 
Superficial - high risk pTa-pT1 G3 CIS N0 M0 > 70% ≥ 30% 60-75% 
Invasive (after Cystectomy) pT2-3 N0 M0 - 20-55% 35-65% 
Locally Advanced / 
Metastasized 
pT3-4 N1 M1 - > 60% < 20% 
  
 
SCOPE OF THE THESIS: 
 The general scope of this study will be to evaluate molecular markers for 
diagnosis in urine and prognosis of UCC in various clinical settings.  
The follow-up of superficial UCC requires frequent cystoscopical 
examinations. Standard practice after TUR of superficial UCC is to follow patients 
by UCS and UC every 3-4 months for 2 years and every 6-12 months thereafter. 
The recurrence rate of superficial bladder cancer is up to 75% and progression to 
invasive disease occurs in around 10-15% of patients, even after long tumor-free 
periods. This approach is invasive, uncomfortable and costly. Even for flexible 
UCS, the risk to develop a urinary tract infection is considerable. Urinary cytology 
is only of limited use because sensitivity is poor, especially for low-grade UCC. 
For these three reasons, many new urine-based tests for UCC have been 
developed. Among them, BTAstat, BTAtrak, NMP22, FDP, ImmunoCyt and FISH 
have been approved by the FDA as adjuncts to cystoscopy. Many other markers 
are under investigation at this time. The literature on the current urine-based 
markers for UCC patients who are under surveillance will be reviewed in chapter 
2. An important part of the thesis is devoted to the validation of urinary 
microsatellite analysis, a PCR-based DNA-test, in different clinical settings 
(chapters 3-5). 
 Clinical and pathological variables for prediction of patient’s prognosis 
have been studied extensively in various types of cancer, including UCC. The 
variability in outcome of pathological assessment is a recognized problem, but 
conventional pathological parameters like grade and stage continue to be one of 
the best predictors of prognosis. Research efforts of the last decades resulted in 
a considerable list of molecular investigations for a more accurate assessment of 
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UCC prognosis. Oncogenes, tumor suppressor genes & associated cell cycle 
proteins, proliferation antigens, growth factors, cell adhesion molecules and 
chromosomal alterations involved in bladder carcinogenesis have been identified. 
Many of these molecular markers hold considerable promise to assess 
aggressive UCC behavior. Nevertheless, the value of molecular markers over 
conventional clinico-pathological indices is still being questioned and their clinical 
use is very limited at this time. The presence of Fibroblast Growth Factor 
Receptor 3 (FGFR3) mutations in a high percentage of UCC was discovered very 
recently.4 In part III (chapters 6-12) of this thesis, the frequency, specificity and 
prognostic value of these mutations in UCC will be studied. The unexpected 
association of these mutations with UCC of favorable prognosis will be described 
in this thesis. Furthermore, the possible implications of FGFR3 mutations for 
future clinical management, their relation to other molecular- and conventional 
UCC parameters and the place of these mutations in molecular pathology and 
disease pathogenesis are some of the items that will be discussed in the 
chapters of part III. 
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ABSTRACT 
 The follow-up of patients with urothelial cell carcinoma (UCC) of the 
bladder is done by cystoscopy and, in most cases, cytology. The last decade, 
many urine-based tests for UCC have been developed and tested in different 
populations. For the urological practice, considering the amount of follow-up 
cystoscopies, especially urine markers for recurrent disease would be useful. 
Therefore, we reviewed the literature on these markers for recurrent UCC and 
compared our findings with recent review-articles. We performed a PubMed 
search. In case of primary and recurrent disease, the study was included if the 
patients under surveillance were reported separately. Patients with no evidence 
of disease at surveillance cystoscopy were considered to determine specificity. A 
marker was included if at least 2 studies from 2 different institutions/authors were 
available. The literature review yielded 64 articles. We found 18 markers 
(BTAstat, BTAtrak, NMP22, FDP, ImmunoCyt, Cytometry, Quanticyt, Hb-dipstick, 
LewisX, FISH, Telomerase, Microsatellite, CYFRA21-1, UBC, Cytokeratin20, 
BTA, TPS, Cytology) that met our criteria. BTAstat, NMP22, ImmunoCyt and 
cytology were evaluated in more than 750 patients. Telomerase, Cytokeratin20 
and Hb-dipstick were tested in less than 250 patients. The highest median 
sensitivities were reported for CYFRA21-1 (85%), Cytokeratin20 (85%) and 
Microsatellite analysis (82%). The highest specificities were reported for Cytology 
(94%), BTA (92%) and Microsatellite analysis (89%). In comparison with recent 
reviews, median sensitivity was ≥5% lower for the surveillance group in 13/18 
urine-based tests while specificity remained relatively constant between different 
patient groups. To our knowledge, this is the first review that assesses sensitivity 
and specificity of urine markers solely for UCC surveillance. In our view, 
Microsatellite analysis, Immunocyt, NMP22, CYFRA21-1, LewisX and FISH are 
the most promising markers for surveillance at this time. Nevertheless, clinical 
evidence is insufficient to warrant the substitution of the cystoscopic follow-up 
scheme by any of the currently available urine marker tests. Future studies may 
test some of the most sensitive and specific assays to reduce the cystoscopy 
frequency. However, our results show that initiators of these studies should 
anticipate a lower sensitivity than reported in the current literature. 
 
INTRODUCTION 
 Around 70% of the patients with urothelial cell carcinoma (UCC) of the 
bladder initially present with superficial (pTa, pT1 or pTis) disease. These UCC 
have a high chance of recurrence (60-85%) but more than 80% remains confined 
to the (sub)mucosa and, therefore, these patients do not influence UCC-related 
survival.1 Nevertheless, extensive and long-term follow-up is needed to prevent 
progression to invasive, potentially lethal UCC. The current standard of care 
consists of urethro-cystoscopy (UCS), the gold standard, and urine cytology 
every 3-4 months for the first two years and at a longer interval in subsequent 
years. This approach is costly, invasive and uncomfortable. Even for flexible UCS, 
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the risk to develop a urinary tract infection is around 10%.2 The current follow-up 
schemes with more than 500.000 UCS per year in the USA for follow-up alone, 
largely contribute to the fact that total Medicare payments per patient are the 
highest for UCC compared to other malignancies.3,4 In addition, especially for the 
low-grade lesions, urine cytology is of limited value because of operator 
dependency and a low sensitivity.5 For these reasons, many new urine-based 
tests for UCC have been developed. Among them, BTAstat, BTAtrak, NMP22, 
FDP, ImmunoCyt and FISH (UroVysion) have been approved by the FDA.6,7  
Initial studies with new markers are mostly promising, but successive 
reports often fail to show comparable results. Patient selection seems the most 
likely explanation for the discrepancies between the studies on urine markers. 
For the urological practice, in terms of cost-reduction and convenience of our 
patients, particularly markers to detect recurrent disease would be useful. In 
order to reduce the number of UCS needed for follow-up, the specificity of a 
urine-based test is important. However, high specificity may be at the cost of 
sensitivity, conventional cytology being a good example of this.6 As outlined 
earlier, positive (percentage in whom the test is positive and the disease is 
present) and negative (percentage in whom the test is negative and the disease 
is absent) predictive values are less useful for comparison of two populations 
with different UCC incidences because they vary by their definition.6,7 Conversely, 
sensitivity and specificity stay constant between populations with different 
numbers of tumor and non-tumor cases and they are more commonly used in 
studies.6,7 
Our systematic review of the literature on the performance (sensitivity and 
specificity) of urine markers was confined to publications on recurrent UCC and 
we compared our findings with data on the same tests that were reported in 
reviews without this selection criterion. 
 
METHODS 
 We performed an online PubMed search up to 2004 to obtain references 
for the various urine tests. The terms used for the PubMed search included urine, 
the name of the individual urine-based test, bladder, cancer, urothelial / 
transitional (cell) carcinoma, tumor marker and recurrence. The material and 
methods section of each article was screened in order to be sure that the 
patients were under surveillance with UCS. In case of a mixed study population 
composed of both primary and recurrent UCC, we only included the particular 
study if the results of the patients under surveillance were reported separately. 
Only patients with no evidence of disease at surveillance cystoscopy or 
pathological evaluation were considered as controls to determine specificity. We 
did not select on FDA-approval, single or multi-center trials, number of patients 
involved in the study, tumor grade, urine or bladder wash cytology and/or 
comparison of more tests in the same study population. A urine marker was 
included in our review if a minimum of two studies from two different 
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institutions/authors were available. A comparison was made with recent review-
articles to investigate whether our selection criterion (recurrent disease) 
influenced the performance of the various urine markers. 
 The usefulness of the urine-based tests for UCC was assessed with 
sensitivity and specificity. Sensitivity of a test was defined as the percentage of 
patients with UCC (as defined by the authors) for whom the test is positive 
(tested positive / patients with recurrent UCC). Specificity was defined as the 
percentage of patients with a negative cystoscopy in whom the test is also 
negative (tested negative / no evidence of disease at follow-up). 
 
RESULTS 
 The literature review on recurrent UCC yielded 64 publications in which 
we found 18 markers (conventional cytology included) that met our strict criteria. 
We have listed the studies per marker in the appendix section. Other promising 
markers (examples: BCLA-4, Survivin, HA-HAase, DD23 and BTF) that were not 
included in our analysis may also prove to be of value for patients under 
surveillance and require further study by other groups. Table 1 shows the median 
sensitivity and specificity as well as the number of studies, institutions and 
patients.  
 
Table 1  
The median sensitivity and specificity, the number of studies, institutions and patients are shown. 
The data applies to patients under surveillance for UCC. na = not analyzed. See appendix for 
references. 
 
Marker studies/ 
institute (n/n) 
no. 
pts. 
median 
Sensitivity 
range 
(min-max) 
no. 
pts. 
median 
Specificity 
range 
(min-max) 
BTAstat 17/14 1377 58 29-74 2084 73 56-86 
BTAtrak 4/4 360 71 60-83 195 66 60-79 
NMP22 15/12 838 71 47-100 1203 73 55-98 
FDP 4/4 168 54 47-68 173 61 25-80 
ImmunoCyt 6/5 276 67 52-100 683 75 62-82 
Cytometry 5/5 364 60 45-85 89 82 50-92 
Quanticyt 5/2 129 58 45-65 227 76 68-87 
Hb-dipstick 2/2 117 40 37-41 113 87 87 
LewisX 3/2 95 75 68-79 215 85 67-86 
FISH 4/4 165 79 70-86 147 70 66-93 
Telomerase 3/3 146 39 29-66 - na na 
Microsatellite 6/4 108 82 75-92 153 89 79-100 
CYFRA21-1 3/2 156 85 75-88 323 82 73-95 
UBC 5/4 267 60 21-80 480 87 72-95 
Cytokeratin20 2/2 117 85 79-87 61 76 76 
BTA 5/5 436 48 32-58 216 92 91-92 
TPS 3/2 179 65 50-80 246 83 63-95 
Cytology 26/20 2213 35 13-75 3322 94 85-100 
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The number of institutions/authors varied from 2 to 14. BTAstat (N=3461), 
NMP22 (N=2041), ImmunoCyt (N=959) and conventional cytology (N=5535) 
were evaluated in more than 750 patients in all studies combined. Telomerase 
(N=146), Cytokeratin20 (N=178) and Hb-dipstick (N=230) were tested in less 
than 250 patients. 
All the 17 urine markers had a higher sensitivity for recurrent UCC than 
conventional cytology. The highest sensitivities were reported for CYFRA21-1 
(85%), Cytokeratin20 (85%) and Microsatellite analysis (82%). Of the FDA 
approved tests, FISH (79%), BTAtrak (71%) and NMP22 (71%) had the highest 
sensitivity. The highest specificities were reported for conventional cytology 
(94%), BTA (92%) and Microsatellite analysis (89%). ImmunoCyt (75%) had the 
highest specificity of the FDA approved tests. The specificity (patients in follow-
up with no evidence of disease) was not investigated in every study. Specificity 
was not determined in 4 cytology, 1 BTAtrak, 1 Quanticyt, 2 FDP, 3 Telomerase, 
1 Cytokeratin20, 2 Cytometry, 1 Hb-dipstick, 1 NMP22, 1 FISH, 1 BTAstat and 1 
BTA studies, respectively. Unfortunately, the rapid point of care tests (BTAstat, 
FDP, Hb-dipstick and UBC) were associated with a lower sensitivity and 
specificity (Table 1).  
In order to see if our selection criterion (recurrent disease) influenced 
sensitivity and specificity, we selected several recent reviews.6-14 The sensitivities 
and specificities reported in the reviews are summarized in Table 2.  
 
Table 2 
Sensitivity and specificity of the data reported in recent reviews are summarized.6-14 A ≥5% lower 
median sensitivity or specificity for recurrent disease (Table 1) is marked with a "yes" at the 5% 
difference column. 
Marker median 
Sensitivity 
range 
(min-max) 
5% 
difference 
median 
Specificity 
range 
(min-max) 
5% 
difference 
BTAstat 70 24-89 yes 75 52-93 - 
BTAtrak 69 57-79 - 65 48-95 - 
NMP22 73 47-100 - 80 56-95 yes 
FDP 61 52-81 yes 79 75-96 yes 
ImmunoCyt 83 50-100 yes 80 69-90 yes 
Cytometry 60 45-83 - 80 36-87 - 
Quanticyt 59 45-69 - 79 70-93 - 
Hb-dipstick 52 41-95 yes 82 68-93 - 
LewisX 83 80-89 yes 85 80-86 - 
FISH 84 73-92 yes 95 92-100 yes 
Telomerase 75 7-100 yes 86 24-93 na 
Microsatellite 91 83-95 yes 94 89-100 yes 
CYFRA21-1 94 74-99 yes 86 67-100 - 
UBC 78 66-87 yes 91 80-97 - 
Cytokeratin20 91 82-96 yes 84 67-97 yes 
BTA 50 28-80 - 86 66-95 - 
TPS 72 64-88 yes 78 55-95 - 
Cytology 48 31-100 yes 94 62-100 - 
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In addition, studies with a ≥5% lower median sensitivity or specificity for recurrent 
disease compared to the numbers extracted from the reviews are also indicated 
in Table 2. Median sensitivity was ≥5% lower for the surveillance group in 13/18 
cytological tests. Telomerase (-36%), UBC (-18%), Immunocyt (-16%), Cytology 
(-13%), BTAstat (-12%), Hb-dipstick (-12%) and LewisX (-12%) showed a 
decrease in sensitivity of more than 10%. A higher median sensitivity for the 
surveillance group was only found for BTAtrak (+2%). Median specificity was 
≥5% lower for the surveillance group in 6/17 tests. FISH (-25%) and FDP (-18%) 
showed a decrease in specificity of more than 10%. Higher specificities were 
reported for BTA (+6%), Hb-dipstick (+5%), TPS (+5%), Cytometry (+2%) and 
BTAtrak (+1%). In general, the sensitivity of urine markers is lower for patients 
who are under surveillance for UCC while their specificity is not much influenced 
by patient selection. 
We also performed a sub-analysis on the sensitivity of the urine markers 
per pathological grade (WHO 1973, G1-3). Data on the identical set of urine 
markers were derived from the same articles as listed in Table 1. Table 3 shows 
the results of this sub-analysis.  
 
Table 3  
The median sensitivity per grade (G1-3) and specificity of the urine markers for patients under 
surveillance are shown. The reference numbers correspond to the ones listed in the appendix 
section. na = not analyzed. 
 
no.pts. / median Sensitivity Marker (reference number) 
G 1 G 2 G 3 
no.pts. / median 
Specificity 
BTAstat (1,7,10,11,13,14,16)  228 / 45 206 / 60 208 / 75 972 / 79 
BTAtrak (1,2,4) 60 / 55 61 / 59 101 / 74 195 / 66 
NMP22 (1,14,15) 56 / 41 77 / 53 81 / 80 235 / 59 
FDP (3) 13 / 62 36 / 64 22 / 86 113 / 80 
ImmunoCyt (5) 23 / 78 10 / 90 18 / 100 83 / 62 
Cytometry (4) 18 / 11 54 / 41 38 / 66 52 / 87 
Quanticyt (5) - 11 / 64 5 / 80 56 / 68 
Hb-dipstick (1) 13 / 15 36 / 39 22 / 73 113 / 87 
FISH (1,3) 25 / 56 9 / 78 20 / 95 130 / 70 
Microsatellite (1,2,3,4,5) 27 / 67 21 / 86 30 / 93 138 / 88 
UBC (3) 29 / 38 29 / 41 16 / 69 79 / 72 
Cytokeratin20 (2) 14 / 71 35 / 80 35 / 100 na 
BTA (2,4) 31 / 16 43 / 47 50 / 52 91 / 91 
TPS (3) 29 / 32 35 / 54 15 / 74 72 / 63 
Cytology (1,5,7,9,13,14,20,23,24,25) 239 / 17 274 / 34 201 / 58 861 / 95 
 
The sensitivity per grade was not separately mentioned for patients under 
surveillance in the studies for LewisX, Telomerase and CYFRA21-1. The 
specificity was not reported in one study on BTAstat (10), Cytokeratin20 (2), BTA 
(2) and in two studies on Cytology (9,24). The numbers between the parentheses 
refer to the appendix section. Only 7 of the 18 markers were tested per grade in 
more than one study with Cytology tested in 10, BTAstat in 7 and Microsatellite 
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analysis in 5 studies, respectively. The sensitivity increased for every marker with 
a higher grade. Of the markers that were determined in more than one study, 
Microsatellite analysis and FISH had the highest sensitivities per grade for 
patients under surveillance and the specificity remained high for Microsatellite 
analysis (88%). In two recent reviews the sensitivity per grade was also 
determined.8,10 In general, the sensitivity per grade of the urine markers is lower 
for the patients who are under surveillance for UCC as compared to the figures 
given by the two reviews on unselected patients.  
 
DISCUSSION 
 Driven by the low sensitivity of conventional cytology, many research 
efforts to develop urine markers have been undertaken. These markers generally 
have a higher sensitivity but a lower specificity than conventional cytology.8,9 
Reviews also showed an increasing sensitivity for urine markers and 
conventional cytology with the increase of tumor grade.8,10 After our selection of 
data on detection of recurrent UCC, we found a ≥5% lower sensitivity for most 
urine markers when we compared the same markers with the sensitivities 
reported in recent review articles.6-14 The reason for this lower sensitivity for 
recurrent UCC may be the overrepresentation of a small, pTa and low-grade 
lesions among these recurrent tumors hampering their detection in urine.15,16 
Nevertheless, it is also possible that a given marker has been evaluated by the 
literature in more recurrent cases than another marker. This may influence the 
extent of the difference in sensitivity. 
 The various urine tests have been extensively discussed in the literature.6-
14 Therefore, we will give a short overview per test and we will discuss some 
advantages and disadvantages. In addition, we will compare the sensitivity and 
specificity of the investigated markers for UCC surveillance, rather than 
discussing every marker in detail. The references as well as the manufacturers of 
each test appear in the appendix section. In the text, the reference numbers 
appear between parentheses. Cytology is not discussed separately as it was 
mostly used as reference for a particular assay under investigation.  
BTA and NMP22 assays. Three BTA tests (BTA, BTAstat and BTAtrak) 
are available. BTAstat is a qualitative assay that can be performed in a few 
minutes, even before cystoscopy, and BTAtrak is a quantitative two-step ELISA 
assay. They both measure the human complement factor H related protein in 
urine whereas the original BTA test is a latex agglutination assay that detects 
basement membrane degradation complexes. NMP22 is a nuclear protein that is 
responsible for the chromatid regulation and cell separation during replication. 
This is a quantitative ELISA assay that requires urine stabilization. In our review, 
the sensitivity and specificity of the original BTA test were comparable to cytology. 
Compared to the other urine markers, the BTAstat and the NMP22 tests have 
been extensively studied. Although the sensitivity of BTAstat was slightly higher 
Chapter 2 
 - 26 -
inflammatory conditions may give false positive results for BTAstat and NMP22 in 
over 25% of cases (5,6). The BTAtrak and the NMP22 assays were more 
sensitive than BTAstat. However, different cutoff values in the reported studies, 
many false negative cases for G1-2 and median specificities of 66% for BTAtrak 
and 73% for NMP22 will impede their applicability in the reduction of the number 
of follow-up cystoscopies. 
FDP and Hb-dipstick. As bladder tumors tend to bleed, hemoglobinuria 
may occur. Moreover, coagulation with the production and degradation of fibrin 
will occur and, consequently, fibrin degradation products may be found in the 
urine. Both tests are rapid point of care tests. However, they do not seem to have 
additional value over cytology for recurrent disease. 
Cytometry and Quanticyt. DNA ploidy abnormalities assessed by either 
flow or image cytometry are important indicators of malignant disease. Flow 
cytometry only added little information to that obtained by cytology (2,4) and 
image analysis was also not more sensitive in direct comparison with cytology in 
two studies (3,5). The Quanticyt system combines ploidy and nuclear 
morphometry. Though this automated system performed as good as 4 expert 
cytologists (3), no proof exists that it may reduce the frequency of cystoscopy. 
The major drawback of cytometry and Quanticyt is the need for a bladder wash 
sample instead of voided urine. 
Immunocytology. The ImmunoCyt test and immunostaining of the 
LewisX antigen are two examples of immunocytology. ImmunoCyt uses three 
fluorescent monoclonal antibodies: 19A211, M344 and LDQ10. Initial data were 
promising (1,3), but successive reports failed to confirm the high sensitivity of 
ImmunoCyt (2,6). A large French multicenter study concluded that the 
ImmunoCyt test improved the diagnostic accuracy of cytology in daily practice (4). 
However, a high inter-observer variability (2) and a 16% lower sensitivity for 
recurrent UCC may hamper the clinical utility of the assay. Unfortunately, the 
sensitivity per grade was only determined by one study (5). LewisX antigen had a 
higher sensitivity (75%) and a good specificity (85%) compared to cytology. 
However, only 3 studies of two institutions were available. Expression of LewisX 
antigen by benign umbrella cells in the urine may interfere with the results of the 
assay. Additional studies by other groups are needed for both tests to determine 
whether these tests indeed have sufficient sensitivity and specificity to be used in 
a study protocol to reduce the cystoscopy frequency. 
Cytokeratin (CK) based assays. We reviewed 4 CK assays. CKs are 
intermediate filament proteins specific for epithelial cells. A given epithelium can 
be characterized by a chain-specific CK expression pattern. In general, 
overexpression of a particular chain-specific CK is associated with UCC. UBC is 
available as an ELISA assay (1-3,5) that takes two hours to perform or as an on 
bench test that gives an immediate result (4). Both tests detect traces of CK8 and 
CK18 in urine. TPS also detects CK18 and requires incubation with a second 
monoclonal antibody (M3 fragment of CK18). If we compare our sensitivity data 
Markers for bladder cancer surveillance 
 
 - 27 -
with other reviews we observed a decrease in sensitivity of 18% for UBC and 7% 
for TPS. Furthermore, the studies by Sanchez et al. (1,2) and Boman et al. (3) 
showed comparable sensitivity and specificity for UBC, TPS and NMP22. 
CYFRA21-1 is an ELISA that detects fragments of CK19 with the help of two 
monoclonal antibodies (BM19.21 and KS19.1). Three studies from two institutes 
reported high sensitivity and specificity for this test. Urinary stones, infection and 
previous intravesical treatment with BCG caused many false positive results (3). 
In addition, Sanchez et al. (1,2) reported similar results for NMP22 and 
CYFRA21-1. CK20 is selectively expressed in bladder and gastrointestinal 
epithelia. Only two studies were available. CK20 expression was determined by 
RT-PCR techniques (2) or as an immunocytological assay (1). Initial results are 
promising but CK20 was not compared to urine markers other than cytology. In 
conclusion, CK based assays, particularly CYFRA21-1, are promising. However, 
the number of studies is relatively low, cutoff values have not yet been defined 
properly and the additional value over NMP22 is not obvious. Clearly, further 
study by more institutions will be required before these tests may be considered 
eligible for studies to reduce the number of follow-up cystoscopies. 
Genetic Alterations. Genetic instability is an important feature of 
malignancy. We reviewed 3 genetic assays. Microsatellites are highly 
polymorphic tiny DNA fragments that are frequently found throughout the 
genome. UCC is characterized by frequent loss of heterozygosity (LOH) at the 
chromosomal locations: 4p, 8p, 9pq, 11p and 17p. Microsatellite analysis 
combines 15 to 20 markers from a region with a high percentage of LOH. This 
method proved very sensitive for low and high grade lesions with sensitivities of 
67%, 86% and 93% for recurrent G1, G2 and G3 lesions, respectively, and a 
specificity of 88%. Moreover, Microsatellite analysis could predict a recurrence 
before cystoscopical evidence in all 3 studies with extended follow-up (1,2,4). 
Although Microsatellite analysis has a very high potential, automation of the 
assay, multi center studies and excluding patients with persistent leukocyturia 
are essential if this analysis is to become clinically important. Fluorescence in 
situ hybridization (FISH) with 4 multitarget probes to the centromeres of the 
chromosomes 3, 7 and 17 and to the 9p21 band form the FISH UroVysion assay. 
Polysomy or the presence of 9p21 loss indicates cancer positivity. The assay 
was more sensitive than BTAstat and capable of predicting a future recurrence 
(1). Nevertheless, a specificity of 70% for patients under surveillance is not 
acceptable to reduce the number cystoscopies. However, as FISH was capable 
of predicting an early recurrence in patients with a negative UCS, specificity may 
be underestimated in the context of surveillance. Further study is clearly 
indicated for this test. Telomeres consist of identical short repetitive DNA 
sequences at chromosomal ends. Telomere length decreases with age, unless 
telomerase is present to prevent this process. Renewed expression of 
telomerase occurs in most cancers and is thought to immortalize cancer cells. 
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However, for the detection of recurrent UCC, the assay lacked sufficient 
sensitivity. 
 
CONCLUSIONS 
 Non-invasive tests for UCC have many potential applications including the 
diagnosis of recurrent UCC. With the help of a urine marker, the bother for the 
patients and costs of follow up may be decreased. If we pursue a 100% 
sensitivity and specificity for a urine test, the discussion can be short because 
such a marker does not exist and UCS, the gold standard, is also not 100% 
sensitive and specific. However, if we consider the follow up of superficial UCC, 
we may discern patients with low grade (G1-2) superficial lesions from the 
patients with high grade (G3/CIS) disease. High grade tumors should be 
detected early and the percentage of tumors missed should be as low as 
possible. Therefore, the optimal approach for these patients will continue to 
include both frequent UCS and cytology as an adjunct to detect invisible disease. 
If this follow up is to include a urine marker other than cytology, is a question 
difficult to answer. Specificity is more important than sensitivity in this subset of 
UCC patients as the urine marker is used as an adjunct to UCS. On the other 
hand, for patients with low grade UCC, it might be acceptable to postpone the 
diagnosis of recurrent low grade tumors. Although a randomized multi-center 
study with a lower follow up frequency has not been done, low progression 
rates1,17 and the safety of the marker lesion model to evaluate the anti-tumor 
activity of intravesical drugs18, support this idea. Moreover, Schrag et al., who 
analyzed the adherence to surveillance among patients with superficial UCC in a 
3 year follow-up period, found that only 40% of patients had undergone all 
cystoscopical examinations as recommended by the clinical guidelines.19 If we 
consider the follow up of low grade UCC, the first target for a urine marker is the 
reduction of the number of UCS needed for follow up by alternation of UCS with 
a urine test. Using such an approach, sensitivity and specificity of a urine marker 
are both important because a low sensitivity will eventually miss too many tumors 
and a low specificity may lead to unnecessary invasive procedures to rule out the 
presence of UCC in the upper urinary tract. As a randomized study with a urine 
marker has not been done in this patient group, it is very difficult to choose a 
particular urine marker or to comment on which sensitivity and specificity levels 
are required for this purpose. As discussed in this review, all the urine markers 
have their advantages and disadvantages. For example, some markers have 
been investigated in many patients and/or give instant test results (BTAstat, FDP, 
Hb-dipstick and UBC) but are associated with lower sensitivity and specificity 
whereas other markers have a higher sensitivity and specificity but require more 
extensive studies for validation. This does not imply that urine markers are 
completely useless on an individual basis at this time. In patients with low grade 
superficial UCC, these tests may help in planning a follow-up UCS. However, 
one should realize that this approach is not supported by sufficient clinical 
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evidence at this time. In our view, Microsatellite analysis, CYFRA21-1 and 
LewisX are the most promising non-FDA approved urine markers while 
ImmunoCyt, NMP22 and FISH are the best FDA approved ones for surveillance. 
The choice for these 6 markers was not only based on sensitivity and specificity 
but also on the other items mentioned in the discussion-section. Future studies 
for urine markers should use these assays in combination with a lower UCS 
frequency. Only in this way, the question, which assay - if any - is the one of 
choice can be answered. Nevertheless, considering the study of Schrag et al.19, 
already many urologists and patients seem to have chosen for a lower UCS 
frequency. A randomized trial will prove if this is feasible and whether a urine 
marker is helpful in the follow up of superficial UCC. 
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ABSTRACT 
It has been shown that microsatellite analysis (MA) is able to detect 
bladder cancer in urine. Relatively small groups of patients with often high stage 
and grade disease were investigated so far. However, more than 85% of 
cystoscopies are performed for follow-up of superficial bladder cancer. We 
evaluated this DNA-based method in a group of consecutive patients in follow-up 
after trans-urethral resection of superficial disease. Matched blood and urine 
samples from 109 patients were obtained before cystoscopy and subjected to 
MA. The BTAstat test and cytology were used for comparison. Sixteen patients 
were excluded: the DNA was of insufficient quality in 7 patients and leukocyte 
abundance rendered the result of MA unreliable in 9 patients. In the remaining 93 
patients, MA detected 18 of the 24 recurrent tumors. The 6 undetected tumors 
were small pTaG1-lesions for which immediate surgery was not necessary. On 
the other hand, 5/9 patients with a positive MA and a negative cystoscopy had a 
tumor-recurrence within 6 months after urine collection. In contrast, a recurrence 
occurred in only 7/60 patients who were negative in both MA and cystoscopy 
(P=0.006). The MA (74%) appeared more sensitive than the BTAstat test (56%) 
or urine cytology (22%). MA is a DNA-test in urine that reliably signals the 
presence of recurrent bladder cancer, sometimes even before cystoscopical 
evidence of the disease. This non-invasive diagnostic tool has the potential to 
replace cystoscopy in many cases. Our results warrant the need for randomized 
trials. 
 
INTRODUCTION 
Bladder cancer is the fifth most common neoplasm in the western world 
with approximately 54.300 new cases in the USA in 2001.1 The patients require 
extensive follow-up after initial treatment. Invasive bladder cancer (i.e. ≥pT2) is 
usually treated by cystectomy in case of non-metastatic disease. However, in the 
majority of patients, bladder cancer is superficial (i.e. pTa, pT1, Tis) at first 
presentation. Standard practice after trans-urethral resection (TUR) of superficial 
bladder cancer is to follow patients by cystoscopy every 3-4 months for 2 years 
and every 6-12 months thereafter. The recurrence rate of superficial bladder 
cancer is up to 75% and progression to invasive disease occurs in around 15-
25% of patients, even after a long tumor-free period.2,3 Urinary cytology is only of 
limited use since sensitivity is poor, especially for low-grade bladder cancer. To 
enhance sensitivity, tests in urine, such as bladder tumor antigen (BTA) and 
nuclear matrix proteins determination (NMP22), have already been approved by 
the Food and Drug Administration as alternatives for cytology. However, they fail 
to diagnose recurrent bladder cancer with sufficient accuracy in order to change 
the current cystoscopy regimens.4-7  
Microsatellites are highly polymorphic DNA repeats that are frequently 
found throughout the human genome. Microsatellite markers can detect cancer-
associated genetic alterations such as loss of heterozygosity (LOH) and 
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microsatellite instability (MSI). Bladder cancer is characterized by a wide variety 
of genetic changes reflected by frequent LOH and MSI.8-10 Chromosomes 4p, 8p, 
9p, 9q, 11p and 17p often display LOH. Particularly the role of chromosome 9 is 
important for follow up purposes, as it is frequently affected in superficial as well 
as in invasive bladder cancer.8,9,11 The group of Sidransky previously showed 
that bladder-, upper tract urothelial and renal cancer could be detected by 
microsatellite analysis (MA) of urine.10,12-15 The same genetic alterations that 
were found in tumor DNA were also found in the DNA derived from the urinary 
sediment in these previous studies. These and other studies16,17 also provide 
evidence for a monoclonal origin of bladder cancer, which makes the use of 
microsatellite markers particularly suitable for the detection of bladder cancer in 
urine.  
Encouraging high sensitivities for the detection of recurrent bladder cancer 
in urine by MA were reported in two independent investigations, limited to 
relatively small subsets of patients.14,18 In the daily clinical practice more than 
85% of the cystoscopies are performed in order to detect recurrent bladder 
cancer in patients who were previously diagnosed with superficial bladder cancer. 
The present study evaluates this novel, non-invasive molecular approach in a 
group of consecutive patients who are in follow-up after TUR of superficial 
bladder cancer. 
 
PATIENTS AND METHODS 
Patients. We included 109 consecutive patients in follow-up after TUR of 
superficial bladder cancer after written informed consent was obtained. The 
mean age was 67.3 ± 11.4 years at time of the study entrance; the male/female 
ratio was 3.4:1. In addition, eight age-matched patients who underwent 
cystoscopy for benign urologic diseases were included as controls. All the 
patients were seen at the outpatient clinic of the University Hospital Rotterdam. 
The medical-ethical committee of the Erasmus University and the University 
Hospital Rotterdam approved the study (MEC 168.922/1998/55). The mean 
number of previous superficial tumors was 2.6 ± 3.0 and varied from 1 to 21 
tumors per patient before inclusion. The patients were followed after complete 
TUR according to the follow-up scheme applied in our hospital: cystoscopy every 
three to four months for the first 2 years and every six to twelve months 
thereafter. The grading of cancers was performed according to the WHO 
classification and the staging according to the 1997 TNM classification guidelines 
(UICC 1997). The highest tumor-stage in the past was pTa, pT1 and carcinoma 
in situ (CIS) in 64, 41 and 4 patients, respectively. The highest tumor-grade in the 
past was G1, G2 and G3 in 27, 45 and 37 patients, respectively. We also 
obtained 6 months clinical follow-up after MA.  
Sample collection and DNA isolation. Before cystoscopy, freshly voided 
urine samples (15-50 ml) and heparinized venous blood (7 ml), as a source of 
reference DNA, were collected from each patient and stored at +4°C. The urine 
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samples were spun at 3,000 rpm for 6 min within 5 hours after voiding. The pellet 
was rinsed with 10 ml phosphate-buffered saline (PBS) and spun again at 3,000 
rpm for 6 min. The pellet was then resuspended in 800 µl PBS, brought to a 1.5 
ml eppendorf-tube and spun down at 10,000 rpm for 2 min. The cells were stored 
at -80°C until DNA isolation. DNA from the urine-pellets was extracted using the 
QIAamp Viral RNA kit (Qiagen GmbH, Hilden, Germany) according to the 
enclosed protocol, isolating both DNA and RNA at the same time. DNA from 
venous blood was isolated using the one-step DNAzol BD Reagent (Life 
Technologies, Inc. [Gibco BRL], Grand Island, NY). This DNA was stored at -
30°C until use.  
Microsatellite analysis. Microsatellite markers were selected on their 
performance on control DNA, informativity, frequency of LOH and MSI in bladder 
cancer on different chromosomal arms8,9,12,14,15,18 and a limited number of 
annealing temperatures for high throughput purposes. The 19 markers and their 
characteristics are depicted in table 1. Polymerase chain reaction (PCR) was 
performed as indicated by the manufacturer of Taq-polymerase (Promega, 
Madison, WI). PCR-products were separated on denaturing 6% polyacrylamide-
urea gels. Autoradiography was performed overnight at -80°C with Fuji Super RX 
film (Fuji Photo Film Co., Ltd., Tokyo, Japan) and followed by a quantitative 
analysis to determine the allelic-imbalance (AI) using the PhosphorImager 
system and ImageQuant software (Molecular Dynamics Inc., Sunnyvale, CA). 
LOH was scored in informative cases if a reduction of 30% in the ratio of the 
signals from urine alleles was calculated in comparison with corresponding 
reference (blood) alleles. MSI was scored if a deletion or expansion of a repeat 
unit was found as a new band. Every microsatellite alteration (LOH and/or MSI) 
was confirmed by a second PCR and the scoring was done independently (BvR, 
IL) without the knowledge of clinical or pathological data.    
BTAstat and urine cytology. The BTAstat test was done if the urologist 
applied for the test. The BTAstat test (Bard Diagnostic Sciences, Inc., Redmond, 
WA) was performed by placing five drops of urine into the sample well of a 
disposable test device. The result was read 5 minutes after placement of the 
urine according to the enclosed protocol. The urine for cytology was 
concentrated by centrifugation. The cells were stained by the standard 
Papanicolaou staining procedure. The final diagnosis from the cytopathology 
department of our hospital was used. The 3 tests were carried out on the same 
urine specimen.   
Statistical analysis. The statistical package for social sciences 8.0 
(SPSS Inc., Chicago, IL) computer software was used for the data 
documentation and analysis. Sensitivity (positive urine-tests / recurrent bladder 
cancers) and specificity (negative urine-tests / no evidence of recurrent bladder 
cancer assessed by cystoscopy or biopsy) were calculated. The two sided 
Fisher’s exact test was used to determine if a urine-test could predict tumor 
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recurrence within 6 months in the patients who were free of disease at urine 
sample collection. 
 
Table 1  
The 19 microsatellite markers used for DNA-analysis in urine. Overview of chromosomal location, 
type of repeat, different annealing temperatures (Temp.) and primer sequences. Data retrieved 
from the Genome Database; http//www.gdb.org/gdb-bin/ 
 
 
 
Marker Locus Type of 
repeat 
Annealing 
Temp °C 
Primer sequence 5’ – 3’ 
ACTBP2 5p tetra 55 AATCTGGGCGACAAGAGTGA ACATCTCCCCTACCGCTATA 
FGA 4q28 tetra 55 CCATAGGTTTTGAACTCACAG CTTCTCAGATCCTCTGACAC 
D16S476 16q tetra 55 TTGCACTCCACTCTGGGCA TTGCCTTGGCTTTCTGTTGG 
D18S51 18q21.33 tetra 55 GAGCCATGTTCATGCCACTG CAAACCCGACTACCAGCAAC 
D4S243 4pq (CA)n 55 TCAGTCTCTCTTTCTCCTTGCA TAGGAGCCTGTGGTCCTGTT 
D9S162 9p22-9p21 (CA)n 55 GCAATGACCAGTTAAGGTTC AATTCCCACAACAAATCTCC 
D9S242 9q32-9q33 tetra 55 ACTCCAGTACAAGACTCTG GTGAGAGTTCCTTCTGGC 
D9S252 9q13-9q22 tetra 55 ACAATGAACATCCATATACCC ACCATGATTTGTCAACTCCTA 
D11S488 11q24.1-11q25 tetra 55 GCCTAGGCAATAGAGACCC GAATTGTTACTGAGAGTTAG 
D9S171 9p (CA)n 55 AGCTAAGTGAACCTCATCTCTGTCT ACCCTAGCACTGATGGTATAGTCT 
D16S310 16q tetra 60 GGGCAAGGAGAGACTCT AAAAAAGGACCTGCCTTTATCC 
THO 11p tetra 60 CAGCTGCCCTAGTCAGCAC GCTTCCGAGTGCAGGTCACA 
D9S752 9q33-9q34 tetra 62 CAGAGGTTGCAGTGAGCTA GCAAAGTCAGGCCATTATAC 
D17S695 17p tetra 62 CTGGGCAACAAGAGCAAAATTC TTTGTTGTTGTTCATTGACTTCAGTCT 
LPL 8p22 tetra 62 ATCTGACCAAGGGATAGTGGGATATA CCTGGGTAACTGAGCGAGACTGTGTC 
D9S144 9p (CA)n 55 AAATATTATAGCAAGTTAATTACTGAA GGATAAATACACTGGAAAAGAGAT 
D20S454 20pq tetra 55 TGAAGTGTAGAGCTTGACA TGCAGTGAGCCATGTTCAT 
D17S786 17p (CA)n 55 TACAGGGATAGGTAGCCGAG GGATTTGGGCTCTTTTGTAA 
D17S960 17p (CA)n 55 TGATGCATATACATGCGTG TAGCGACTCTTCTGGCA 
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RESULTS 
Microsatellite analysis. We tested urine-DNA samples from 109 
consecutive patients who were in regular follow-up after resection(s) of 
superficial bladder cancer and from 8 control patients without bladder cancer. For 
the MA we used a panel of 19 microsatellite markers comparing DNA isolated 
from urine and control DNA from blood of the same patient. Several 
representative microsatellite migration patterns from gel-electrophoresis and the 
calculation of allelic-imbalance ratios to determine LOH are shown in figure 1. 
The 8 control patients without bladder cancer showed no microsatellite alteration 
in their urine DNA. We had to exclude 16 of the 109 consecutive patients 
because of the following reasons. Firstly, the amount of urine DNA was not 
enough for reproducible PCR results in 7 patients. All these 7 patients were 
tumor-free at the time of urine analysis. The design of the study did not allow us 
to obtain a second urine sample of the same patient. Secondly, in another 9 
patients, 20 or more leukocytes were seen per microscopic view (magnification 
400x). In these 9 patients, 4 of the 5 tumor-recurrences were undetectable due to 
contamination by the “normal” leukocyte DNA. Possibilities to circumvent this 
drawback are addressed in the discussion section. 
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We discovered at least 1 microsatellite alteration in 27 of the remaining 93 
patients (table 2). The mean number of altered microsatellite markers was 3.0 ± 
2.6 and varied from 1 to 9 per patient. LOH accounted for 88% of the micro-
satellite alterations; a MSI was only observed 10 (12%) times in a total of 7 
patients and 6 of these 7 patients also showed LOH. Our data indicate that MSI 
may not be as frequent as initially reported in bladder cancer.10 Our observations 
were more in agreement with the study by Bonnal et al.19 The cystoscopy results 
in relation to MA and tumor-characteristics at time of urine sample collection of 
the 93 patients are shown in table 2. The MA detected bladder cancer recurrence 
in 18/24 (75%) patients at time of urine collection. The 6 tumors that were missed 
were all small (<0.5 cm) pTaG1 lesions and therefore acute surgical treatment 
was not necessary. The 18 tumors that were detected by MA were in 15 cases 
G2 or G3 and consequently in need for surgery on short term. Three of the 24 
patients had concomitant CIS and one patient had CIS only. All these 4 patients 
were also positive in the urinary MA. In the 3 patients with concomitant CIS, it 
remains unclear whether the microsatellite alteration(s) originate from the CIS or 
the papillary lesion in the bladder. 
All the 69 patients without evidence of disease (negative cystoscopy and 
T0; table 2) at time of MA underwent at least one cystoscopical examination 
during 6 months clinical follow-up. We detected 9 microsatellite alterations in 
these 69 patients resulting in a specificity of 87% (60/69). However, five of the 9 
(56%) patients with a positive MA but a negative cystoscopy had a tumor 
recurrence within 6 months after MA. We were able to obtain DNA from tumor 
tissue in 4 of 5 cases. In these 4 patients, the MA pattern in tumor matched with 
the previous urine profile. 
 
 
 
Legend of figure 1 
I to IV: 4 representative examples of the microsatellite analysis in urine. The migration patterns 
from gel electrophoresis are shown on the left side. Paired lanes are normal blood DNA (B) and 
urine DNA (U). The corresponding calculation of the allelic-imbalance ratios is shown on the right 
side. The Allelic Imbalance (AI) was calculated by division of the ratio in urine DNA (U) and the 
ratio in blood DNA (B). Loss of Heterozygosity (LOH) was scored if the AI was ≥1.43 or <0.70, 
depending on loss of the upper or lower allele. Every microsatellite alteration (LOH/MSI) is 
indicated by an arrowhead in the gel-migration pattern and in the AI-calculation figure. The 
notation of the microsatellite marker and the appearance of LOH or MSI in this particular marker 
are indicated below.  
The AI in patient I was 8.09 (urineDNA 6.63 / bloodDNA 0.82), indicating LOH of the lower allele. 
A recurrent lesion was detected at simultaneous cystoscopy and a pTaG3 tumor was removed at 
subsequent TUR.  
The AI in patient II was 7.14, also indicating LOH of the lower allele. In this case a pTaG1 tumor 
was removed at the same time.  
The AI in patient III was 0.38, indicating LOH of the upper allele. In this patient a pT2G3 tumor 
was removed, but the microsatellite analysis of urine already pointed at the presence of tumor 
activity 6 months before clinical diagnosis.  
A MSI was discovered in patient IV. A pTaG2 tumor was removed at the same time. 
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The stage and grade distribution of the 5 tumors detected by MA in advance of 
cystoscopy was pTaG1, pTaG2 (twice), pT1G2 and pT2G3. The detection in 
urine of the invasive pT2G3 tumor before cystoscopical evidence of tumor activity 
is of particular interest in this respect. In contrast, a recurrence was found in only 
7/60 (12%) patients negative in both MA and cystoscopy. Those 7 recurrences 
were pTaG1 in three, pTaG2 in three and pTaG3 in one patient. The P-value to 
determine if MA could predict a tumor recurrence within 6 months after MA in 
these patients was 0.006 (two-sided Fisher’s Exact test). The corrected 
specificity was 94% (60/64). 
 
Table 2 
Cystoscopy, microsatellite analysis and tumor-characteristics of the remaining 93 patients at time 
of urine sample collection. 
 
Grade of recurrences Tumor size Microsatellite analysis in urine  
 
G1 
 
G2 
 
G3 
<0.5 
cm 
≥0.5 
cm 
 
No LOH/MSI
 
LOH/MSI 
 
Total 
Negative Cystoscopy - - - - - 55 7 62 
Positive Cystoscopy         
T0 - - - - - 5 2 7 
pTa 9 5 1 10 5 6 9 15 
pT1 0 1 1 0 2 0 2 2 
Tis 0 0 1 1 0 0 1 1 
 
≥pT2 0 0 6 1 5 0 6 6 
Total 9 6 9 12 12 66 27 93 
LOH : loss of heterozygosity, MSI: microsatellite instability, Tis = carcinoma in situ 
 
Comparison with BTAstat and urine cytology. In 72 of the 109 included 
patients, data on the BTAstat test, conventional cytology and MA were available 
for a comparison of the 3 tests in urine. Five patients with leukocyte abundance 
(>20 per microscopic view) were excluded. In these 5 patients, two tumor 
recurrences (pTaG1 and pT2G3) were discovered. The MA was negative in 5 
cases; the BTAstat test was positive in 5 cases. Only the pT2G3 tumor was 
found by cytology and the other 4 urine samples were negative at cytological 
examination. Thus, leukocyte abundance interfered with 2 of the 3 tests in urine, 
resulting in false negative MA and false positive BTAstat tests. 
The results of the 67 patients that could be evaluated for the performance 
of the 3 tests are shown in table 3. The MA (74%) reached the highest sensitivity 
of the 3 tests in urine. The sensitivities of the BTAstat test and conventional 
cytology for detection of recurrent bladder cancer were 56% and 22%, 
respectively (table 3). Moreover, the MA was the only test in urine that could 
predict the presence of tumor-activity while at the same time, cystoscopy or 
biopsy showed no evidence of the disease (P=0.009, table 3). 
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Table 3 
Data on the 3 bladder cancer tests in urine for 67 of the 93 patients.  
Sensitivity and specificity for detection of recurrent bladder carcinoma at time of urine sample 
collection are shown as well as prediction of recurrence in patients who were free of disease at 
time of urine sample collection (n=44). 
 
At urine sample collection Recurrence within 6 months after test in urine  
  
Sensitivity 
(%) 
 
Specificity 
(%) 
NED, Urine 
test positive 
(%) 
NED,Urine 
test negative 
(%) 
 
p-value* 
Microsatellite 
analysis 
17/23 
(74) 
36/44 
(82) 
5/8 
(63) 
5/36 
(14) 
0.009** 
BTAstat test 13/23 
(56) 
35/44 
(79) 
3/9 
(33) 
7/35 
(20) 
0.402 
Urine cytology 5/23 
(22) 
42/44 
(95) 
0/2 
(0) 
10/42 
(24) 
1.000 
NED = No Evidence of Disease at time of urine-sample collection as assessed by cystoscopy or 
biopsy 
* P-values were calculated for 2x2 tables by Fisher’s Exact test (2-sided). 
** Note that this P-value indicates that the real sensitivity and specificity of microsatellite analysis 
are higher than the percentages calculated at urine sample collection. 
 
DISCUSSION 
It can be calculated on the basis of incidence numbers and recurrence 
rate,1-3 that more than half a million cystoscopies per year for superficial bladder 
cancer follow-up are performed in the USA alone. A reduction of the number of 
cystoscopies based on a reliable, non-invasive test in urine would greatly benefit 
the patients and may also reduce the costs of monitoring.  
We evaluated the possible clinical utility of a multi-marker DNA test, called 
microsatellite analysis (MA), in urine to provide a non-invasive diagnosis of 
recurrent bladder cancer. The present study is to our knowledge the first phase II 
trial conducted in a cross-section of a superficial bladder cancer population who 
undergoes frequent cystoscopy. We reported a sensitivity of 75% (18/24) in our 
patient group. The previous phase I studies on urinary MA by Steiner et al.14 and 
Mourah et al.18 reported sensitivities of 91% (10/11) and 83% (10/12), 
respectively. However, those studies included patients with previous invasive as 
well as superficial bladder cancer. Our somewhat lower sensitivity can be 
explained by the fact that we solely included patients with superficial bladder 
cancer. These tumors generally are of lower grade and display a lower number of 
genetic alterations.8,9,20 Nevertheless, we were able to diagnose all recurrent 
tumors that were staged and graded higher than pTaG1. Possible reasons for a 
lower sensitivity of MA for small pTaG1 lesions may be a scarcity of genetic 
alterations or the tumors may be just too small to detect a microsatellite alteration 
in the corresponding urine.14 However, the tumors missed by MA proved to be 
relatively innocent, i.e. small pTaG1, tumors that are not in need of immediate 
surgery. Some studies indeed advocate a lower follow-up frequency for these 
patients.21,22  
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We reported a specificity of 87% (60/69) in our series. However, five of the 
9 patients with a positive MA result without evidence of bladder cancer, appeared 
to develop an evident bladder tumor recurrence within 6 months. This result, 
together with the matching MA patterns of urine and the later removed tumor, 
indicated that sensitivity and specificity of MA are underestimated if cystoscopy is 
considered the golden standard for tumor detection. The real specificity was 94% 
(60/64). Our results were in agreement with the specificities mentioned in the 
previous studies.14,18 In their study, Steiner et al. also found 2 tumors in advance 
of cystoscopy and the tumor they could not detect was also a pTaG1 lesion.14 
The considerable value of MA is also evident from the grade 2/3 status of 4 
tumors that were detected in advance of cystoscopy. One of these patients had 
even developed an invasive pT2G3-tumor. Several molecular markers, like TP53 
and RB, which indicate bladder tumors with a tendency towards a more invasive 
tumor behavior, have been described.16,23 In the future, these markers may be 
included in the urinary DNA analysis in order to serve as prognostic indicators. 
An explanation for the detection of tumors by MA that are not visible at 
cystoscopy is the possibility that flat lesions, like CIS, exfoliate easily, yet remain 
undetected by the cystoscopist.24 Furthermore, the frequent occurrence of 
genetic alterations in normal looking urothelium adjacent to or distant from the 
histologically confirmed bladder tumor,11 even in patients diagnosed with low 
stage and grade papillary tumors,25 is of interest in this respect. These studies 
indicate that larger areas in the bladder are affected by genetic alterations than 
the tumor site(s) alone. In addition, tumors originating from the upper urothelial 
tract may also cause microsatellite alterations in absence of bladder cancer.13,15 
This item will also be addressed further on in this section.  
Cytology and the BTAstat test were used for comparison with MA of urine. 
The sensitivity and specificity of both tests was too low to justify a less frequent 
cystoscopy regimen in our patient-population. The low sensitivity of conventional 
urinary cytology in the follow up of superficial bladder cancer is known and was 
recently confirmed in a large series of 1672 patients.26 A reason for a higher 
sensitivity of MA in comparison with urine cytology may be the earlier mentioned 
areas of normal looking bladder epithelium with cancer associated genetic 
alterations.11,25 Although the BTAstat test is a simple and quick test kit, the 
literature sustains that the test lacks sufficient sensitivity to detect recurrent 
bladder cancer.5-7,27 
Some important issues concerning the MA of urine should be considered 
in future investigations. Firstly, the design of our study did not allow us to obtain a 
sufficient quantity of urine in all consecutive patients, probably because they are 
nervous prior to their cystoscopical examination. Consequently, not enough DNA 
could be isolated from the urinary sediment for reproducible PCR result in 7 of 
the 109 patients. Obtaining a larger urine sample one or two days prior to 
cystoscopy may solve this problem. Since these 7 patients were all tumor-free, it 
is also possible that insufficient DNA was obtained because normal cells may 
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have a shorter lifespan in urine and/or shed less easily than cancer cells as 
hypothesized by Steiner et al.14 Secondly, leukocytes impose a problem for 
bladder cancer detection in urine. The present study shows that the abundance 
of leukocytes interferes with at least 2 of the 3 tests that we performed in urine. 
This problem has not been mentioned in the previous studies on MA.10-15,18 The 
number of patients was probably too small in these studies. The interference of 
inflammatory conditions with the BTAstat test is mentioned by Sharma et al.27 A 
second urine sample will have to be obtained for instance one week later in these 
patients. In case of persistent leukocyturia, antibiotic therapy might be 
considered and finally, future studies should investigate if the separation of 
leukocytes from urothelial cells in the laboratory is feasible.  
Another attractive possibility of the urinary MA would be the screening of 
the upper urothelial tract for the presence of neoplastic lesions. The incidence of 
upper tract urothelial cancer will probably rise in the near future since the 
population ages and intravesical treatment, especially bacillus Calmette Guérin 
(BCG), has proven to be effective to prevent bladder cancer recurrence and 
progression.28 In a retrospective study with a median follow-up of 12 years, 25% 
(78/307) of the patients with initial superficial bladder cancer developed a 
recurrent tumor in the upper urothelial tract.29 The upper tract urothelium is 
currently monitored by an intravenous urogram (IVU) every one to two years. 
However, an IVU does not allow a direct view of the urothelium and is therefore 
less sensitive than cystoscopy with regard to cancer detection. This also may 
explain the high percentage (77%) of invasive tumors among upper urothelial 
tumors.29 Two studies already showed that it is possible to detect upper urothelial 
cancer by MA of voided urine.13,15 Therefore, patients with a microsatellite 
alteration in their urine but without cystoscopical evidence of the disease might 
have a so far undetected lesion in the upper tract urothelium and the MA may 
identify the patients at a relative early stage of the upper tract disease. Thereby, 
MA of urine might even prevent cancer-related death. In addition, other 
malignancies originating from the urogenital tract can also be detected by MA of 
the urine sediment.13,18 
We have demonstrated that MA of the urinary sediment is able to compete 
with cystoscopy in a group of consecutive patients with a history of superficial 
bladder cancer. In line with our findings, a positive MA justifies a cystoscopic 
examination and additionally, the data suggest that a cystoscopic examination 
may be omitted if MA is negative. Before clinical introduction of this molecular 
diagnostic tool for bladder cancer, the results of this study need to be confirmed 
in larger cohorts of (randomized) patients. In a future randomized trial, possible 
pitfalls like insufficient DNA quality, abundance of leukocytes in the urinary 
sediment and lesions of the upper urothelial tract should be recognized and 
accounted for in the randomization schemes. Future study should also confirm 
our suggestion that the frequency of cystoscopy can be reduced considerably 
based on MA of urine. Nowadays, up to 4 cystoscopies per patient are needed 
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per year to monitor superficial bladder cancer. The present study is to our 
knowledge the first phase II trial and it provides a basis for a randomized phase 
III trial that addresses important issues like cost savings and the anticipated 
quality of life improvement for these patients. For the USA alone, the cost-
savings would amount to 140 million dollars per year if the cystoscopy frequency 
could be reduced by 50%.30 Moreover, the molecular analysis may also detect 
cancers in the upper urinary tract at an earlier stage, which may contribute to an 
increase in survival for this particular patient group. 
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ABSTRACT 
Fibroblast growth factor receptor 3 (FGFR3) mutations were recently 
reported at a high frequency in low-grade urothelial cell carcinoma (UCC). We 
investigated the feasibility of combining microsatellite analysis (MA) and the 
FGFR3 status for the detection of UCC in voided urine. In a prospective setting, 
59 UCC-tissues and matched urine-samples were obtained and subjected to MA 
(23 markers) and FGFR3 mutation analysis (exons 7, 10 & 15). In each case, a 
clinical record with tumor- and urine features was provided. Fifteen patients with 
a negative cystoscopy during follow-up served as controls. A mutation in the 
FGFR3 gene was found in 26 (44%) UCCs of which 22 concerned solitary 
pTaG1/2 lesions. These mutations were absent in the 15 G3 tumors. For the 6 
cases with leukocyturia, 46 microsatellite alterations were found in the tumor. 
Only one of these was also detected in the urine. This was 125/357 for the 53 
cases without leukocyte contamination. The sensitivity of MA on voided urine 
was lower for FGFR3 positive UCC (15/21; 71%) as compared to FGFR3 wild-
type UCC (29/32; 91%). By including the FGFR3 mutation, the sensitivity of 
molecular cytology increased to 89% and was superior to the sensitivity of 
morphological cytology (25%) for every clinical subdivision. The specificity was 
14/15 (93%) for the two (molecular and morphological) cytological approaches. 
Molecular urine cytology by MA and FGFR3 mutation analysis enables a highly 
sensitive and specific detection of UCC. The similarity of molecular profiles in 
tumor and urine corroborate their clonal relation. 
 
INTRODUCTION 
Urothelial cell carcinoma (UCC) of the bladder is the fifth most common 
non-skin malignancy in the western world with approximately 54.300 new cases 
in the USA per year 1. In most patients, UCC is superficial at first presentation. 
After trans-urethral resection (TUR), these patients require repeated long-term 
surveillance since up to 75% experiences one or more recurrences and 15-25% 
will progress to invasive UCC 2-4. Cystoscopy currently remains standard practice 
for primary diagnosis and follow-up of UCC but it is an uncomfortable, invasive 
and expensive procedure. Although urinary cytology is the most widely used 
method for non-invasive detection, its application is limited by poor sensitivity, 
especially for low-grade UCC 5,6. To enhance sensitivity, a wide variety of 
biological markers has been developed, of which the bladder tumor antigen (BTA) 
and the nuclear matrix protein (NMP22) assays have been extensively studied. 
However, current data on these urinary tests, do not justify their clinical 
integration 6,7. 
Microsatellites are tandem iterations of polymorphic di-, tri- or 
tetranucleotide repeats that are frequently found throughout the genome. 
Microsatellite markers are altered in many cancers reflected by loss of 
heterozygosity (LOH) and microsatellite instability (MSI). In UCC, the 
chromosomal arms 4p, 8p, 9p, 9q, 11p and 17p often display LOH 8. In contrast 
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with other LOHs, loss of chromosome 9 is considered an early event in bladder 
tumorigenesis as it can be detected in the majority of UCCs regardless of the 
histopathology 8-12. In addition, it has become clear that the number of altered 
microsatellite markers per UCC increases with parameters of unfavorable clinical 
outcome 8,9,13. 
The group of Sidransky previously showed the feasibility of microsatellite 
analysis (MA) for non-invasive detection of bladder cancer in urine 14-16. 
Subsequently, several independent groups have confirmed the superior 
sensitivity of MA (75-96%) compared to morphological cytology (13-50%) 15-21. 
However, low grade and low stage tumors are still sometimes missed by MA, 
especially, if these tumors concern recurrent pTaG1 lesions, as these are usually 
smaller than primary cancers 16,20.  
Activating fibroblast growth factor receptor 3 (FGFR3) gene mutations, 
responsible for several inherited skeletal disorders, have recently been detected 
in bladder cancer 22-25. Surprisingly, somatic FGFR3 mutations in UCC are 
related to favorable disease with 84% of pTaG1 tumors having a mutation as 
compared to only 7% of ≥pT2G3 tumors 25. Therefore, the detection of these 
mutations in urine may provide an additional mode of non-invasive UCC 
detection for “favorable” UCC. To our knowledge, no report exists on the 
feasibility of FGFR3 mutation detection in urine.    
In the present prospective study, we explored the possibility to improve 
the molecular cytology diagnosis of UCC by addition of FGFR3 mutation analysis 
to MA of urine. We also investigated the molecular profiles found in the tumor 
and the corresponding urine. In addition, we compared our molecular findings 
with multiple clinical variables. 
 
METHODS 
Patients. In a series of 51 patients who underwent surgery at the 
University Hospital Rotterdam in 1998-2000, 59 UCCs were removed in a 
prospective setting. Voided urine samples were obtained one day prior to surgery 
on admittance to the clinic. The UCCs were graded according to the WHO 
classification for urothelial neoplasms and staged according to the TNM 
classification guidelines 26,27. In case of multifocality, the papillary lesion with the 
highest grade/stage was taken. The largest tumor was taken if grade/stage were 
the same for multiple UCCs. Four patients had one recurrent UCC and two 
patients 2 recurrent UCCs. This population consisted of 41 males and 10 females 
with a mean age of 64.9 years (range, 35-89) at study entrance. TUR was 
performed in 54, cystectomy in 4 and nephro-ureterectomy in 1 case(s), 
respectively. In addition, 15 consecutive control patients with a negative 
cystoscopical examination who were in follow up after superficial UCC of different 
grades and who had a clean urinary sediment at sample collection, were 
included. This control population consisted of 12 males and 3 females with a 
mean age of 65,1 years (range, 30-77) at cystoscopy. The patients signed written 
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informed consent prior to study inclusion. The medical ethical committee of the 
Erasmus University and the University Hospital Rotterdam approved the study 
(MEC 168.922/1998/55). For morphological cytology, cells were stained by the 
standard Papanicolaou staining procedure. The final diagnosis from the 
cytopathology department of our hospital was used. These results were obtained 
on a routine basis. 
Sample collection and DNA extraction. Freshly voided urine samples 
(25-100 ml) and venous blood (7 ml), as a source of reference (germline) DNA, 
were collected from each patient and stored at +4°C. Within 6 hours after voiding, 
the urine samples were divided and processed further for morphological- and 
molecular (MA and FGFR3 status) cytology. For the molecular cytology, the 
urine- and blood samples were handled to obtain DNA as described before 20. 
Standard H&E slides were made of the 59 paraffin-embedded tissue samples for 
the microdissection procedure. The UCC tissue was manually dissected under a 
microscope avoiding contamination of the DNA sample with regions of normal 
mucosa, leukocytes or stroma. The samples used for the molecular analyses 
contained a minimum of 80% UCC cells, as assessed by histological examination. 
This DNA was extracted using Dneasy Tissue kit (Qiagen GmbH, Hilden, 
Germany). All the DNA samples were coded and stored at -30°C until use. 
FGFR3-mutation analysis. FGFR3 mutation analysis of the various DNA 
samples was performed in two institutes (Josephine Nefkens Inst., Rotterdam 
and Inst. Curie, Paris) by polymerase chain reaction (PCR) - single strand 
conformation polymorphism (SSCP) analysis as described 24,25. In brief, three 
regions encompassing activating FGFR3 mutations previously found in severe 
skeletal dysplasia and UCC were amplified. The primer-sequences were as 
reported 24. The 32P-labeled PCR-products were separated on 6% 
polyacrylamide gels in 0.2x (exon 7) or 1x SSCP-buffer (exons 10 & 15) (10x 
SSCP-buffer = 0.5M Tris-borate, 1mM EDTA). The PCR-SSCP procedure was 
checked by including the appropriate positive DNA controls and H2O as a 
negative control. Samples with an aberrant band at SSCP were sequenced with 
T7 Sequenase v2.0 (Amersham life Science, Inc., Cleveland, OH) to check the 
identity of the mutations. These analyses were carried out in a blinded fashion, 
without knowledge of the clinical status. 
Microsatellite analysis. In a previous study, we selected 19 microsatellite 
markers (ACTBP2, FGA, D16S476, D18S51, D4S243, D9S162, D9S242, 
D9S252, D11S488, D9S171, D16S310, THO, D9S752, D17S695, LPL, D9S144, 
D20S454, D17S786 and D17S960) by their performance on control DNA, 
informativity and frequency of LOH in bladder cancer 20. These 19 markers are 
located on 12 chromosomal arms. In addition to these 19, we selected 4 
microsatellite markers located within the FGFR3 gene (4p16.3) for this study. 
The sequences of these 4 new primer pairs were as follows: D4S412, F= 5’-
ACTACCGCCAGGCACT and R= 5’-CTAAGATATGAAAACCTAAGGA; D4S1614, 
F= 5’-CAAATGCATCATGGCACATCT and R= 5’-
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ACCATGAGCATATTTCCATTTC; D4S3034, F= 5’-CTGCCAATAAACTGGGT 
and R= 5’-TTGCTCACCAAAGAGGTT; D4S3038, F= 5’-
CTATAGGGGGGTGAAGCAACAG and R= 5’-TGAGAGAATATGGCTATGTGGG. 
The annealing temperature for these 4 additional markers was 60°C. The 
polymerase chain reaction (PCR) was performed as indicated by the 
manufacturer of Taq-polymerase (Promega, Madison, WI). The PCR-products 
were separated on denaturing 6% polyacrylamide-urea gels. We performed a 
quantitative analysis to determine the allelic-imbalance (AI) ratio between blood- / 
tumor- and blood- / urine DNA using the PhosphorImager system and the 
ImageQuant software (Molecular Dynamics Inc., Sunnyvale, CA). LOH was 
scored in informative cases if a reduction of 30% in the AI ratio of the signals 
from tumor or urine alleles was calculated in comparison with the corresponding 
reference (blood) alleles. MSI was scored if a deletion or expansion of a repeat 
unit was found as a new band on the gel. Every microsatellite alteration (LOH 
and/or MSI) was confirmed by a second PCR. The AI ratio closest to 1.0 was 
entered into the database. The microsatellite analyses were performed in the 
Josephine Nefkens Institute, Rotterdam. These analyses were also done in a 
blinded fashion, without knowledge of the clinical status. 
Statistical analysis. The statistical package for social sciences 9.0 
(SPSS Inc., Chicago, IL) computer software was used for data documentation 
and analysis. The χ-square test and ANOVA (for comparison of means) were 
used to analyze the possible correlations between clinical variables, FGFR3 
status and microsatellite alterations. A proportional correction for the number of 
non-informative (homozygote) cases at MA was performed when we compared 
the mean number of microsatellite alterations for distinct variables. Statistical 
significance was assumed if P<0.05. 
 
RESULTS 
We have tested 59 UCC tissue samples and the matched urine DNA with 
MA and FGFR3 mutation screening. In addition, 15 control patients were 
included to determine the specificity of the molecular UCC diagnosis in urine. 
FGFR3 status and microsatellite alterations in tumor. In the 59 
UCCs analyzed, we found 26 (44%) mutations in the FGFR3 gene. The 
mutations resulted in the amino acid changes R248C (n=2), S249C (n=22) and 
G372C (n=2). No activating mutations were found in the 51 DNA samples from 
venous blood indicating the somatic nature of FGFR3 mutations in UCC. In the 8 
recurrent UCCs, the same mutations (S249C, 3 times) were detected as in the 
first tumor. Five recurrent cases had no mutation, which was in line with the 
FGFR3 status of their previous tumor(s). Most (85%) mutations were identified in 
solitary pTaG1/2 UCC whereas in none of 15 Grade 3 UCCs these mutations 
were found (Table 1). There was no correlation between the FGFR3 mutation 
and tumor size or primary/recurrent UCC (Table 1). MA of the 59 tumors 
revealed MSI for 7 markers and LOH for 396. Only two tumors had no alteration 
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in any of the 23 microsatellite markers confirming that LOH is very frequent in 
UCC. There was no relation between LOH at a specific chromosomal arm and 
primary/recurrent UCC, tumor size or multifocality (not shown). Yet, the 
microsatellite alterations on the chromosomal arms 4p, 11q, 17p and 20q were 
related to higher-stage UCC; P-values (χ-square): 0.035, 0.035, <0.001 and 
0.016, respectively and the alterations on the chromosomal arms 4q and 17p 
were related to higher-grade UCC; P-values (χ-square): 0.049 and <0.001, 
respectively. Twenty-eight UCCs had microsatellite alterations at 17p (14/15 
tumors staged ≥pT1; 11/28 G2 and 14/15 G3 UCCs). In addition, MA revealed 
significant relations between the mean number of altered markers and tumor 
stage (P=0.002) and grade (P=0.001) (Table 1). Conversely, the mean number of 
altered markers was significantly lower in FGFR3 mutant tumors as indicated by 
Figure 1 (P=0.006). Taken together, the above-presented data provide strong 
evidence for the association of the FGFR3 mutation with a more favorable kind of 
UCC.  
 
Table 1 
Correlation of clinical tumor characteristics with molecular findings in tumor tissue.  
The FGFR3 status and the mean number of altered markers at microsatellite analysis are shown 
for the 59 cases of urothelial cell carcinoma. The clinical tumor variables are primary/recurrent 
UCC, size, multifocality, stage and grade. 
 
FGFR3 status Microsatellite analysis  
 
No 
mutation 
 
Mutation 
 
P  
(χ-square)
Mean # of altered 
markers (95% CI 
for mean) 
 
P 
(ANOVA) 
Primary 14 12 7.5 (5.9 – 9.0) UCC 
Recurrent 19 14 
=0.775 
6.3 (4.8 – 7.8) 
=0.293 
<0.5 cm 11 7 7.1 (5.3 – 8.9) 
0.5-2.0 cm 10 10 5.7 (3.4 – 7.9) 
Tumor size 
>2.0 cm 12 9 
=0.781 
7.7 (6.1 – 9.3) 
=0.253 
Solitary 16 22 6.6 (5.4 – 7.9) # of tumors 
Multiple 17 4 
=0.004 
7.1 (5.1 – 9.1) 
=0.664 
pTa 18 26 5.9 (4.8 – 7.0) Tumor stage 
≥pT1* 15 0 
<0.001 
9.6 (7.2 – 12.0) 
=0.002 
G1 8 13 4.3 (3.0 – 5.6) 
G2 10 13 7.9 (6.0 – 9.7) 
Tumor grade 
G3 15 0 
<0.001 
8.8 (6.8 – 10.8) 
=0.001 
Total 33 26  6.8 (5.8 – 7.9)  
 * pT1 in 3, pT2 in 8, pT3 in 2 and pT4 in 1 case(s) 
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correlation FGFR3 mutation and number of altered microsatellite markers in urothelial cell 
carcinoma. The figure shows the mean number of microsatellite alterations for the 33 tumors 
without FGFR3 mutation, i.e. 8.1 alterations per tumor (95% CI, 6.6 – 9.6), and for the 26 tumors 
with a mutation in the FGFR3 gene, i.e. 5.2 alterations per tumor (95% CI, 4.0 – 6.4).   
 
FGFR3 mutation and LOH at 4p16.3. We also analyzed the possible 
relationship between LOH in the FGFR3 gene (chromosomal location: 4p16.3) 
and a mutation of FGFR3. Fifteen (25%) of the 59 analyzed UCCs had LOH at 
4p16.3. Only seven of these 15 also displayed a mutation in the FGFR3 gene. As 
a consequence, 19/26 patients with a mutation had no LOH at 4p16.3. Moreover, 
in contrast with the FGFR3 mutation, we found no association between a clinical 
variable, i.e. primary/recurrent UCC, multifocality, size, stage or grade, and LOH 
at 4p16.3. These data suggest that the occurrence of LOH at 4p16.3 and the 
FGFR3 mutation are separate events in UCC tumorigenesis as recently reported 
by Sibley et al 23.  
Molecular- and morphological cytology. Several representative 
examples of the molecular analyses on tumor- and urine DNA and the 
corresponding clinical records are given in Figure 2. We investigated whether the 
presence of leukocytes had an impact on the outcome of our urine analyses. In 6 
of the 59 urine samples, more than 50 leukocytes per microscopic view 
(magnification 400x) were found (example Figure 2D). Both molecular- (MA and 
FGFR3 status) and morphological cytology detected only one of these 6 cases. 
Therefore, we excluded these 6 cases. For the remaining 53 urine samples, the 
sensitivity of MA, the FGFR3 mutation and morphological cytology were 44/53 
(83%), 11/53 (21%) and 13/51 (25%), respectively. In this group of 53 UCCs, 21 
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tumors were found to have a FGFR3 mutation. Eleven of these displayed the 
same mutation in the urine whereas the 32 FGFR3 wild-type tumors displayed no 
mutations in the urine. Because the sensitivity of MA was lower for UCCs with 
FGFR3 mutation (15/21; 71%) compared to FGFR3 wild-type UCC (29/32; 91%), 
we explored the possibility to combine MA and FGFR3 mutation screening to 
enhance the sensitivity. Indeed, we detected three more UCCs by including the 
FGFR3 status to the MA of urine. Consequently, the molecular detection of 
FGFR3 positive UCC increased from 15/21 to 18/21 and the overall sensitivity of 
molecular cytology increased to 47/53 (89%). The combination of molecular 
cytology and morphological cytology did not further enhance the sensitivity or 
decrease the specificity (not shown).  
 
 
 
 
 
 
 
 
 
 
 
Legend of Figure 2 
Representative examples (A - F) of the molecular analyses on tumor- and urine DNA and the 
corresponding clinical records. Per case, the FGFR3 mutations and the altered markers at 
microsatellite analysis are shown. In addition, at the bottom of each case, a clinical record is 
given. For the FGFR3 status, a mutation is indicated by a box that contains the amino acid 
change caused by the mutation and the affected codon. Wild type (wt) indicates the absence of a 
mutation in the investigated exons 7, 10 and 15 of the FGFR3 gene. For the microsatellite 
analysis, the altered markers in tumor and/or urine are presented. Loss of the upper allele, loss of 
the lower allele and microsatellite instability are indicated as shown at the bottom of the figure. No 
LOH (allelic imbalance (AI) ratio ≥ 0.70) or MSI is indicated by a white box. Non informative 
markers are not shown. In the clinical record, information on the tumor, i.e. primary or recurrent 
lesion, size, multifocality, pathological stage and grade and localization, as well as information on 
the urine, i.e. morphological cytology diagnosis and number of leukocytes per microscopic view in 
the urinary sediment, are given.  
Example A shows a FGFR3 positive tumor of the right upper urinary tract (ureter) that is detected 
in the corresponding urine by FGFR3 mutation analysis and microsatellite analysis.  
Example B, a pTaG1 lesion, is not detected by microsatellite analysis but is detected by the 
FGFR3 mutation analysis of the urine.  
In example C, a loss of heterozygosity for the marker ACTBP2 was observed in the urine, which 
was not observed in the tumor.  
Example D shows the microsatellite analysis of a bladder-tumor patient with leukocyturia.  
Next to multiple losses, example E shows microsatellite instability of tumor and urine for the 
marker D11S488.  
Example F is the opposite of example B. It shows a pTaG1 lesion that is detected by 
microsatellite analysis but not by FGFR3 mutation analysis of urine.    
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
nr. 5/01 Tumor Urine
FGFR3 gene:
Exon 7 S249C S249C
Microsatellite Analysis:
FGA
D4S243
D11S488
THO
D9S752
D9S144
D17S786
D17S960
Clinical Record: Primary Cytol.: -
>2.0 cm 0-10 leuc.
Solitair
pTa G2
mid-Ureter
A 
nr. 157/01 Tumor Urine
FGFR3 gene:
wt wt
Microsatellite Analysis:
ACTBP2
FGA
D16S476
D9S242
D11S488
D9S171
D16S310
THO
D9S752
D17S695
D9S144
D20S454
D17S786
D4S1614
Clinical Record: Primary Cytol.: -
0.5-2.0 cm 0-10 leuc.
Solitair
pT1 G2
Left wall
E 
nr. 86/01 Tumor Urine
FGFR3 gene:
Exon 7 S249C S249C
Microsatellite Analysis:
D9S752
Clinical Record: Primary Cytol.: +
>2.0 cm 10-50 leuc.
Solitair
pTa G1
Right wall
B
nr. 137/02 Tumor Urine
FGFR3 gene:
wt wt
Microsatellite Analysis:
ACTBP2
FGA
D16S476
D18S51
D4S243
D9S252
D16S310
D17S695
D17S960
D4S1614
Clinical Record: Recurrent Cytol.: -
0.5-2.0 cm >50 leuc.
Multiple
pT2 G3
Multiple loc.
D
nr. 13/01 Tumor Urine
FGFR3 gene:
wt wt
Microsatellite Analysis:
ACTBP2
FGA
D16S476
D18S51
D4S243
D9S242
D16S310
D17S695
LPL
D4S412
Clinical Record: Primary Cytol.: +
>2.0 cm 0-10 leuc.
Solitair
pTa G3
Posterior
C 
nr. 22/02 Tumor Urine
FGFR3 gene:
Exon 10 G372C wt
Microsatellite Analysis:
ACTBP2
D16S310
D4S412
Clinical Record: Recurrent Cytol.: -
0.5-2.0 cm 0-10 leuc.
Solitair
pTa G1
Right wall
F
loss of the lower allele 
loss of the upper allele 
microsatellite instability
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Table 2 
Molecular and morphological urine cytology for different clinical and molecular tumor-features. 
Sensitivity (n=53) and specificity (n=15) are shown. 
 
 Molecular Cytology+ Morphological Cytology* 
UCC Primary 22/23 (95) 8/21 (30) 
 Recurrent 25/30 (83) 5/30 (17) 
Tumor size <0.5 cm 14/18 (78) 2/18 (11) 
 0.5-2.0 cm 14/16 (88) 3/16 (19) 
 >2.0 cm 19/19 (100) 8/17 (47) 
No of tumors Solitary 30/34 (88) 4/32 (13) 
 Multiple 17/19 (89) 9/19 (47) 
Tumor stage pTa 34/39 (87) 7/38 (18) 
 ≥pT1** 13/14 (93) 6/13 (46) 
Tumor grade G1 14/18 (78) 2/17 (12) 
 G2 20/21 (95) 4/21 (19) 
 G3 13/14 (93) 7/13 (54) 
Mutation 18/21 (86) 2/20 (10) FGFR3 status (tumor) 
No mutation 29/32 (91) 11/31 (36) 
LOH / MSI 47/51 (92) 13/49 (27) Microsatellite Analysis 
(tumor) No LOH / MSI 0/2 (0) 0/2 (0) 
Sensitivity Total 47/53 (89) 13/51 (25) 
Specificity Total 14/15 (93) 14/15 (93) 
+ combination of Microsatellite Analysis and FGFR3 mutation detection in voided urine. 
* In 2 cases, cytology diagnosis was not possible. 
** See footnote Table 1 
 
Table 2 shows the performance of molecular- and morphological cytology for the 
different clinical and molecular variables of the tumors. The superior sensitivity of 
the molecular detection compared to the morphological approach is evident for 
all clinical- and molecular variables. Furthermore, we determined the specificity 
of molecular and morphological cytology on the urine samples of fifteen patients 
who were in follow up after TUR of superficial UCC. These patients had a 
negative cystoscopy and a clean (leukocytes: 0-10 per microscopic view) 
sediment at time of urine collection. Fourteen of these 15 had no microsatellite 
alterations, FGFR3 mutations and morphological cytology diagnosis was 
negative. Consequently, the specificity of molecular- and morphological cytology 
was 93% (Table 2). In the one remaining patient, all 3 urine analyses were 
positive. A tumor obtained from the archive showed the same microsatellite 
alterations and the same FGFR3 mutation as were found in the urine, suggesting 
that the LOHs observed in the urine were caused by a recurrence that preceded 
cystoscopical detection. In summary, the molecular cytology by the MA and the 
FGFR3 mutation provided a highly sensitive and specific mode of non-invasive 
UCC detection. 
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Comparison of genetic aberrations in tumor and corresponding urine. 
For the 53 patients without leukocyturia, we found 141 microsatellite alterations 
and 13 FGFR3 mutations in the urine. In every case, at least one match between 
urine and tumor was found with both molecular methods. The AI ratios obtained 
at the MA for tumor and urine are plotted against each other in Figure 3. In case 
of LOH for tumor and urine (N=125), the same allele (upper or lower band on the 
gel) was always lost. In addition, a LOH in urine, which was not observed in the 
analyzed tumor, was only found in 16/914 (1.8%) of the informative cases (Figure 
3). These data indicate that the urine contained the same genetic aberrations as 
the analyzed tumor.  
 
Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Allelic (imbalance) ratios of tumor and urine for the 23 microsatellite markers. This scatterplot 
contains the microsatellite data of the 23 markers for the 53 urothelial cell carcinoma cases with 
no leukocyturia. In 305 cases, the particular microsatellite marker was not informative 
(homozygote). Thus, 914 informative cases remained. In 541 cases, no loss in tumor and urine 
was observed. Sixteen cases showed an alteration (Allelic (imbalance) ratio < 0.70) in urine, 
which was not found in the analyzed tumor. On the other hand, 232 alterations were only 
detected in tumor. In 125 cases, the tumor and the urine were found to contain loss of 
heterozygosity for the same allele. For the samples below the dashed line (N=96), the allelic 
(imbalance) ratio was higher, i.e. closer to 0.70, in urine as compared to tumor. 
 
We also observed that the AI ratios in urine were generally higher (closer to 0.70) 
than the AI ratios in tumor pointing to a, so-called, dilution effect caused by the 
presence of normal and malignant cells in the urine. In this light, it is not 
surprising that contamination of the urine by “normal” leukocytes leads to a less 
sensitive detection of UCC as reported in the previous paragraph and in Table 3. 
In this Table, we compared the molecular findings in tumor and urine for the 
Allelic Ratio Urine
1.41.31.21.11.0.9.8.7.6.5.4.3.2.10.0
A
lle
lic
 R
at
io
 T
um
or
1.4
1.3
1.2
1.1
1.0
.9
.8
.7
.6
.5
.4
.3
.2
.1
0.0
Allelic Ratio Tumor ≥ 0.70
and  
Allelic Ratio Urine ≥ 0.70 
N=541
N=16 
N=232
N=125 
Chapter 4 
 
 - 64 -
cases without and with leukocyturia. Of the 357 microsatellite alterations in tumor, 
125 (35%) were also found in the corresponding urine in case of no leukocyturia. 
For patients with FGFR3 mutant tumors, 33/100 (33%), and for patients with 
FGFR3 wild type tumors, 92/257 (36%) microsatellite alterations were also found 
in the corresponding urine (P=0.20). Taking into account that UCCs 
characterized by the presence of a FGFR3 mutation (see also Figure 1) are 
associated with a lower number of microsatellite alterations, this provides an 
additional explanation for the lower sensitivity of urinary MA in case of “favorable” 
UCC. Furthermore, we investigated whether the clinical variables had an 
influence on the detection of the same alterations in the urine. If multifocality was 
present, significantly more microsatellite (tumor) alterations were observed in 
urine. The numbers were 62/132 (47%) in case of multiple tumors and 63/225 
(28%) in case of a solitary lesion (P<0.001). In contrast, no such differences were 
found for the other variables, i.e. primary/recurrent UCC, size, stage or grade. 
In addition to the variables mentioned above, associated carcinoma in situ 
(present in 6 cases) was also considered. The stage and grade of the papillary 
UCCs was as follows: pT1G2 in 1, pT1G3 in 1 and ≥pT2G3 in 4 case(s), 
respectively. None of these tumors had a FGFR3 mutation and no additional 
microsatellite alterations or FGFR3 mutations in urine were seen for these cases. 
 
Table 3 
Correlation of FGFR3 status and LOH between tumor and urine, and the effect of Leucocyte 
abundance. 
 
FGFR3 status 
 Mutation 
(Tumor) 
Same mutation (%) 
(Urine) 
P (χ-square) 
Leuc. <50 (N=53) 21 11 (52%) 
Leuc. ≥50 (N=6) 5 0 (0%) 
P=0.033 
Microsatellite analysis 
 Microsatellite alterations 
(Tumor) 
Same microsatellite alteration (%) 
(Urine) 
P (χ-square) 
Leuc. <50 (N=53) 357 125 (35%) 
Leuc. ≥50 (N=6) 46 1 (2%) 
<0.001 
 
DISCUSSION 
Bladder cancer has a high incidence and requires continuous clinical 
attention after initial treatment. The urine of these patients may offer a convenient 
mode of non-invasive UCC detection. However, morphological cytology and 
other urinary tests approved by the FDA can only be used as adjuncts to 
cystoscopy 5-7,20. For this reason, research efforts for non-invasive methods for 
detection and follow up, which eventually could reduce the number of 
bothersome cystoscopical examinations, are still warranted. 
The current study is to our knowledge the first to combine FGFR3 
mutation analysis and MA on matched tumor- and voided urine samples. We 
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detected 26 FGFR3 mutations in 59 UCCs. These mutations were strongly 
associated with favorable (solitary pTaG1/2) UCC. The association of the FGFR3 
mutation with a lower number of LOHs per tumor and the association with solitary 
UCC further underlines the “favorable” nature of tumors with a FGFR3 mutation 
found in two earlier studies 24,25. These two recent studies described the relation 
of the FGFR3 mutation with low-stage and low-grade UCC, a lower recurrence 
rate of superficial tumors in a series of 72 UCCs 24 and absence of FGFR3 
mutations in 20 cases of carcinoma in situ (the putative precursor of invasive 
UCC) 25. Moreover, only 4/28 UCCs with LOH on chromosome 17p 
simultaneously had a FGFR3 mutation in the present study. As LOH at 17p 
(TP53 gene locus) is indicative for high-grade and invasive UCC 2, 9, 28, this again 
pointed to the favorable nature of UCC with the FGFR3 mutation. 
The high incidence and the association of the FGFR3 mutation with 
favorable UCC prompted us to explore its potential as a molecular marker in 
urine. We chose to combine the FGFR3 mutation analysis to MA of urine 
because MA has proven to be a very accurate molecular method for detection 
and follow up of UCC in the hands of several independent groups 14-21. We here 
reported the highest sensitivities for MA in large (100%), invasive (93%) and 
poorly differentiated (93%) UCC. Similarly, Schneider et al. 18 who evaluated MA 
in a large group of 183 patients also found the highest sensitivities in invasive 
(95%) and G3 (96%) UCC. The sensitivities for the detection of G1 UCC by MA 
were 78% in the present study and 79% in the study by Schneider et al. 18. 
Because we could enhance the sensitivity of molecular cytology to 89% (47/53) 
by adding the FGFR3 mutation analysis, without compromising the specificity 
(93%, 14/15), we advocate the addition of the FGFR3 mutation analysis, 
particularly the exons 7 & 10, to MA of urine to optimize the molecular cytological 
diagnosis for patients with low-grade UCC. 
We compared the molecular profiles of our patients in UCC tissue and the 
corresponding urine. Interestingly, additional alterations in the urine, which were 
not observed in tumor tissue were only found in 16/914 (1.8%) of cases for MA 
(23 markers) and 2/159 (1.3%) for FGFR3 mutation analyses (exons 7, 10 &15). 
These results show that tumor cells in the urine are clonally related to the 
tumor(s) in the bladder. Earlier studies on smaller numbers of UCCs and their 
corresponding urine samples also pointed to this clonal relation 14-16. In addition, 
the data presented here show that significantly more microsatellite alterations 
reappeared in the urine if multifocality was present. Since we only analyzed one 
tumor in each case, this again provided an indication that multiple tumors are 
clonally related. Our results are in line with other studies that found clonal 
relations between multiple UCC 29,30, upper- and lower tract UCC 10,11, and 
metachroneous UCC 31. In the present study, 52% (11/21) of the FGFR3 
mutations and 35% (125/357) of the microsatellite alterations that were found in 
tumor tissue were also present in the urine. Much higher percentages (>80%) 
were reported in two studies using p53 mutations as biomarkers 32,33. This may 
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indicate that tumor-cells of UCC with p53 mutations shed more easily than 
FGFR3 mutant tumor-cells. However, recently developed methods for the 
detection of single nucleotide changes may further increase the sensitivity for 
detection of FGFR3 positive UCC in urine 34. 
In a previous study on MA for follow up of superficial bladder cancer 20, we 
found that leukocyte abundance induced false negative results in MA. In this 
study, only 2% of the tumor-associated microsatellite alterations were detected in 
urine if leukocyturia was present. This was 35% for the patients with a clean 
urinary sediment. Consequently, the contamination with "normal" leukocyte DNA 
rendered the result unreliable. Surprisingly, Chistensen et al. 35 reported frequent 
(59%) MSI in urine of patients with cystitis caused by benign prostatic 
hyperplasia. As a possible explanation for their discrepant outcome, Chistensen 
et al. 35 pointed to the use of different (more prone to MSI) microsatellites in their 
study. Nevertheless, leukocyte abundance may be considered a drawback for 
the molecular cytology diagnosis in urine. Possibilities to circumvent this 
drawback were discussed before 20.     
In conclusion, the clonal relation of UCC allows a detection of tumor 
activity in voided urine. We have shown that molecular cytology by MA and 
FGFR3 gene analysis enables a highly sensitive and equally specific detection of 
UCC compared to morphological cytology. As molecular methods become more 
available with the introduction of automated techniques, our results and those of 
others strongly suggest that PCR-based molecular cytology may be a useful tool 
to improve the detection and monitoring of patients with UCC. 
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ABSTRACT 
The interpretation of cystoscopy and cytology may be troublesome in 
bladder cancer patients previously treated by radiotherapy. We evaluated PCR-
based molecular cytology by microsatellite analysis (MA) and routine- (RUC) and 
expert (EUC) urine cytology as modes of surveillance for patients previously 
treated by radiotherapy with curative intent. Eighty-one voided urine-samples 
were obtained from 49 patients prior to cystoscopy and subjected to MA, RUC 
and EUC. During the follow-up period, 6 patients developed a recurrence. 
Sensitivity of MA, RUC and EUC was 83%, 50% and 33%, respectively. The 
specificity of MA, RUC and EUC was 93%, 85% and 97%, respectively. 
Cystoscopy was positive in 15 cases. Therefore, the positive predictive value of 
cystoscopy remained limited to 40%. Next to recent studies demonstrating a high 
accuracy for MA in non-irradiated patients, our results indicate that molecular 
cytology by MA may also be a useful tool to improve the surveillance of bladder 
cancer patients previously treated by radiotherapy. 
 
INTRODUCTION 
Close surveillance and intravesical treatment are the keystones in the 
management of early stage, superficial bladder cancer.1,2 On the other hand, the 
treatment of muscle invasive bladder cancer (i.e. ≥T2) mostly relies on radical 
cystectomy. For a selected group of patients, bladder sparing strategies, such as 
trans-urethral resection (TUR) followed by partial cystectomy, radiotherapy or 
combinations of these have shown to be effective in controlling invasive disease 
and result in definitive tumor control.3-6 The patients treated with a bladder 
preserving strategy also require close and life-long surveillance for a possible 
recurrence of their disease. Currently, cystoscopy is the standard practice for 
follow-up of bladder cancer but it remains an uncomfortable procedure for many 
patients. Although urinary cytology is widely used as non-invasive detection 
method, its application is largely limited by low sensitivity and operator 
dependency, especially for low-grade tumors.7,8 Moreover, cystoscopy as well as 
cytology are often less reliable in case of previous radiotherapy.9,10 
Microsatellite markers are altered in many cancers reflected by loss of 
heterozygosity (LOH) and microsatellite instability (MSI). In bladder cancer, LOH 
is frequently found on the chromosomal arms 4p, 8p, 9p, 9q, 11p and 17p11 
whereas MSI is less common12. The same genetic alterations have also been 
used to detect these cancer-related features in body fluids.13 The group of 
Sidransky has previously shown the feasibility of microsatellite analysis (MA) for 
the detection of bladder cancer in voided urine.13-15 Subsequently, several 
independent groups have recently confirmed the superior sensitivity of MA (75-
96%) compared to cytology (13-50%) in various clinical settings.16-20 However, to 
our knowledge, no report exists on MA of urine in patients under surveillance 
after radiotherapy. 
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In the present study, we evaluated routine urine cytology (RUC), expert 
urine cytology (EUC) and MA for a cross-section of patients in follow-up who 
previously received radiotherapy with curative intent. 
 
METHODS 
Patients. Forty-nine (38 male, 11 female) patients who regularly attended 
the Department of Radiation Oncology of the Erasmus MC - Daniel den Hoed 
Cancer Centre (DHCC) for follow-up were included. The patients were referred to 
the DHCC after TUR and underwent radiation therapy with curative intent for 
bladder cancer. Their tumor- and radiation characteristics are shown in Table 1.  
 
Table 1 
Tumor- and radiation characteristics of the 49 studied patients. 
 
 No Patients (%) 
T1 11 (22) Stage 
T2 38 (78) 
G2 8 (16) Grade 
G3 41 (84) 
Transitional Cell Carcinoma 45 (92) 
Adenocarcinoma 2 (4) 
Small Cell Carcinoma 1 (2) 
Histological type 
Squamous Cell Carcinoma 1 (2) 
EBRT followed by IRT 40 (82) 
IRT 3 (6) 
Radiation type 
EBRT 6 (12) 
Total 49 (100) 
EBRT=external-beam radiotherapy, IRT=interstitial radiotherapy 
 
The histology slides were reviewed according to the 1973 WHO grading system 
and the 1997 TNM classification guidelines. In addition, the patients had a CT-
scan and chest X-ray, which were negative for (lymph node) metastases. Prior to 
radiotherapy, six patients had intravesical treatment and one patient had 
systemic chemotherapy. Three patients with a T1 tumor received interstitial 
radiotherapy (IRT) 60 Gy and six patients received external-beam radiotherapy 
(EBRT) 66 (33x2.0) Gy. Most patients (n=40) underwent EBRT 20x2.0 Gy 
followed by IRT 30 Gy. Three of these patients who were treated before 1990, 
had IRT via caesium needles. In 37 patients, the IRT was given using the 
afterloading iridium wire technique as described.5 The IRT was applied in case of 
solitary bladder cancer with a limited (<5 cm) surface diameter. Most patients 
treated by IRT had a partial cystectomy of the original tumor-site. After 
completion of the radiation therapy, the follow-up was done with cystoscopy and 
cytology every three months for the first 2 years and every six months thereafter. 
An intravenous urogram was made every 2 years to monitor the upper urinary 
tract. The patients local urologist alternated with the DHCC executed this follow-
up. At least one follow-up visit per year was performed at the DHCC. The 
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medical-ethical committee of Erasmus MC approved the study (MEC 
168.922/1998/55, AZR 99/01). The patients signed written informed consent prior 
to study inclusion. The mean age at time of study inclusion was 66,9 years 
(range, 42-85). Eighty-nine urine samples were obtained. In eight cases, more 
than 50 leukocytes per microscopic view (magnification x400) were seen. These 
samples were excluded from further analysis since leukocyte abundance causes 
false negative results for MA.19 The remaining 81 urine samples were retrieved 
from the 49 patients as follows: one, two, three and four samples in 29, 10, 8 and 
2 patients, respectively. In case of a positive cystoscopy, TUR was scheduled. 
Recurrence was defined as histological confirmed cancer at TUR.  
Sample collection and DNA extraction. Freshly voided urine samples 
(15-50 ml) and venous blood (7 ml), as a source of reference (germline) DNA 
were collected. Venous blood was only collected at the first follow-up visit after 
study inclusion and stored at -80°C. Within 6 hours after voiding, the urine 
samples were divided and processed for cytology and MA. The cytological 
material was stained by standard Papanicolaou staining. The final diagnosis of 
the cytopathology department was used as result of RUC. The results of the EUC 
and a leukocyte count were provided by VK-B who reviewed the cytology slides. 
The urine samples for MA were spun at 2,000 rpm for 6 min. The pellet was 
rinsed with 10 ml phosphate-buffered saline (PBS) and spun again at 2,000 rpm 
for 6 min. This pellet was resuspended in 800 µl PBS, brought to a 1.5 ml tube 
and spun down at 14,000 rpm for 2 min. These tubes were also stored at -80°C. 
DNA from venous blood was isolated using the QIAamp DNA Blood Mini kit 
(Qiagen GmbH, Hilden, Germany) and DNA from the urine-pellets was extracted 
using the QIAamp Viral RNA kit (Qiagen GmbH, Hilden, Germany). The DNA 
samples were coded and stored at -30°C. 
Microsatellite analysis. In a previous study, we selected 19 microsatellite 
markers (ACTBP2, FGA, D16S476, D18S51, D4S243, D9S162, D9S242, 
D9S252, D11S488, D9S171, D16S310, THO, D9S752, D17S695, LPL, D9S144, 
D20S454, D17S786 and D17S960) by their performance on control DNA, 
informativity and frequency of LOH in bladder cancer.19 These 19 markers are 
located on 12 chromosomal arms. The polymerase chain reaction (PCR) was 
performed as indicated by the manufacturer of Taq-polymerase (Promega, 
Madison, WI). The PCR-products were separated on denaturing 6% 
polyacrylamide-urea gels. We performed a quantitative analysis to determine the 
allelic-imbalance (AI) ratio between blood- / urine DNA using the 
PhosphorImager system and the ImageQuant software (Molecular Dynamics Inc., 
Sunnyvale, CA). LOH was scored in informative cases if a reduction of 30% in 
the AI ratio of the signals from urine alleles was calculated in comparison with the 
corresponding reference (blood) alleles. MSI was scored if a deletion or 
expansion of a repeat unit was found as a new band on the gel. Every 
microsatellite alteration was confirmed by a second PCR. The AI ratio closest to 
1.0 was used. These analyses were done in a blinded fashion, without 
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knowledge of the clinical status. The statistical package for social sciences 9.0 
(SPSS Inc., Chicago, IL) computer software was used for data documentation 
and analysis. The sensitivity, specificity and the positive- and negative predictive 
value were determined for each test in urine. 
 
RESULTS 
We have tested 81 urine samples of 49 patients who were under 
surveillance after radiotherapy with curative intent. The mean time between final 
irradiation and first urine collection (study inclusion) was 38.9 months (range, 3-
172). Twelve urine samples were collected within one year from completion of 
the radiation therapy. Six recurrences were found at TUR. The stage and grade 
of these tumors were TaG1, T2G3 and T3G3 in 1, 4 and 1 case(s), respectively. 
The Tumor and radiation characteristics of the 6 patients who developed a 
recurrence are depicted in Table 2.  
 
Table 2 
Tumor & radiation characteristics of the 6 patients who developed a recurrence. Initial pT/G refers 
to the stage and grade of the original tumor that was treated by radiotherapy. The histological 
types also refer to the original tumor. The time interval was calculated from the initiation of 
radiotherapy to the date of recurrence.   
 
Case# Initial pT/G Recurrent pT/G Histological type Radiation type Time interval 
(years) 
20 pT2/G3 pTa/G1 TCC EBRT 3.8 
27 pT1/G3 pT3/G3 TCC EBRT 4.7 
45 pT2/G3 pT2/G3 TCC EBRT/IRT 1.8 
59 pT2/G3 pT2/G3 Adeno EBRT/IRT 2.0 
60 pT2/G3 pT2/G3 TCC EBRT/IRT 1.1 
70 pT2/G3 pT2/G3 TCC EBRT/IRT 8.7 
TCC=Transitional cell carcinoma, Adeno=Adenocarcinoma, EBRT=External-beam radiotherapy, 
EBRT/IRT= External-beam radiotherapy followed by Interstitial radiotherapy. 
 
Several representative examples of MA are shown in Figure 1. MSI was 
not found at all. LOH was found in 5/6 patients with a recurrence (sensitivity: 
83%). The urine of the patient with the TaG1 lesion did not show LOH. In the 
urine of 5 patients with LOH and a recurrence, 16 LOHs were found at MA. In the 
samples of patients without a recurrence (n=75), 70 MAs were negative 
(specificity: 93%). In the 5 samples with LOH but without a recurrence, only 6 
LOHs were found. No false positive results were found within one year from 
completion of the radiation therapy. 
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Two representative examples (roman numerals I and II) of microsatellite analysis in voided urine. 
The migration patterns after gel electrophoresis are shown on the left side. The notation of the 
particular microsatellite marker is indicated below. The lanes represent normal, i.e. blood, DNA (B) 
and urine DNA (U). The corresponding calculation of the allelic-imbalance ratios is shown on the 
right side. The Allelic Imbalance (AI) ratio was calculated by division of the ratio in urine DNA (U) 
and the ratio in blood DNA (B). Loss of Heterozygosity (LOH) for a microsatellite marker was 
scored if the AI ratio was ≥1.43 or <0.70, depending on loss of the upper or lower allele. In 
example I, the AI ratio was 0.54 (U=0.56/B=1.03). In example II, two urine samples (U1 and U2) 
of the same patient were tested. The AI ratios were 0.16 and 0.38, respectively. In this case, the 
microsatellite analysis was already positive (U1) 3 months before biopsy was performed (U2). 
 
RUC and EUC were positive for 3 and 2 of the six recurrences, 
respectively. A definitive cytological diagnosis was not possible for 4 cases (RUC) 
and 1 case (EUC). RUC was negative for 60/71 urine samples without a 
recurrence (specificity: 85%). EUC was negative for 72/74 samples without a 
recurrence (specificity: 97%). Table 3A shows the sensitivity, specificity and the 
positive- and negative predictive values for the 3 different tests in urine. 
Cystoscopy was positive in 15/81 cases. However, 9/15 TUR-specimens 
showed no malignancy at histopathological examination; in other words, the 
D9S752 
B      U 
B U
LPL 
 B  U1  U2 
B 
U1 U2
II 
I 
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positive predictive value of cystoscopy was limited to 40%. The specificity of 
cystoscopy for the diagnosis of bladder cancer was 88% (66/75) in the present 
study. Table 3B shows the relation between the cystoscopical result and the 
recurrences detected at TUR. 
 
Table 3A 
Results of routine urine cytology (RUC), expert urine cytology (EUC) and urinary microsatellite 
analysis (MA) based on 81 voided urine samples of 49 patients. RC and EC yielded no diagnosis 
in 4 and 1 case(s), respectively. Absolute numbers are between parentheses.  
 
 %RUC %EUC %MA 
Sensitivity 50 (3/6) 33 (2/6) 83 (5/6) 
Specificity 85 (60/71) 97 (72/74) 93 (70/75) 
Pos predictive value 21 (3/14) 50 (2/4) 50 (5/10) 
Neg predictive value 95 (60/63) 95 (72/76) 99 (70/71) 
Pos=positive, Neg=negative 
 
Table 3B 
The number of histologically confirmed recurrences and the results of the 81 cystoscopies 
performed in 49 patients are shown. The specificity and the positive predictive value of 
cystoscopy amount to 88% (66/75) and 40% (6/15), respectively. The relative low positive 
predictive value supports the assumption that the interpretation of cystoscopy in patients who 
underwent radiotherapy is often troublesome. 
 
 Cystoscopy negative Cystoscopy positive 
No recurrence 66 9 
Recurrence 0* 6 
Total 66 15 
 *By definition 0 as the cystoscopical result forms the indication for a biopsy.  
 
DISCUSSION 
Bladder cancer surveillance after radiotherapy is cumbersome and expert 
opinions are often warranted.9,10 Even so, the follow-up scheme is more or less 
the same as for patients with superficial bladder cancer with frequent cystoscopy 
as the gold standard and cytology as an adjunct. However, a reliable assay on 
urine may greatly benefit the patients and help the clinicians to determine the 
strategy for their patients. 
We evaluated whether MA of urine was a reliable method for surveillance 
after radiotherapy. The same urine samples were also examined by cytology, i.e. 
RUC and EUC. For MA, we reported a sensitivity of 83%, which was comparable 
to previous observations of our group and others in non-irradiated patients.13-20 
The sensitivity of cytology (50 and 33%) was also in line with these previous 
studies. However, these results are to be interpreted with caution as only 6 
recurrences were documented. Possible reasons for few recurrences in this 
patient population may be the variable time between the first TUR and the follow-
up visit, the selection criteria for brachytherapy and the use of multiple urine 
samples per patient. In contrast with the low sensitivity, the advantages of urinary 
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cytology are its high specificity and high negative predictive value.8,21 However, 
after irradiation, specificity may lag behind.9,10 We reported a specificity of 85% 
for RUC and of 97% for EUC confirming that EUC is required in case of previous 
radiation therapy, as suggested by others.10 
A wide variety of biological markers has been developed to address the 
shortcomings of cytology (low sensitivity, observer variability).7,8,21 The FDA-
approved tests encomprise the bladder tumor antigen (BTA) test, the BTAstat 
test, the fibrinogen/fibrin degradation products (FDP) assay, the nuclear matrix 
protein-22 (NMP-22) assay and the UroVysion assay. In general, these are 
characterized by a higher sensitivity but a lower specificity than cytology.8,21 On 
the other hand, MA of urine showed a high specificity (>85%) in several 
studies15,17-20 and also showed a higher specificity in comparison with other 
diagnostic tests in urine19,20. However, no study in bladder cancer patients and 
only one study by Crane et al.22 who prospectively investigated 18 patients with 
non-bladder pelvic cancer by the BTAstat test after radiotherapy, have been 
performed in patients who received radiotherapy. Crane et al.22 reported positive 
BTAstat tests in 56% of patients during a median follow-up of 42 weeks 
indicating that irradiation by itself can cause false-positive BTAstat tests in the 
first year after radiotherapy. However, we here report a specificity of 93% (70/75) 
and a negative predictive value of 99% (70/71) for MA. These high percentages 
indicate that MA may serve as an additional tool for surveillance after 
radiotherapy for bladder cancer. 
Radiation induced genomic instability is a well-known phenomenon.23 
However, the clinical implications of this information for the treatment of cancer 
with irradiation are not known. Moreover, Boyd et al.24 found an increase of 
microsatellite alterations in human somatic cells in culture when they increased 
the radiation dose. Theoretically, radiation therapy could induce LOH, especially, 
shortly after the irradiation is given. However, the high specificity and high 
negative predictive value in the present series do not support this hypothesis. 
Moreover, the genetic changes that may have been induced by irradiation will 
only become apparent in a clinical setting if clonal outgrowth of the genetically 
altered cell in question occurs. 
A cystoscopical examination in a patient who received radiotherapy can 
be difficult.25 The radiation effects, such as ulceration or reactive epithelial 
proliferations, frequently accompanied by hematuria, may prompt the urologist to 
schedule a TUR or a biopsy. In a previous study in 93 non-irradiated patients 
who were followed after TUR of superficial bladder cancer, we found a specificity 
of 90% and a positive predictive value of 77% for cystoscopy.19 The positive 
predictive value of cystoscopy was only 40% in the present study. This low 
positive predictive value indeed supports the assumption that the interpretation of 
cystoscopical findings in patients who underwent radiotherapy is often 
problematic.  
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CONCLUSIONS     
Like others, we have shown that both cystoscopy and cytology may be 
cumbersome in bladder cancer patients previously treated with radiation. 
However, studies on how to improve the follow-up of these patients are very rare. 
Nevertheless, a reliable method in urine to complement cystoscopy, like EUC or 
MA, is especially relevant for these patients because the positive predictive value 
of cystoscopy remains limited after radiotherapy. Here, we show that molecular 
cytology by MA enables a highly sensitive and specific mode for surveillance. As 
molecular methods become increasingly available with the introduction of 
automated techniques, our results suggest that PCR-based molecular urinary 
cytology may be a useful tool to improve the surveillance of bladder cancer 
patients including those previously treated by radiotherapy. 
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ABSTRACT 
 Urothelial Cell Carcinoma is the fifth most common cancer in humans. For 
superficial UCC, 70% of the patients develop recurrence(s) and in 10-15% the 
tumor becomes invasive. Therefore, these patients are intensively monitored by 
cystoscopy after a trans-urethral resection. In UCC, two types of genetic 
alterations prevail: multiple losses of heterozygosity pockmark the cancer 
genome and point mutations are found in the genes for FGFR3 and P53. 
Mutations in FGFR3 occur predominantly in UCC whereas P53 mutations are 
found in over 50% of human cancers. We here give a short overview of the 
histopathological and clinical parameters of (superficial) UCC. In addition, some 
background information on the FGFR3 gene that is mutated in a high percentage 
of superficial UCCs, is provided. 
 
CLINICO-PATHOLOGICAL FEATURES OF BLADDER CANCER 
 Urinary bladder cancer is the fifth most common neoplasm in western 
society with approximately 54 400 new cases in the USA in 1998.1 In the 
Netherlands, approximately 2550 new cases present each year.2 Histologically, 
90-95% of bladder cancer in the western world is urothelial cell carcinoma (UCC). 
The majority of UCCs are found in the bladder. UCCs of the renal pelvis, ureter 
and urethra together account for less than 10% of the UCCs. Staging is 
performed according to the TNM97 system. Clinically, a distinction is made 
between superficial and invasive UCC. Superficial UCC are neoplasms that do 
not infiltrate (pTa) or do so superficially (pT1). Patients with solitary pTaG1-2 
UCC have a good prognosis (5-year survival around 95%). Invasive bladder 
cancer has invaded the detrusor muscle. Therapy with curative intent generally 
consists of cysto(prostat)ectomy provided that the cancer has not yet 
metastasized. Invasive UCC is a life-threatening disease, as the 5-year survival 
is about 50%, even after curative surgery. 
 Carcinoma in situ (CIS) of the urinary tract is a flat lesion, which may 
occur as an isolated lesion in about 5% of patients with bladder cancer. It may be 
widespread in the mucosa as a manifestation of field cancerization. CIS is 
regarded as the precursor of non-papillary pT1 UCC and invasive UCC. The 
biological behavior of isolated CIS is variable, but ultimately about 50% of the 
cases show progression.3 Conversely, CIS is frequently found next to papillary 
G3 UCC. Thus, CIS can be considered as a precursor lesion of invasive cancer 
or as a manifestation of intra-epithelial spread of high-grade UCC. The lesions 
that may be found in association with low-grade papillary neoplasms are flat 
urothelial hyperplasia and papillary hyperplasia. The cytonuclear features of 
these lesions do not reveal abnormalities. However, a recent paper described 
genetic changes in papillary hyperplasia5 that are similar to those found in 
papillary UCC, suggesting that this lesion also represents a precursor lesion. 
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PROGNOSTIC FEATURES OF SUPERFICIAL UCC 
 Superficial UCCs are generally treated by a trans-urethral resection (TUR) 
and by intravesical treatment in an adjuvant setting. Although the majority of 
these superficial UCCs behave rather indolent, their recurrence rate is high, up to 
75%, either as a re-growth at the original site or as new lesion(s) elsewhere. This 
high recurrence rate causes considerable morbidity to this group of patients. 
Close monitoring of superficial UCC is warranted as, in due time, about 10-15% 
show progression to invasive UCC.6 Currently it is routine to monitor our patients 
with superficial UCC by urethro-cystoscopy (UCS) every 3-4 months for the first 
two years after a TUR and subsequently at a reduced interval. This procedure is 
associated with anxiety and physical complaints, including dysuria and cystitis in 
about 10%. Therefore, much research efforts are undertaken to reduce the UCS 
frequency for follow up by applying new cancer markers in urine or by defining a 
subset of patients with superficial UCC and a favorable recurrence frequency. 
 A major problem to assess prognosis is the inter-observer variation among 
pathologists.7 This has obviously stimulated the search for more objective 
molecular markers to distinguish aggressive from indolent superficial UCC. 
Multiplicity as a clinical parameter is also of help to predict the chance for future 
recurrence(s).6 In addition, presence of CIS is a very unfavorable sign that is 
associated with a high likelihood of UCC progression.8 In patients with an upper 
urinary tact UCC, a considerable risk for future bladder recurrence(s) exists. On 
the other hand, patients with a single, small-sized, Grade 1 UCC at first 
presentation are at a low risk for subsequent lesion(s). Molecular indices which 
have been shown to be associated with a higher risk for recurrence(s) include the 
P53 mutation, DNA-aneuploidy and a high expression of the proliferation marker 
MIB-1.9,10 A drawback of these markers is that they are relatively rare in 
superficial UCC, which implies that their absence does not define a subset of 
patients who have a lower risk for recurrence. Moreover, these markers were 
found to be strongly correlated with the conventional parameters grade and 
stage.9 Recently, the FGFR3 mutation has been identified as a favorable 
molecular marker for UCC.11-13 
 
FGFR3 MUTATIONS AND BLADDER CANCER 
 The fibroblast growth factor receptor 3 (FGFR3) is a glycoprotein 
composed of three extracellular immunoglobulin-like domains, a transmembrane 
domain and a split tyrosine-kinase domain.14 Ligand binding induces FGFR 
dimerization, resulting in autophosphorylation of the kinase domain and 
interaction with and phosphorylation of effector signaling proteins.15 FGFR3 
belongs to a family of four highly conserved and closely related cell membrane 
associated receptors (FGFR1-4). The FGFRs are involved in cell signaling 
pathways regulating embryonic growth, cell proliferation, angiogenesis, 
development and differentiation.15 Point mutations in specific domains of FGFR3 
are associated with autosomal dominant dwarfism and craniosynostosis 
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syndromes that sometimes coincide with dermatological disorders.16 Several 
reports have demonstrated that these mutations lead to constitutive activation of 
the receptor and that specific mutations lead to different levels of constitutive 
FGFR3 activation. Probably because of these different activation levels of the 
receptor, complex phenotype-genotype correlations exist.16 For example: 
achondroplasia (the most common form of genetic dwarfism) entails a relative 
normal life span whereas thanatophoric dysplasia is considered a lethal form of 
skeletal dysplasia. 
 Besides the inhibitory role of FGFR3 mutations in skeletal disorders, an 
oncogenic role for FGFR3 in human cancer has emerged. Indeed, somatic 
activating mutations in FGFR3 have been reported in multiple myeloma and, 
more recently, in two epithelial malignancies, i.e. bladder- and cervix 
carcinomas.16-18 FGFR3 mutations are rare in multiple myeloma and cervix 
carcinomas, whereas their high incidence in bladder carcinomas (74% of non-
invasive papillary tumors) suggests that the constitutive activation of FGFR3 is 
an important event for bladder tumorigenesis.11,12 It has been shown that 
mutated FGFR3 can transform NIH 3T3 cells and act as an oncogene.19 Since 
the FGFR3 gene is expressed in bladder cancer and normal urothelium,17 it is 
likely that the mutant gene has an oncogenic role in bladder cancer pathogenesis. 
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ABSTRACT 
We analyzed the possible prognostic value of the recently discovered 
fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer. A 
FGFR3 mutation was found in 34/53 pTaG1/2 bladder cancers, whereas none of 
the 19 higher staged tumors had a mutation (P<0.0001). In 57 patients with 
superficial disease followed prospectively by cystoscopy for 12 months, 14 of 23 
patients in the wild type FGFR3 group developed recurrent bladder cancer 
compared to only 7 of 34 patients in the mutant group (P=0.004). The recurrence 
rate per year was 0.24 for the FGFR3 mutant tumors and 1.12 for tumors with a 
wild type FGFR3 gene. In addition, FGFR3 mutation status was when compared 
to stage and grade the strongest predictor of recurrence (P=0.008). This is the 
first mutation in bladder cancer that selectively identifies patients with favorable 
disease characteristics. Our results suggest that the frequency of cystoscopic 
examinations can be reduced considerably in patients with FGFR3 positive 
tumors. 
 
INTRODUCTION 
Urinary bladder cancer is the fifth most common neoplasm in western 
society with approximately 54 400 new cases in the United States per year.1 In 
the majority of patients bladder cancer is superficial (i.e. pTa-pT1) at first 
presentation. After trans-urethral resection (TUR) of superficial bladder cancer, 
patients are monitored by cystoscopy at regular intervals since the recurrence 
rate of superficial bladder cancer is up to 70%.2-4 Progression to invasive disease 
occurs in around 15-20% of patients.2,3 Clinical and histopathological factors for 
prediction of tumor recurrence and progression of bladder cancer have been 
studied extensively.2-4 Especially tumor grade, stage and recurrence rate are 
important. In addition, it appeared that mutations in the tumor suppressor genes 
TP53 and retinoblastoma (RB) are of additional value to assess aggressive 
tumor behavior.5 The fibroblast growth factor receptor 3 (FGFR3) is a 
glycoprotein composed of three extracellular immunoglobulin-like domains, a 
transmembrane domain and a split tyrosine-kinase domain. Several reports have 
shown that constitutive activation of the FGFR3 gene by specific point mutations 
leads to congenital anomalies such as achondroplasia and thanatophoric 
dysplasia.6,7 A frequent t(4;14)(p16.3;q32.3) chromosomal translocation with the 
breakpoint near FGFR3 in multiple myelomas (MM) suggested an oncogenic role 
for the FGFR3 gene.8 However, an activating mutation in the FGFR3 gene 
occurred rarely in MM.9 The same missense mutations (R248C, S249C, G372C 
and K652E) that were observed in thanatophoric dysplasia were recently found in 
9 of 26 bladder carcinomas and 3 of 12 cervix carcinomas.10 It has been shown 
that mutated FGFR3 can transform NIH 3T3 cells when targeted to the cell 
membrane.11 Since the FGFR3 gene is expressed in bladder cancer and normal 
urothelium10, it is likely that the mutant gene has an oncogenic role in bladder 
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cancer pathogenesis. The present study assesses the possible prognostic value 
of the FGFR3 mutation in bladder cancer.  
 
MATERIAL AND METHODS 
Patients. Seventy-two consecutive patients who underwent TUR at the 
University Hospital Rotterdam in 1998-1999 were entered into this study. The 
patients were not selected on any clinical or other parameter. All patients signed 
written informed consent. The medical ethical committee of the Erasmus 
University and the University Hospital Rotterdam approved the study (MEC 
168.922/1998/55). Median age at time of diagnosis was 65.4 years (range, 30-
89), male/female ratio was 4.2:1. We examined patient’s history and obtained 12 
months clinical follow-up on a prospective basis, including a cystoscopic 
examination every 3 months, from all patients that were diagnosed with 
superficial bladder cancer at time of FGFR3 mutation analysis. Grading of 
cancers was performed according to the WHO classification and staging 
according to the 1997 TNM classification guidelines (UICC 1997). A recurrence 
was defined as the presence of histologically proven bladder cancer at a positive 
cystoscopy following a complete previous TUR. The recurrence rate per year 
was defined as the number of recurrences divided by the total number of months 
of follow-up. The result was then multiplied by 12. Hence, the recurrence rate 
takes into account the clinical course of patients during a longer interval and not 
only the time to first recurrence. 
Sample collection and DNA extraction. The bladder tumors were 
subjected to careful microdissection after confirmation of the histopathological 
diagnosis. Venous blood (7 ml) was obtained from every patient to be used as 
control. DNA from paraffin embedded, formalin fixed neoplastic tissue was 
extracted using Dneasy Tissue kit (Qiagen GmbH, Hilden, Germany) according 
to enclosed protocol. DNA from venous blood was isolated using one step 
DNAzol BD Reagent (Life Technologies, Inc. [Gibco BRL], Grand Island, NY). 
We checked the accuracy of the microdissection procedure by loss of 
heterozygosity (LOH) analysis in 18 of the 19 patients with ≥ pT1 tumors 
comparing the allele intensities of normal and tumor DNA of the same samples 
that were used for the FGFR3 mutation analysis. A 50% reduction of allele 
intensity was considered LOH. We used 23 microsatellite markers on 9 different 
chromosomes as described before.12 Every LOH was confirmed in a second 
PCR.  
FGFR3 mutation analysis. FGFR3 mutation analysis was performed by 
polymerase chain reaction (PCR) - single strand conformation analysis (SSCA) 
on tumor- and control blood DNA of all patients. Three regions of interest 
containing the 4 previously identified mutations were amplified by PCR. The 
primer sequences were the same as used by Capellen et al. (10). The following 
primer pairs were used: exon 7, 5’-AGTGGCGGTGGTGGTGAGGGAG-3’ and 5’-
TGTGCGTCACTGTACACCTTGCAG-3’; exon 10, 5’-CAACGCCCATGTCTTTG-
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CAG-3’ and 5’-CGGGAAGCGGGAGATCTTG-3’; exon 15, 5’-GACCGAGGAC-
AACGTGATG-3’ and 5’-GTGTGGGAAGGCGGTGTTG-3’. All tumors with an 
aberrant band at SSCA were sequenced with T7 Sequenase v2.0 (Amersham life 
Science, Inc., Cleveland, OH) on both strands to check the identity of the 
mutations. Analysis of all samples was carried out in a blinded fashion, without 
knowledge of clinical or histopathological status. 
Statistical analysis. Statistical package for social sciences 8.0 (SPSS 
Inc., Chicago, IL) and StatXact version 2 (Cytel Software Corporation, Cambridge, 
MA) computer software were used for data documentation and analysis. Fisher’s 
exact test was used to analyze the FGFR3 mutation in relation to stage, grade, 
highest stage and prediction of tumor recurrence. Logistic regression analysis 
with the backward elimination method was used for comparison of variables to 
predict recurrence. All P-values are two sided. Statistical significance was 
assumed if P<0.05. 
 
RESULTS 
We performed a mutation analysis of the FGFR3 gene in a group of 72 
bladder carcinomas from 72 consecutive patients. Thirty-seven patients were 
diagnosed with bladder cancer for the first time. All the 72 bladder cancers were 
transitional cell carcinomas, except for one squamous cell carcinoma that was 
pT2, Grade 3.  
SSCA detected aberrant bands (Figure 1) in DNA samples from 34 tumors 
but not in DNA from corresponding venous blood, indicating the somatic nature 
of FGFR3 mutations in bladder cancer. Thirty mutations concerned the already 
described codon 249 mutation (S249C). Codon 248 (R248C) and 372 (G372C) 
mutations were found once and twice, respectively (Figure 1A,C,D). An additional 
mutation, not observed in bladder cancer before, was also detected (Figure 1E). 
DNA sequence analysis revealed the point mutation leading to A393E, previously 
known in a hereditary skeletal syndrome.13 The two mutations, R248C and 
S249C, can be found in one amplification region. This region represented 91% of 
the observed FGFR3 mutations in our group of bladder cancers. The identity of 
all mutations was confirmed by DNA sequence analysis. Five samples from 
blood DNA were also sequenced as negative controls. No mutations were found 
in these samples. Figure 1 shows that the 5 detected mutations can easily be 
identified by SSCA. 
All 34 mutations were found in the 53 pTa bladder cancers (64%), 
whereas none of the 4 pT1 and 15 higher staged tumors had a mutation in the 
gene (Table 1A). Furthermore, all the tumors with a mutation in the FGFR3 gene 
were Grade 1 or 2. The mutation did not occur in 19 Grade 3 tumors (P<0.0001). 
The stages of these 19 G3 tumors were pTa in 3, pT1 in 1 and ≥pT2 in 15 cases, 
respectively. When we compared the patient’s history (median history of 5.4 
years, range 0.8-26.9 years) with histopathological and FGFR3 mutation status, 
we observed that patients with only a pTa history, had a mutation in 33/45 (73%) 
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cases. In patients whose history revealed at least 1 pT1 tumor, the FGFR3 
mutation occurred in only 1/12 (8%) tumors (P<0.0001, Table 1B). These results 
suggest that the FGFR3 mutations are linked with a disease course in which 
lower staged (i.e. pTa) tumors prevail. 
 
Figure 1 
 
PCR-SSCA of the FGFR3 gene. The figure shows examples of the FGFR3 gene mutations in our 
population. Paired lanes are normal blood DNA (N) and tumor DNA (T) from the same patient. 
Solid arrowheads indicate mutations leading to R248C (patient A), S249C (patient B), G372C 
(patient C), G372C (patient D) and A393E (patient E). In patient B, the same activating point 
mutation (S249C) was found in the original (T1) and the recurrent tumor (T2). In patient C, an 
additional silent mutation (G to T transition) at nucleotide position 1113, adjacent to codon 372, 
was observed. The codon and nucleotide numbering corresponds to the cDNA open reading 
frame of the FGFR3b isoform. This isoform is expressed in epithelium and contains two 
aminoacids more than the FGFR3c isoform expressed in bone. 
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Table 1A 
Relation between the tumor stage and the FGFR3 mutation status (n=72).  
 
FGFR3 mutation analysis  
Wild Type Mutation Pa 
pTa 19 34 
pT1 4 0 
Stage 
≥pT2 15 0 
Total  38 34 
<0.0001 
a P values were determined by two-sided Fisher’s exact test calculated for 3x2 tables. 
 
Table 1B 
Relation between the highest stage throughout patient’s history and the FGFR3 mutation status 
(n=72). 
 
FGFR3 mutation analysis  
Wild Type Mutation Pa 
Highest Stage Only pTa 12 33 
 ≥ once pT1 11 1 
 ≥ once pT2 15 0 
Total  38 34 
<0.0001 
a P values were determined by two-sided Fisher’s exact test calculated for 3x2 tables. 
 
To further investigate the link between FGFR3 mutations and stage, we 
performed a prospective follow-up analysis. Twelve months follow-up after 
mutation analysis revealed that bladder cancer recurrence was far more frequent 
in the group of patients whose initial tumors were wild type with respect to the 
FGFR3 gene (P=0.004, Table 2). It should be noted that only patients (n=57) 
diagnosed with superficial bladder cancer (i.e. pTa, pT1) at time of mutation 
analysis were included in this follow up analysis since patients with invasive 
tumors underwent cystectomy or radiotherapy. Moreover, in logistic regression 
analysis with the backward elimination method, using recurrence as dependent 
variable and tumor stage, grade, highest stage and FGFR3 mutation status as 
independent variables, the FGFR3 mutation status remained as the only 
significant (P=0.008) predictor of recurrence.  
 
Table 2 
Relation between disease recurrence within 12 months in superficial (i.e. pTa, pT1) bladder 
cancer patients and the FGFR3 mutation status (n=57). 
FGFR3 mutation analysis  
Wild Type Mutation Pa 
12 months follow-up Recurrence-free 9 27 
 Recurrence 14 7 
Total  23 34 
=0.004 
a P value was determined by two-sided Fisher’s exact test calculated for a 2x2 table. 
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We also determined the number of recurrent tumors per patient. In 14 of 
the 23 patients that were wild type for the FGFR3 gene, 24 TURs revealed 
recurrent bladder cancer during the 12 months of follow-up. In 17 of the removed 
tumors FGFR3 mutation analysis was performed. No mutations were found. Two 
patients, both with a wild type FGFR3 gene, already progressed to invasive (i.e. 
≥pT2) disease after 3 months. They were removed from subsequent 
cystoscopical follow-up. On the other hand, in 7 of the 34 patients with a mutation 
in their initial tumor, only 8 TURs revealed recurrent bladder cancer (pTaG1 6x 
and pTaG2 2x). All 8 analyzed tumors retained the FGFR3 mutation that was 
initially observed. Consequently, 24 of 86 (28%) cystoscopies were positive in 
the FGFR3 wild type group, resulting in a recurrence rate per year of 1.12. In the 
FGFR3 mutant group, only 8 of 136 (6%) cystoscopies were positive after 12 
months of follow-up, resulting in a recurrence rate per year of 0.24. The 
recurrence rate per year was calculated at the 3, 6, 9 and 12 month’s 
cystoscopical evaluation points (Figure 2). We also performed a subset analysis 
of primary and recurrent superficial tumors. The recurrence rates were higher 
shortly after TUR (3 months) for both patientgroups (Figure 2). The recurrence 
rates per year were similar if the patients were divided into cases with primary 
and recurrent cancers (results not shown). In addition, we observed a difference 
in mutation frequencies between primary and recurrent superficial tumors: where 
18/25 (72%) of primary superficial tumors had a mutation in the FGFR3 gene, 
this was only 16/32 (50%) for the recurrent tumors.  
 
Figure 2 
n=57
0,00
0,20
0,40
0,60
0,80
1,00
1,20
1,40
1,60
1,80
3 6 9 12
months of follow-up
re
cu
rre
nc
e 
ra
te
 / 
ye
ar
wt (n=23)
mt (n=34)
 
Recurrence rate of superficial bladder cancer for patients with wild type and mutant tumors. The 
recurrence rate per year was calculated at the 3, 6, 9 and 12 months cystoscopical evaluation 
points. After 12 months, 24 of 86 (28%) cystoscopies were positive in the FGFR3 wild type group. 
This was only 8 of 136 (6%) in the FGFR3 mutant group. wt = wild type FGFR3 gene; mt = 
mutated FGFR3 gene; n = number of patients who entered cystoscopical follow-up. 
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DISCUSSION 
Bladder cancer is a common type of cancer that has a high incidence, but, 
more importantly, requires major clinical attention after initial treatment. 
Nowadays patients are monitored intensively by cystoscopy for possible 
recurrence. Standard practice following TUR of bladder cancer is to screen 
patients with a cystoscopic examination every 3-4 months for 2 years and every 
6-12 months thereafter. Based on incidence numbers and recurrence rate1-4, it 
can be calculated that more than half a million cystoscopies per year are 
performed in the United States alone. 
Our results show that FGFR3 mutations occur in nearly 50% of bladder 
cancers. The mutations were exclusively observed in superficial tumors and 
absent from invasive carcinomas. Moreover, bladder cancer recurrence rates 
were dramatically lower for tumors with a mutant FGFR3 gene. We therefore 
conclude that the FGFR3 mutations identify a large cohort of bladder cancer 
patients with favorable disease characteristics. As a consequence, molecular 
FGFR3 mutation analysis represents a novel, technically simple and potentially 
powerful tool for adjustment of clinical management in bladder cancer. Nowadays, 
all patients undergo frequent cystoscopy to monitor their disease. Our results 
suggest that the frequency of this uncomfortable, invasive and expensive 
diagnostic procedure can be reduced considerably in patients with FGFR3 
positive tumors. 
We observed a difference in mutation frequencies between primary and 
recurrent superficial tumors in our study. It has been noted by others that patients 
who already have recurrent disease continue to develop recurrences more often 
than patients with a primary tumor.2,4 We suggest that this difference in mutation 
percentage is caused by the fact that patients who are cured after a single TUR, 
approximately 30%, do by definition not take part in the group of patients with 
recurrent disease. Combining these observations, we feel that it is likely that the 
group of patients with primary bladder cancer containing a FGFR3 mutation 
encompasses patients who will not develop a recurrence at all. Thus, the FGFR3 
mutation itself, being an indicator of superficial bladder cancer with a low 
recurrence rate, is at least part of the explanation of the differences between 
these groups. Capellen et al.10 were the first to report on somatic FGFR3 
mutations in bladder cancer. They found 9 mutations in 26 tumors. Three of the 9 
mutations occurred in invasive (i.e. ≥pT2) tumors. The stage distribution of the 
wild type tumors was not given in their study. In contrast, we found no mutations 
in invasive tumors. In addition, the correlation between the presence of a 
mutation and low stage was highly significant in our study. To ensure that no 
mutations were missed by contamination of benign cells in the invasive tumors, 
we also performed LOH analysis on these DNA samples. Multiple allelic losses 
were observed in 17/18 evaluable tumors (results not shown). These losses 
sustained that the DNA samples used for mutation and LOH analysis indeed 
contained mainly DNA derived from tumor cells. Thus, the apparent discrepancy 
FGFR3 mutation in bladder cancer 
 - 97 -
between our study and that of Capellen et al.10 remains difficult to explain. It may 
be due to the relatively small number of tumors examined by Capellen et al.10            
The finding that tumors with FGFR3 mutations are less likely to lead to 
recurrences can be explained by the hypothesis that such tumors shed cells with 
a lower frequency than those tumors that do not carry a FGFR3 mutation. In the 
7 patients with recurrence in the mutant FGFR3 group, 6/8 tumors occurred at 
the same region in the bladder and 6/8 recurrent lesions were single growths. In 
contrast, in most of the 14 patients who had recurrence in the non-mutant group, 
multiple tumors were found and these tumors occupied several different sites in 
the bladder. These preliminary data indeed suggest that superficial bladder 
tumors without a FGFR3 mutation shed cells more easily and/or that these cells 
are better equipped to reimplant into the bladder epithelium. In addition, it may be 
possible that the FGFR3 mutated tumors proliferate not as fast as the non-
mutated tumors. Further experiments are required to test these hypotheses. 
Molecular markers for bladder cancer may provide information to be used 
in clinical decision making. The incidence of TP53 gene mutations and an altered 
expression of the retinoblastoma gene product (RB) appeared to be much higher 
in invasive, high-grade bladder cancers than in superficial low-grade ones.14,15 
These reports suggest that these molecular markers are relatively late events in 
disease pathogenesis and identify tumors with aggressive biological behavior. 
The clinical value of these 2 tumor suppressor genes is of importance to patients 
presenting with invasive bladder cancer 15,16 and for prediction of progression in 
patients with high-grade superficial bladder cancer. Barton Grossman et al. 5 
advocated stratification of pT1 bladder cancer patients based on P53 and RB 
status. Their results suggest that patients with normal protein expression for both 
genes can be managed conservatively, whereas patients with alterations in one 
and particularly both genes require more aggressive treatment to prevent 
progression to invasive disease. In contrast, chromosome 9q deletions, 
determined by LOH analysis, are found with similar frequency in superficial and 
invasive bladder cancer17,18 and therefore can not be used for prognostic 
purposes. The FGFR3 gene is the first gene identified in bladder cancer to be 
mutated selectively in those cancers that are characterized by favorable clinical 
parameters. Future studies should determine whether a combination of TP53, RB 
and FGFR3 gene analyses could lead to a more accurate prediction of the 
disease course with regard to recurrence and progression. Furthermore, 
treatment strategies may also be determined based on these molecular markers. 
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ABSTRACT 
We recently identified activating mutations of fibroblast growth factor 
receptor 3 (FGFR3) in bladder carcinoma. In this study we assessed the 
incidence of FGFR3 mutations in a series of 132 bladder carcinomas: 20 
carcinoma in situ (CIS), 50 pTa, 19 pT1, and 43 pT2-4. All 48 mutations identified 
were identical to the germinal activating mutations that cause thanatophoric 
dysplasia, a lethal form of dwarfism. The S249C mutation, found in 33 of the 48 
mutated tumors (69%), was the most common. The frequency of mutations was 
higher in pTA Tumors (37 of 50, 74%) than in CIS (0 of 20, 0%; P<0.0001), pT1 
(4 of 19, 21%; P<0.0001) and pT2-4 tumors (7 of 43, 16%; P<0.0001). FGFR3 
mutations were detected in 27 of 32 (84%) G1, 16 of 29 (55%) G2, and 5 of 71 
(7%) G3 tumors. This association between FGFR3 mutations and low grade was 
highly significant (P<0.0001). FGFR3 is the first gene to be found to be mutated 
at a high frequency in pTa tumors. The absence of FGFR3 mutations in CIS and 
the low frequency of FGFR3 mutations in pT1 and pT2-4 tumors are consistent 
with the model of bladder tumor progression in which the most common 
precursor of pT1 and pT2-4 tumors is CIS. 
 
INTRODUCTION 
Bladder cancer is the fourth most common malignancy in men and the 
ninth most common in women in the Western world. In these countries, more 
than 90% of bladder tumors are urothelial carcinomas. At the time of initial 
diagnosis, approximately 80% of urothelial carcinomas are confined to the 
epithelium (pTa, CIS) or lamina propria (pT1), whereas the remaining 20% 
invade the muscularis propria (pT2, pT3, pT4). pTa lesions, the most common 
form of bladder carcinoma, are papillary tumors. Carcinoma in situ (CIS) are flat, 
cytologically high grade carcinomas. Primary isolated CIS is a very rare entity, 
CIS being more commonly associated with other malignant bladders lesions.1 
Clinical evidences and molecular studies suggest that there are two 
pathways in bladder carcinogenesis responsible for generating two types of 
urothelium-confined tumors (pTa and CIS) with very distinctive behavior.1-6 pTa 
tumors are associated with a high rate of recurrence (50-75%) but low probability  
(<5%) of progression to lamina propria-invasive (pT1) and muscle-invasive (pT2-
4) tumors. CIS may be the most common precursor to invasive bladder cancer 
because CIS shows a strong tendency to progress (40-50%), and because most 
muscle-invasive lesions arise with no history of a pTa precursor lesion. This 
clinical evidence is supported by various molecular studies showing that CIS and 
invasive tumors have many genetic alterations in common, such as specific 
chromosomal deletions and a high frequency of p53 mutations.2,7 
 In our search for new markers of carcinoma progression, we recently 
reported specific missense mutations in a gene encoding a growth factor 
receptor, fibroblast growth factor receptor 3 (FGFR3), in a series of 26 bladder 
and 12 cervical tumors.8 FGFR3 belongs to a family of structurally related 
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tyrosine kinase receptors encoded by four different genes (FGFR1-4). These 
receptors are glycoproteins composed of two or three extracellular 
immunoglobulin (Ig)-like domains, a hydrophobic transmembrane domain, and a 
cytoplasmic region that contains the tyrosine kinase domain. Binding to members 
of the fibroblast growth factor family induces FGFR dimerization, resulting in 
autophosphorylation of the kinase domain and interaction with and 
phosphorylation of effector signaling proteins. Alternative mRNA splicing 
mechanisms generate many different receptor isoforms.9 Isoforms FGFR3b and 
FGFR3c result from a mutually exclusive splicing event in which the second half 
of the juxtamembrane Ig-like domain of FGFR3 is encoded by either the 150 
nucleotides of exon 8 or the 144 nucleotides of exon 9.10 FGFR3b and FGFR3c 
have different tissue distributions; for example, FGFR3b is the main form in 
epithelial cells, whereas FGFR3c is the form found in chondrocytes.11 Specific 
point mutations in various domains of FGFR3 are associated with autosomal 
dominant human skeletal disorders such as hypochondroplasia, achondroplasia, 
severe achondroplasia with developmental delay and acanthosis nigricans 
(SADDAN) and thanatophoric dysplasia.12,13 Several reports have demonstrated 
that these mutations lead to constitutive activation of the receptor.12-14 The 
identification in multiple myeloma and, more recently, in bladder and cervical 
carcinomas of somatic mutations of FGFR3 identical to the activating mutations 
responsible for thanatophoric dysplasia and SADDAN 8,15-17 suggested that 
FGFR3 plays an oncogenic role for FGFR3. 
We investigated the involvement of FGFR3 in bladder carcinogenesis by 
assessing the incidence of FGFR3 mutations in a series of 132 bladder tumors of 
various stages and grades. The frequency of FGFR3 mutations (74%) in non-
invasive papillary pTa tumors shows that FGFR3 is a major oncogene in this, the 
most common form of bladder carcinoma. This high frequency of FGFR3 
mutations in pTa tumors contrasts with the absence of FGFR3 mutations in 
carcinoma in situ and the low percentage of mutations in pT1 and pT2-4 tumors. 
These data are consistent with the existence of two pathways of progression in 
bladder cancer. 
 
MATERIAL AND METHODS 
Tumor samples. Tumors were staged according to the TNM 
classification18 and graded according to criteria recommended by the World 
Health Organisation.19 All slides were reviewed by two pathologists (CB, MPB). 
For cases where lamina propria invasion was unclear, we performed 
immunohistochemical analysis with an anti-cytokeratin antibody. The bladder 
tumor series consisted of 20 carcinoma in situ (CIS), 50 pTa, 19 pT1, 14 pT2, 20 
pT3 and 9 pT4 tumors; 32 were grade G1, 29 grade G2, and 71 grade G3. The 
series of 112 pTa and pT1-pT4 tumors were obtained from 112 patients. The 20 
CIS were obtained from an additional 17 patients. Nine CIS occurred as isolated 
lesions; eleven were associated with pTa or pT1-T4 tumors. All of the pTa and 
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pT1-pT4 tumors and 10 of the CIS were obtained from patients diagnosed at the 
Henri Mondor Hospital (Créteil, France).The 10 remaining CIS were obtained 
from patients diagnosed at the Rotterdam University hospital (Rotterdam, The 
Netherlands. DNA from pTa and pT1-pT4 tumors was extracted from samples 
frozen immediately in liquid nitrogen as previously described20 or from formalin- 
fixed, paraffin-embedded tissue, using the tissue DNA extraction kit from Qiagen 
(Courtaboeuf, France). All samples retained for this analysis contained more than 
80% tumors cells, as assessed by histological examination. For CIS, tumor cells 
were isolated from paraffin-embedded sections by laser-assisted microdissection, 
using the PALM Laser-Microbeam System (PALM, Wolfratshaussen, Germany) 
and DNA was extracted using the Qiagen kit. Normal DNA samples from 
peripheral blood were available from 45 patients. 
FGFR3 mutation analysis. Mutations were screened by single-strand 
conformation polymorphism (SSCP) in four regions of the FGFR3 gene, located 
in exons 7, 10, 15 and 19. These four regions contain the FGFR3 point mutations 
previously identified in thanatophoric dysplasia, SADDAN, achondroplasia, 
Crouzon syndrome with acanthosis nigricans, multiple myeloma and bladder and 
cervical carcinomas.8,12,13 
For most of the samples (all pTa and pT1-pT4 tumors and 16 CIS), a 
single round of PCR was carried out, using the following primer pairs: exon 7,  
5'-AGTGGCGGTGGTGGTGAGGGAG-3' and 5'-TGTGCGTCACTGTACACCTT-
GCAG-3'; exon 10, 5'-CAACGCCCATGTCTTTGCAG-3' and 5'-CGGGAAGCG-
GGAGATCTTG-3'; exon 15, 5'-GACCGAGGACAACGTGATG-3' and 5'-GTGTG-
GGAAGGCGGTGTTG-3'; exon 19, 5'-TGTCGGCGCCTTTCGAGCAGTA-3' and 
5'-AGCAGCAGGGTGGGCTGCTA-3'. PCR was performed in a final volume of 
50µl  containing 50 ng genomic DNA or 1/20th of the purified DNA from 
microdissected samples, 100 µmol/L each of dATP, dCTP, dTTP and dGTP, 1 
µmol/L forward and reverse primers, 1X of amplification buffer provided with the 
polymerase, 1 µCi [α33P]dATP. The Taq polymerase (1 U; Finnzymes Oy, 
Espoo, Finland) was added after heating the reaction mixture for 5 min at 95°C. 
The mixture was then subjected to 35 cycles of 94°C for 1 minute, 60°C for 1 
minute and 72°C for 1 minute, 20 seconds. 
A two stage seminested PCR was used to amplify DNA from 4 CIS that 
gave a weak signal in single-round PCR. For the first round of the seminested 
PCR we used the following PCR primers: exon 7, 5'-AGTGGCGGTGGTGGT-
GAG-GGAG-3' and 5'-TGTGCGTCACTGTACACCTT-3'; exon 10, 5'-GCCAGGC-
CAGGCCTCAAC-3' and 5'-CTTGAGCGGGAAGCGGGAGATCTTG-3'; exon 15, 
5'-TGGTGACCGAGGACAACGTGATG-3' and 5'-CTCTGGTGAGTGTAGACT-
CG-3'. For The second round of the seminested we used the following PCR 
primers: for exon 7, 5'-AGTGGCGGTGGTGGTGAGGGAG-3' and 5'-TGTGCGT-
CACTGTACACCTTGCAG-3'; exon 10 5'-CCTCAACGCCCATGTCTTTTCAGC-3' 
and 5'-CTTGACGGGAAGCGGGAGATCTTG-3'; exon 15, 5'-TGGTGACCGAGG-
ACAACGTGATG-3' and 5'-AGGGTGTGGGAAGGCGGTGTTG-3'. First round 
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PCR conditions were the same as for single-round PCR, except that no 
radioactive isotope was included in the reaction and only 15 cycles were 
performed. The first-round product (1 µl) was subjected to a second round of 
PCR comprising of 35 cycles with conditions identical to those for single-round 
PCR except that the annealing temperature was 68°C. 
Aliquots of the labeled PCR products were subjected to electrophoresis in 
non-denaturing (MDE)/8.5% glycerol gels at room temperature for 13 hours. 
Samples displaying a mobility shift in SSCP-analysis were further analyzed by 
direct bidirectional DNA sequencing. The PCR products were sequenced using 
the following primers: exon 7, 5'-AGTGGCGGTGGTGGTGAGGGAG-3' and 5'-
CAGCACCGCCGTCTGGTTGG-3'; exon 10, 5'-CAACGCCCATGTCTTTGCAG-
3' and 5'-GAGCCCAGGCCTTTCTTGG-3'; exon 15, 5'-AGGACAACGTGATG-
AAG-ATCG-3' and 5'-GTGTGGGAAGGCGGTGTTG-3'; exon 19, 5'-TGTCGGC-
GCCTTTCGAGCAGTA-3'  and 5'-TGCTAGGGACCCCTCACATT-3'. Matched 
normal DNA, if available, was sequenced on both strands to demonstrate the 
somatic nature of these mutations.  
 
RESULTS 
Identification of FGFR3 point mutations. We used SSCP and 
sequencing to analyze the regions of FGFR3 harboring the point mutations found 
in multiple myelomas and in skeletal disorders, in a series of 132 bladder 
carcinoma samples. We detected 5 different single-nucleotide substitutions in 48 
of 132 bladder carcinomas (Table I).  
 
Table 1 
Point mutations of the FGFR3 gene in bladder carcinomas 
 
Codon Nt position Exon Mutation Predicted 
effect 
Number of 
tumors 
248 742 7 CGC Æ TGC Arg Æ Cys 8 
249 746 7 TCC Æ TGC Ser Æ Cys 33 
372 (370) 1114 10 GGC Æ TGC Gly Æ Cys 3 
375 (373) 1124 10 TAT Æ TGT Tyr Æ Cys 2 
652 (650) 1954 15 AAG Æ GAG Lys Æ Glu 2 
Codon and mutated nucleotide (nt position) are numbered according to cDNA open reading frame 
corresponding to the FGFR3b isoform. This isoform is produced in epithelial cells and contains 
two more amino-acids than the FGFR3c isoform present in bones. The codon number according 
to FGFR3c cDNA open reading frame is indicated in parentheses. 
 
These mutations affected codons 248, 249, 372, 375, 652 (FGFR3b isoform 
numbering). Four of these 5 mutations were located in the extracellular domain 
(codons 248 and 249) or transmembrane domain (codons 372 and 375), with the 
mutated codon encoding a cysteine residue in each case. The fifth mutation, 
located in the kinase domain (codon 652), resulted in the replacement of a 
positively charged residue by a negatively charged residue. The S249C mutation 
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was the most frequent and was found in 33 of the 48 mutated tumors (69%). The 
Y375C mutation is reported here for the first time in bladder tumors. All 5 
mutations identified in bladder carcinomas were identical to the germinal 
activating mutations responsible for thanatophoric dysplasia, a lethal form of 
dwarfism. As expected, matched constitutional DNA, available in 15 cases with 
mutations, contained wild type sequences demonstrating the somatic nature of 
these mutations. 
Relationship between FGFR3 mutation status, tumor stage and 
histological grade. We assessed frequency of FGFR3 mutations in the two 
types of non invasive bladder cancer  (CIS and pTa tumors), in lamina propria-
invasive (pT1) and muscle-invasive (pT2-4) tumors. The distribution of FGFR3 
mutations as a function of stage is shown on Figure 1 (leftside).  
 
Figure 1  
 
 
 
 
 
 
 
 
 
 
 
 
                             
 
 
        
FGFR3 mutations in relation to stage or grade 
Left: Percentage of FGFR3 mutations in carcinoma in situ, pTa, pT1 and pT2-4 tumors. 
Right: Percentage of mutations as a funtion of tumor grade. 
 
FGFR3 mutations were observed in 37 of 50 pTa tumors (74%), whereas no 
mutation was detected in the 20 CIS examined. This difference in mutation 
frequency between these two groups of tumors was highly significant (P<0.0001; 
two-sided P, Fisher's exact test). FGFR3 mutations were detected in 4 of 19 
(21%) pT1 tumors and in 7 of 43 (16%) pT2-4 tumors. This difference in mutation 
frequency of FGFR3 mutations between pTa and pT1 tumors was highly 
significant (P<0.0001). The difference in frequency of FGFR3 mutations between 
CIS and pT1 was at the limit of significance (P=0.05). In contrast, there was 
clearly no difference in the frequency of FGFR3 mutations between pT1 and pT2-
4 tumors (P=0.7). 
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The distribution of FGFR3 mutations according to histological grade is 
shown in Figure 1 (rightside). FGFR3 mutations were detected in 27 of 32 (84%) 
G1 tumors, 16 of 29 (55%) G2 tumors but in only 5 of 71 (7%) G3 tumors. This 
association between FGFR3 mutations and low grade was highly significant 
(P<0.0001; two-sided P, Chi-squared test). Table 2 shows the distribution of 
FGFR3 mutations as a function of grade for the three groups of tumors classified 
according to stage (pTa, pT1 and ≥pT2 tumors). A highly significant correlation 
was found between FGFR3 mutations and low grade (G1+G2 versus G3) within 
the pTa tumor group (P=0.009; two-sided P, Fisher’s exact test) and within the 
≥pT2 tumor group (P=0.02; two-sided P, Fisher's exact test).The correlation 
between FGFR3 mutations and low grade was not significant for pT1 tumors, 
probably due to the small number of samples in this group. 
 
Table 2 
FGFR3 mutations in relation to grade in pTa, pT1 and pT2-4 tumors 
 
Stage Grade FGFR3 wild-type FGFR3 mutant P-value* 
 G1 5 27 (84%)  
pTa G2 4 9 (69%) 0.013 
 G3 4 1 (20%)  
 G1 0 0  
pT1 G2 1 2 (67%) 0.097 
 G3 14 2 (12.5%)  
 G1 0 0  
≥pT2 G2 8 5 (38%) 0.019 
 G3 28 2 (7%)  
For each grade, the percentage of tumors with mutations in FGFR3 is indicated. 
* Comparison G1+G2 versus G3, two-sided P, Fisher’s exact test. 
** According to the consensus classification of 1998,21 the pTaG1 + pTaG2 group of tumors 
corresponds to papillary neoplasms of low malignant potential + low-grade papillary carcinomas, 
wheras pTaG3 tumors correspond to high-grade pailllary carcinomas. 
 
DISCUSSION 
Germinal point mutations resulting in FGFR3 activation are responsible for 
dwarfism syndromes. Surprisingly, similar FGFR3 mutations have also been 
implicated in tumorigenesis. Somatic FGFR3 mutations identical to those found 
in thanatophoric dysplasia (neonatal lethal dwarfism syndrome) and SADDAN 
(severe achondroplasia with developmental delay and acanthosis nigricans) have 
been associated with rare cases of human multiple myeloma.12,13 We recently 
identified, in a series of 26 bladder and 12 cervix carcinomas, several FGFR3- 
activating mutations previously identified as associated with thanatophoric 
dysplasia.8 To investigate futher the role of of FGFR3 mutations in bladder 
carcinogenesis, we assessed the incidence of FGFR3 mutations in a large series 
of 132 bladder tumors of various stages and grades. 
The high frequency of mutations that we found (48 of 132) confirmed that 
FGFR3 mutations are a frequent event in bladder carcinomas. Five different 
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mutations were identified, four of which (R248C, S249C, G372C, K652E) were 
detected in our previous series: the remaining mutation (Y375C) was identified 
for the first time in this series. This fifth mutation is also known to be involved in 
thanatophoric dysplasia. The S249C mutation (TCC Æ TGC) is the most frequent 
FGFR3 mutation in bladder tumors (33 of 48, 69%). In contrast, this mutation 
was found in only 7 of 62 (11.5%) thanatophoric dysplasia cases, the most 
common mutation in this syndrome being R248C (CGC Æ TGC) (26 of 62; 42%;  
J. Bonaventure, unpublished data). This probably reflects differences in etiology:  
many FGFR3 mutations in bladder cancer could be caused by carcinogens 
whereas the germinal mutations in thanatophoric dysplasia are spontaneous 
mutations that preferentially create C-to-T transition of CG dinucleotide. 
We investigated the relationship between FGFR3 mutations and tumor 
stage and found that the frequency of FGFR3 mutations was very high in pTa 
tumors (74%). FGFR3 mutations were present in only 21% of pT1 and 16% of 
pT2-4 tumors. No mutations were found in the 20 CIS examined. We performed 
laser microdissection on all of the CIS samples to exclude the possibility of 
contamination by normal DNA. FGFR3 is therefore the first gene found to be 
preferentially mutated in pTa tumors. Unlike FGFR3 mutations, loss of 
chromosome 9, the only other frequent genetic alteration found in pTa tumors, is  
also common in invasive tumors. FGFR3 mutations were also strongly 
associated with low grade. No mutations were found in CIS, which were all grade 
3 lesions. The percentage of FGFR3 mutations in non-CIS G3 tumors was low in 
all stages examined, including Ta and T1 tumors. 
Clinical evidence and molecular studies have suggested that there are two 
different pathways of bladder carcinogenesis, generating two different non-
invasive bladder tumors: CIS, which often progress to pT1 and pT2-4 tumors, 
and pTa, which rarely progress. The highly significant difference in the frequency 
of FGFR3 mutations between pTa tumors and CIS (P<0.0001) provides 
additional evidence that these two noninvasive bladder cancers are different 
entities. Few studies have carried out a genetic analysis of CIS.2,7 These studies 
have shown that CIS and invasive tumors have many genetic alterations in 
common, such as a high frequency of p53 mutations and specifical chromosomal 
losses not found in pTa tumors. The high frequency of FGFR3 mutations in pTa 
tumors, their absence in CIS and their low frequency in pT1 and pT2-4 tumors 
are consistent with the model of bladder tumor progression in which the most 
common precursor of invasive tumors is CIS (CIS Æ pT1 Æ pT2-4) and not pTa 
tumors.1-6 The mutated invasive tumors may arise from mutated pTa tumors that 
progress or from CIS that acquire FGFR3 mutation during progression to 
invasive tumors. There is also a third possibility that cannot be excluded: some 
mutated CIS may be the precursors of some mutated pT1 lesions. Studies on 
larger series and further detailed analyses of the genetic profiles (chromosomal 
losses and amplifications and P53 mutations) of recurrent tumors from patients 
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with progressive disease may help to distinguish between these three 
possibilities.  
Somatic FGFR3 mutations are probably tumor-specific, as no FGFR3 
mutations were found in 9 random urethelial biopsy samples of normal 
appearance from 9 patients known to have a FGFR3 mutation in their papillary 
lesions (data not shown). The high frequency of FGFR3 mutations in pTa tumors 
indicates that FGFR3 activation is a key event in the development of these 
tumors. It would be interesting to analyze other molecules of the FGFR3 pathway 
such as FGFR3 ligands or downstream signaling molecules, in pTa tumors 
without mutations in FGFR3. 
pTa tumors are the most common type of primary bladder tumor. These 
tumors rarely progress but recur in more than 50% of cases. Because most of 
these tumors carry FGFR3 mutation, the detection of such mutations in urine 
may provide an accurate additional means of follow-up and identification of tumor 
recurrences. This could be especially useful for low grade lesions, which are 
difficult to detect by urine cytology and which harbor FGFR3 mutations in more 
than 80% of cases. 
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ABSTRACT 
Fibroblast growth factor receptor 3 (FGFR3) mutations were recently 
found at a high frequency in well-differentiated urothelial cell carcinoma (UCC). 
We investigated the relationship between FGFR3 status and three molecular 
markers (MIB-1, P53 and P27kip1) associated with worse prognosis and 
determined the reproducibility of pathological grade and molecular variables. In 
this multi-center study, we included 286 patients with primary (first diagnosis) 
UCC. The histological slides were reviewed. FGFR3 status was examined by 
PCR-SSCP and sequencing. Expression levels of MIB-1, P53 and P27kip1 were 
determined by immuno-histochemistry. Mean follow-up was 5.5 years (range, 
0.4–18.4 years). FGFR3 mutations were detected in 172/286 (60%) of UCCs. 
G1-tumors had a FGFR3 mutation in 88% of cases, G3-tumors in 16%. 
Conversely, aberrant expression patterns of MIB-1, P53 and P27kip1 were seen in 
5%, 2% and 3% of G1-tumors and in 85%, 60% and 56% of G3-tumors, 
respectively. In multivariate analysis with recurrence rate, progression and 
disease specific survival as endpoints, the combination of FGFR3 and MIB-1 
proved of independent significance in all 3 cases. Using these 2 molecular 
markers, three molecular grades (mG) could be identified: mG1 (mutation; 
normal expression), favorable prognosis; mG2 (two remaining combinations), 
intermediate prognosis; mG3 (no mutation; high expression), poor prognosis. 
The molecular variables were more reproducible than pathological grade (85–
100% vs. 47–61%). The FGFR3 mutation represents the favorable molecular 
pathway of UCC. Molecular grading provides a new, simple and highly 
reproducible tool for clinical decision making in UCC patients.  
 
INTRODUCTION 
Urothelial cell carcinoma (UCC) of the urinary bladder is a serious health 
problem. Over 260.000 cases are diagnosed worldwide each year, accounting for 
3.2% of all new cancer cases.1 For 2001, 54.000 new cases and 12.000 deaths 
predicted for the USA make UCC the 5th most common cancer and the 9th 
leading cause of cancer death.2 The patients can be divided into two groups for 
clinical management depending on the pathological stage. In most patients, UCC 
is superficial (i.e. pTa-pT1) at first presentation. After trans-urethral resection, 
these patients are intensively monitored by cystoscopy since up to 70% 
experiences one or more recurrences and 10-15% will progress to invasive, 
potentially lethal UCC.3-5 Patients with intermediate or high risk superficial UCC 
usually receive adjuvant intravesical instillations with, in most cases, bacillus 
Calmette Guérin (BCG).6,7 Cystectomy, radiation- or systemic chemotherapy are 
the preferred treatment options in case of invasive (i.e. ≥pT2) disease depending 
on presence of metastasis and patients co-morbidity and life expectation.  
Clinical and pathological variables for prediction of patient’s prognosis 
have been studied extensively.3,5,8 Although variability in pathological 
assessment is a recognized problem,9,10 it still is one of the best predictors of 
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prognosis. Research efforts of the last decades resulted in a long list of 
molecular investigations for a possible better assessment of UCC prognosis. 
Oncogenes, tumor suppressor genes & associated cell cycle proteins, 
proliferation antigens, growth factors, cell adhesion molecules and chromosomal 
alterations have been identified in UCC.11-21 Of these, the P53 gene is the most 
investigated molecular marker.12 Some molecular markers hold considerable 
promise to assess aggressive UCC behavior (examples: P53, RB, P27kip1, P21, 
Ki-67/MIB-1, E-Cadherin). Only few studies have analyzed the performance of 
multiple molecular markers. Analogous to clinical and pathological indices, 
combinations lead to a more tailored prediction of prognosis.3,8,11,16,18 
Nevertheless, the value of molecular markers over clinico-pathological indices is 
still being questioned and their clinical use limited.12-15 
Point mutations in the human FGFR3 gene are well documented in 
inherited skeletal anomalies associated with dwarfism in most cases, such as 
achondroplasia and thanatophoric dysplasia.22-24 In addition, an oncogenic role 
has been proposed for mutant FGFR3.25,26 Recently, FGFR3 mutations were 
found in over 40% of UCC cases27-29 whereas a low frequency was observed in 
multiple myeloma30 and cervical carcinoma31. Surprisingly, FGFR3 mutations in 
UCC were related to favorable disease with 84% of pTaG1 tumors having a 
mutation as compared to 7% of ≥pT2G3 tumors.29 Moreover, in a prospective 
study with a 1-year follow up, we showed that FGFR3 mutations were associated 
with a low recurrence rate of superficial UCC.28 However, so far, nothing is 
known on the FGFR3 mutation in relation to long term clinical follow up or other 
molecular markers. 
Based on these initial observations, we designed this multi-center study to 
compare the relationship between three immuno-histochemical markers 
associated with worse UCC prognosis i.e. the proliferation marker MIB-1, P53 
nuclear overexpression and reduced expression of the cell cycle inhibitor P27kip1 
and the FGFR3 mutation in a large patient group. In addition, we investigated the 
reproducibility of pathological grading and molecular variables in the same series. 
 
PATIENTS AND METHODS 
Patients. This study consists of 286 patients with papillary UCC. They 
were between 23 and 90 years old (mean, 65.7±12.0 years). None of them had a 
hereditary skeletal disorder documented. The patient and tumor characteristics at 
first diagnosis are reported in Table1.32-34 Of the 286 patients, 246 (86%) had 
superficial (i.e. pTa, pT1) UCC. The patients were seen at the Urology 
departments of the University Hospital Rotterdam (N=139), the Sint Franciscus 
Gasthuis (N=121) or at one of 3 Urology departments in the Rotterdam 
surroundings (N=26). A paraffin-embedded, formalin fixed tissue block was 
obtained. These were freshly cut into 4 µm thick sections and mounted on amino 
alkylsilane (AAS)-coated glass slides for immuno-histochemistry. Standard H&E 
slides were made from the last cut section. These slides were reviewed by a 
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specialized genitourinary pathologist (TvdK) with the criteria of the 1998 
WHO/ISUP classification system.34 Furthermore, two additional pathologists with 
a special interest in uro-pathology (AJ, EO) graded 210 slides for reproducibility 
purposes. 
 
Table 1 
The patient and tumor characteristics of the 286 studied cases. 
 
Variable Patients 
 No. % 
Female 69 24 sex 
Male 217 76 
Solitary 212 74 Multiplicity 
 Multiple 74 26 
Upper UT 21 7.5 Site 
 Lower UT 265 92.5 
Bladder neck 13 4.5 
Anterior wall 14 5.0 
Dome 10 3.5 
Posterior wall 23 8.0 
Trigone/ostia 37 13 
Left lateral wall 44 15 
Right lateral wall 46 16 
Ureter 7 2.5 
Pyelum 14 5.0 
Multiple 65 23 
Localization 
 
Unknown 13 4.5 
< 1 cm 33 11 
1-3 cm 122 43 
3-5 cm 66 23 
Tumor size 
(diameter) 
> 5 cm 65 23 
pTa 183 64 
pT1 63 22 
pT2 32 11 
pT3 6 2.0 
Stage (TNM ’97)+ 
pT4 2 1.0 
G1 93 32 
G2 125 44 
Grade (WHO ’73)* 
G3 68 24 
PUN-LMP 84 29 
LG-PUC 94 33 
Grade (WHO/ 
ISUP ’98)^ 
 HG-PUC 108 38 
Yes 19 6.5 Associated CIS 
No 267 93.5 
Total 286 100 
+Stage (TNM ’97): according to TNM 1997 guidelines.32 *Grade (WHO ’73): Routine 
morphological grading according to the 1973 WHO classification system.33 ^Grade 
(WHO/ISUP ’98): Reviewed morphological grading by one pathologist according to the 1998 
WHO/ISUP classification system.34  
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Abbreviations: No Pts, number of patients; UT, urinary tract; PUN-LMP, papillary urothelial 
neoplasia of low malignant potential; LG-PUC, low grade – papillary urothelial carcinoma; HG-
PUC, high grade – papillary urothelial carcinoma; CIS, carcinoma in situ.    
Fifty UCCs from the archive served as a teaching set to agree upon grading 
parameters.34 In case of multifocality, the papillary lesion with the highest 
grade/stage was taken. The largest tumor was taken if grade/stage were the 
same for multiple UCCs. 
Follow up. Clinical information and follow up data were collected by chart 
review. Disease specific survival was determined for all patients. For patients 
with primary superficial UCC, recurrence, recurrence rate and progression were 
additional endpoints. Recurrence rate was defined as the number of histologically 
proven recurrences divided by years of follow up. Hence, the recurrence rate 
takes into account the clinical course of patients during a longer interval and not 
only covers the time to first recurrence. Progression was defined as development 
of invasive (i.e. ≥pT2) UCC. Mean follow up was 5.5 years (range, 0.4-18.4 years) 
for all patients and 5.9 years (range, 0.8-18.4 years) for the patients with 
superficial UCC. After superficial UCC, 153 (62%) patients experienced one or 
more recurrence(s). Median time to first recurrence was 1.0 years (range, 0.2-9.7 
years). An upper-tract (ureter, renal pelvis) recurrence was found in 15 (5.2%) 
patients. Sixty patients had a recurrence rate of more than 0.50 per year. 
Progression was found in 28 (11.4%) patients. Median time to progression was 
3.1 years (range, 0.3-14.3 years). Twenty-six (9.1%) patients died of UCC. 
Fifteen of these were initially diagnosed with superficial UCC. Median time to 
decease was 3.8 years (range, 0.4-14.2 years). During follow up, 160 patients 
received intravesical treatment involving BCG in 101 cases. A cystectomy was 
performed in 22 patients. Eleven of these were performed after progressive 
disease. Twenty-nine patients of whom 22 with curative intent were treated by 
radiotherapy and 14 patients received systemic chemotherapy for metastatic 
UCC. The patients were censored at their last visit to the Urology department or 
at the date of their decease. 
Immuno-histochemistry. All cases were routinely processed with 3 
monoclonal antibodies by the immuno-histochemical laboratory of the University 
Hospital Rotterdam as described.35 The incubation with the primary antibody P53 
(clone DO-7, DAKO, Denmark) took 30 minutes at an optimal dilution of 1:200 in 
PBS/BSA 5% or overnight at 4°C with p27kip1 (clone 1B4, Novocastra, Newcastle, 
UK) at 1:40. The murine antibody MIB-1 (Immunotech, Marseille, France) against 
the Ki-67 antigen was incubated for 30 minutes at 1:200. Positive and negative 
controls were always included. The conventional avidin-biotin complex method 
was applied for all immuno-stainings as described.35 Two medical researchers 
(BvR, AV) independently assessed the slides without knowledge of clinical data. 
The slides were scored in a semi-quantitative manner, estimating the percentage 
of tumor cells that show positive nuclear staining. It is assumed that aberrant 
expression of MIB-1, P53 and P27kip1 are associated with worse patient 
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prognosis. Therefore, in case of heterogeneity, the parts within the tumor that 
showed highest (MIB-1, P53) or lowest (P27kip1) positive to total ratio were 
particularly assessed. This was performed if these regions comprised at least 
10% of the tumor load in the examined tissue section. Cutoff levels were defined 
at 25% (MIB-1), 10% (P53) and 50% (P27kip1) using a teaching set of 40 UCCs 
collected from a previous study28. In case of discrepancy between the observers, 
the slides were reassessed in a combined session without the information of the 
previous scores. 
FGFR3-mutation analysis. The H&E slides made from the last cut 
section were used as templates for the microdissection procedure. A 
representative area of the tumor was dissected avoiding contamination with 
stroma, normal mucosa or leukocytes. The samples used for FGFR3 mutation 
analysis contained a minimum of 70% tumor cells, as assessed by histological 
examination. The DNA was extracted using the DNeasy Tissue kit (Qiagen 
GmbH, Hilden, Germany). The FGFR3 mutation analysis was performed by 
polymerase chain reaction (PCR) - single strand conformation polymorphism 
(SSCP) analysis as described.26,28,29 In brief, four regions encompassing all 
activating FGFR3 mutations previously described in severe skeletal dysplasias 
and cancers were amplified. The primer-sequences were as reported.29 The 32P-
labeled PCR-products were separated on 6% polyacrylamide gels in 0.2x (exon 7) 
or 1x SSCP-buffer (exons 10, 15 & 19) (10x SSCP-buffer = 0.5M Tris-borate, 
1mM EDTA). Samples with a shift were sequenced with T7 Sequenase v2.0 
(Amersham life Science, Inc., Cleveland, OH). In addition, DNA extracted from 
venous blood for control purposes was available from 75 patients who attended 
the Urology department of the University Hospital Rotterdam. Five of these 
samples were used as negative controls for sequencing. When we detected a 
new FGFR3 mutation in UCC and no blood-DNA was available, DNA of paraffin-
embedded, non-malignant tissue of the same patient was isolated and processed 
as described above to examine whether the mutation was somatic. These 
laboratory analyses were performed without knowledge of clinical data. To test 
the reproducibility of the FGFR3 mutation analysis, eighty-one DNA samples 
were analyzed in two institutes (Josephine Nefkens Inst., Rotterdam and Inst. 
Curie, Paris). 
Statistical analysis. The statistical package for social sciences 9.0 
(SPSS Inc., Chicago, IL) computer software was used for the data 
documentation and analysis. Clinical and pathological variables were combined 
in the Clinico-pathological index constituted of 4 adverse tumor characteristics in 
primary superficial UCC.8 The significance of single and combinations of 
variables with regard to follow up was analyzed by applying the Kaplan-Meier 
method. ANOVA (for comparison of means) was used for comparison of 
recurrence rate. Two-sided Fisher’s exact test was applied for the relation of 
FGFR3 mutations in papillary UCC and associated carcinoma in situ (CIS). 
Multivariate Cox regression analysis was used to find independent prognostic 
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factors. The odds ratios and their 95% confidence intervals were calculated for 
the significant predictors in the multivariate analyses. Statistical significance was 
assumed if P<0.05. 
 
RESULTS 
We studied the performance of four molecular markers in a series of 286 
primary UCC. 
FGFR3 mutations. We detected activating FGFR3 mutations in 172 (60%) 
of the 286 tumors. In the 246 superficial UCCs, 164 (67%) tumors had a mutation 
in the FGFR3 gene. Examples of these mutations determined by PCR-SSCP and 
sequencing are shown in Figure 1.  
 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FGFR3 mutations. PCR-SSCP: Arrowheads indicate aberrant bands with the mutations R248C 
(A), S249C (B), G372C (C) and Y375C (D). Sequencing: The C to A transition at codon 393 
results in A393E and the A to C transition at codon 652 results in K652T. The mutations are 
absent in normal DNA. Abbreviations: N, normal DNA; T, tumor (UCC) DNA. 
 
The mutations were found in 6 different codons (Table 2). In 3 cases, two 
concurrent mutations were found in one tumor. S249C accounted for 120 (69%) 
 
PCR-SSCP 
 
Sequencing
Exon 7 Exon 10 
A C G TCodon
393 
392 
391 
394 
N
A C G T
T
G A T C G A T CCodon
652
651
650
653
N T
A   B C   D 
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of the 175 mutations. We found no difference between S249C and other FGFR3 
mutations in relation to clinical data (not shown). No activating FGFR3 mutations 
were found in 75 matched normal (blood) DNA samples nor in normal tissue 
confirming the somatic nature of FGFR3 mutations in UCC. 
 
Table 2 
Somatic mutations of the FGFR3 gene in the studied population.  
The codon and nucleotide (nt) numbering refers to the open reading frame of the FGFR3b 
isoform that is expressed in epithelial cells.26 Three cases showed two concurrent FGFR3 
mutations in one tumor. No activating FGFR3 mutations were found in exon 19.  
 
 
Exon(s) 
Activating FGFR3 mutations  
Mutation, predicted effect 
Number of 
tumors 
7 nt742 C→T, R248C 12 
7 nt742 ins GCT, R248RC 1 
7/7 nt742 C→T, R248C and nt746 C→G, S249C 1 
7 nt746 C→G, S249C 117 
7/10 nt746 C→G, S249C and nt1114 G→T, G372C 1 
7/10 nt746 C→G, S249C and nt1178 C→A, A393E 1 
10 nt1114 G→T, G372C 7 
10 nt1124 A→G, Y375C 25 
10 nt1178 C→A, A393E 3 
15 nt1954 A→G, K652E 1 
15 nt1955 A→C, K652T 1 
15 nt1955 A→T, K652M 2 
 
Molecular markers and histo-pathology. Examples of normal and 
aberrant expression of the 3 immuno-histochemical markers are shown in Figure 
2. Table 3 shows the correlation of the molecular markers and histo-pathological 
data. The highest percentage (88%) of FGFR3 mutations was seen in G1-tumors, 
the lowest percentage (16%) in G3-tumors. Conversely, aberrant expression 
patterns of MIB-1, P53 and P27kip1 were seen in 5%, 2% and 3% of G1-tumors 
and in 85%, 60% and 56% of G3-tumors, respectively. Therefore, the FGFR3 
mutation is generally associated with a favorable histo-pathological diagnosis, 
whereas aberrant expression of MIB-1, P53 and P27kip1 point to unfavorable 
disease. When we compared the performance of the molecular markers in the 22 
patients who underwent cystectomy, we retrospectively observed aberrant MIB-1 
expression in all 22 patients whereas a FGFR3 mutation was only observed in 3 
of these patients. Combining two UCC related molecular features, i.e. FGFR3 
mutation and high MIB-1 expression, we could define 249 (87%) tumors. This 
combination defined the highest percentage of UCC.  
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Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immuno-histochemical staining showing normal (A, C, E) and aberrant (B, D, F) protein 
expression levels. The molecular markers used in this study are the proliferation marker MIB-1 (A, 
B), P53 (C, D) and the cell cycle inhibitor P27kip1 (E, F). Example F shows that stromal cells may 
serve as internal control for P27kip1 staining.   
A 
C 
E F
D
B
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Table 3 
Comparison of the four molecular markers and histo-pathology.  
For each molecular marker, its relation to Grade in pTa, pT1 and invasive (≥pT2) urothelial cell 
carcinoma is shown. The % of positive, UCC-related molecular features (FGFR3 mutation, MIB-
1>25%, P53>10% and P27kip1<50%) are given for each histo-pathological category between 
parentheses. The WHO 1973 classification system33 was used as it allows a better comparison 
with previous studies and because we observed no substantial difference for the two 
morphological grading systems33,34 concerning the molecular features in this series. 
 
FGFR3 gene MIB-1 expr. P53 expr. P27kip1 expr.  
wt mt 
(%) 
≤25
% 
>25% 
(%) 
≤10
% 
>10% 
(%) 
≥50
% 
<50% 
(%) 
 
Total 
G1 11 81 
(88) 
87 5 
(5) 
90 2 
(2) 
89 3 
(3) 
92 
G2 24 59 
(71) 
62 21 
(25) 
68 15 
(18) 
75 8 
(10) 
83 
pTa 
G3 7 1 
(13) 
0 8 
(100) 
2 6 
(75) 
5 3 
(38) 
8 
G1 0 1 
(100) 
1 0 
(0) 
1 0 
(0) 
1 0 
(0) 
1 
G2 18 17 
(49) 
16 19 
(54) 
21 14 
(40) 
27 8 
(23) 
35 
pT1 
G3 22 5 
(19) 
7 20 
(74) 
11 16 
(59) 
17 10 
(37) 
27 
G2 4 3 
(43) 
2 5 
(71) 
4 3 
(43) 
4 3 
(43) 
7 ≥pT2 
G3 28 5 
(15) 
3 30 
(91) 
14 19 
(58) 
8 25 
(76) 
33 
Total  114 172 
(60) 
178 108 
(38) 
211 75 
(26) 
226 60 
(21) 
286 
wt: wild type (no mutation), mt: mutation, expr.: expression 
 
A molecular grading model for prediction of prognosis. The first 
endpoint of interest was the prediction of disease progression for patients with 
superficial UCC. The corresponding Kaplan-Meier analyses for the performance 
of the four molecular markers are shown in Figure 3A-D. This figure illustrates, 
analogous to the histo-pathological data in Table 3, that UCC patients with a 
FGFR3 mutation have a significantly better prognosis than those without the 
FGFR3 mutation and that the opposite is the matter in patients with aberrant 
expression of an immuno-histochemical marker. These results prompted us to 
perform multivariate analysis for the prediction of progression with the single and 
combinations of variables listed in Table 4. The combination FGFR3/MIB-1 
(P<0.001) and the clinico-pathological index (P=0.007) proved independent 
predictors of progression. Further details on multivariate analyses are explained 
below.  
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Figure 3  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Kaplan-Meier analyses of the 4 molecular markers for disease progression. A) FGFR3 gene, 
B) MIB-1 expression, C) P53 expression and D) P27kip1 expression. P-values (log-rank) were 
<0.001 for each marker. The dashed lines show the follow up of patients with positive, UCC-
related molecular features. Abbreviations, see footnote Table 3. 
 
Figure 4A shows the Kaplan-Meier plot for the combination FGFR3/MIB-1. 
The difference in behavior between the groups FGFR3 mutation / MIB-1 normal 
(N=138) and FGFR3 wild type / MIB-1 high (N=47) was evident. Interestingly, the 
61 remaining patients with tumors characterized by no FGFR3 mutation and 
normal MIB-1 expression or by a FGFR3 mutation and high MIB-1 expression 
behaved more or less the same representing an intermediate prognosis with 
regard to disease progression. These results from Figure 4A led us to propose a 
molecular grading model for UCC distinguishing three molecular grades (mG1-3): 
mG1 (favorable prognosis), mG2 (intermediate prognosis) and mG3 (poor 
prognosis) as shown in Figure 4B. This Figure illustrates the different disease 
courses for the various molecular Grades. The combinations of FGFR3 status 
with P53 and P27kip1 expression were only significant predictors in univariate 
analysis (not shown). 
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Table 4 
Variables for multivariate analysis to predict patient’s prognosis. 
 
Single variables: Combination of variables: 
Age 
Hospital 
Sex 
Multiplicity 
Site 
Localization 
Tumor size 
Stage (TNM ’97)* 
Grade (WHO ’73)* 
Grade (WHO/ISUP ’98)* 
Associated CIS 
FGFR3 status 
MIB-1 
P53 
P27kip1 
Clinico-pathological index^ 
FGFR3/MIB-1 
FGFR3/P53 
FGFR3/P27kip1 
MIB-1/P53 
MIB-1/P27kip1 
P53/P27kip1 
*See fotnote Table 1. ^Index adopted from Allard et al.8 based on 4 adverse tumor characteristics 
(ATC): i.e. tumor-size >3cm, Stage pT1, Grade G2-3 and multifocality. 
 
Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecular grading of UCC. A) Kaplan-Meier plot for progression-free survival based on 
FGFR3/MIB-1 status, i.e. mt (mutant) or wt (wild type) FGFR3 and ↑ (high) or ↓ (low) MIB-1 
staining. Note that the combinations mt/↓ and wt/↑ behave similarly. B) Molecular Grading based 
on these parameters: mG1: mt FGFR3 / ↓ MIB-1; mG2: mt FGFR3 / ↑ MIB-1 and wt FGFR3 / ↓ 
MIB-1; mG3: wt FGFR3 / ↑ MIB-1.   
 
Multivariate analyses illustrate the value of molecular Grade. We also 
performed multivariate analyses for the other study endpoints, i.e. recurrence, 
recurrence rate and disease specific survival. Table 5A shows the significant 
predictors in multivariate analysis for patients with superficial UCC. Besides 
progression, the molecular Grade was also an independent predictor for 
recurrence rate and disease specific survival. The recurrence rate per year 
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calculated for the independent variables, i.e. molecular- and morphological 
Grade is shown in Figure 5. In Table 5B, the significant predictors in multivariate 
analysis for all patients (N=286) concerning disease specific survival are listed.  
 
Table 5A 
Independent predictors in superficial urothelial cell carcinoma (N=246). 
 
Prognostic Factor Odds Ratio 95% CI P-value 
Recurrence  
Multiplicity 
 
Solitary 
Multiple 
1 
1.8 
 
1.3 – 2.5 
 
0.002 
Recurrence rate (>0.50 / year)  
Grade 1998* 
 
PUN-LMP 
LG-PUC 
HG-PUC 
1 
2.6 
2.9 
 
1.2 – 5.7 
1.2 – 6.9 
 
 
0.019 
     
FGFR3/MIB-1** 
 
mG1 
mG2 
mG3 
1 
1.2 
2.5 
 
0.6 – 2.2 
1.2 – 5.4 
 
 
0.046 
Progression  
Clinico-pathological index^: 
 
0-1 ATC 
2 ATC 
3-4 ATC 
1 
3.8 
4.8 
 
0.5 – 32.3 
0.6 – 39.7 
 
 
0.007 
     
FGFR3/MIB-1** 
 
mG1 
mG2 
mG3 
1 
4.5 
9.3 
 
1.3 – 16.0 
2.9 – 29.8 
 
 
<0.001 
Disease specific survival  
FGFR3/MIB-1** 
 
mG1 
mG2 
mG3 
1 
15.6 
19.6 
 
1.7 – 149.2 
1.4 – 273.8 
 
 
0.008 
 
Table 5B 
Independent predictors in urothelial cell carcinoma for disease specific survival (N=286) 
 
Prognostic Factor Odds  Ratio 95% CI P-value 
Disease specific survival    
Stage pTa 
pT1 
≥pT2 
1 
1.5 
8.2 
 
0.5 – 4.4 
2.7 – 24.9 
 
 
<0.001 
    
FGFR3/MIB-1** mG1 
mG2 
mG3 
1 
8.5 
10.0 
 
1.9 – 45.7 
2.0 – 48.5 
 
 
<0.001 
* See footnote Table 1 for explanation & abbreviations 
^ Table 4 for explanation & abbreviation 
** Figure 4 for explanation 
CI: Confidence Interval 
mG: molecular Grade 
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Figure 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The recurrence rate per year for molecular (A) and morphological (B) grading of UCC. The solid 
dots indicate the mean recurrence rate per year for each category. Abbreviations, see Table 1 
and Figure 4. 
 
Figure 6 shows the Kaplan-Meier plots for the independent predictors of disease 
specific survival, i.e. pathological Stage and molecular Grade. In addition, we 
investigated the possible influence of treatment variables, i.e. intravesical 
treatment for progression and cystectomy for disease specific survival. When we 
added these covariates to the multivariate analyses, they were not significant.  
 
Figure 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Independent variables in multivariate analysis for disease free survival (N=286). A) pathological 
Stage B) molecular Grade (FGFR3/MIB-1) were the two independent predictors. P (log-rank) 
<0.001 for both variables. Abbreviations: mol, molecular; mG, molecular Grade; N, number of 
patients who entered follow up. 
 
To further clarify the relation between the molecular grading and disease specific 
survival as depicted in Table 5B and Figure 6B, we calculated the absolute 
numbers and time to decease for each molecular Grade. Of the patients with 
mG1, two patients (1.4%) died of UCC. Nine patients (13%) with mG2 and 15 
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patients (20%) with mG3 died of UCC. Median time to decease was 5.1, 6.2 and 
2.3 years respectively, for mG1, mG2 and mG3. These data pointed to two 
conclusions. Firstly, the molecular variables were at least as predictive as clinico-
pathological indices and secondly, combinations of variables provided a more 
accurate prediction of prognosis than single variables. 
FGFR3 status and carcinoma in situ. The presence of CIS next to a 
papillary UCC generally points to a worse prognosis. Therefore, we analyzed the 
incidence of FGFR3 mutations in patients with associated CIS. In the 19 cases 
with associated CIS, only 5 mutations were found (P=0.003, 2-sided Fisher’s 
exact test). In addition, only 14 mutations were detected in the 42 patients who 
had associated CIS with their primary UCC or who developed CIS during follow 
up (P<0.001). Taken together, FGFR3 mutations were, as expected, not frequent 
in UCC patients with associated CIS. These data are in line with the absence of 
FGFR3 mutations in CIS itself.29   
Reproducibility. In addition to prognosis, we determined the 
reproducibility of molecular assays and pathological grading. The histological 
slides were reviewed by 3 pathologists with a special interest in uro-pathology. 
Two medical researchers assessed immuno-histochemisty scores. Because the 
FGFR3 mutation analysis was reproducible in 100% of cases, the variability of 
molecular Grade was only dependent on immuno-histochemistry. Table 6 clearly 
demonstrates the superior reproducibility of the molecular markers over 
pathological grade.  
 
Table 6 
Reproducibility of molecular variables and pathological grade. 
 
Variable Source of Variability No. of Patients % Agreement 
MIB-1 2 scorers / 1 slide 286 91 
P53 2 scorers / 1 slide 286 88 
P27kip1 2 scorers / 1 slide 286 85 
FGFR3 status 2 institutes / 1 DNA sample 81 100 
Pathological Grade 3 pathologists (A,B,C) / 1 slide 210 47 (A vs. B) 
60 (A vs. C) 
61 (B vs. C) 
 
DISCUSSION 
 Intense research efforts are being made to identify and characterize 
molecular markers for various malignancies. However, the value of these 
markers over traditional clinico-pathological indices for diagnosis and prognosis 
may still be questioned. We here show that molecular markers can be used to 
assess patients prognosis for UCC more accurately and reproducibly than with 
traditional clinico-pathological indices. In this respect, the identification of the 
FGFR3 mutation as a selective marker for favorable disease is of major 
importance.  
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 Multiple endpoints were determined for the prediction of prognosis in our 
series of patients. Firstly, definitive cure reflected by a long recurrence free follow 
up is most likely to be achieved in patients with solitary tumors, as reported 
earlier.5 The independent predictors for assessment of the biological behavior of 
superficial UCC reflected by recurrence rate and disease progression were the 
molecular Grade, the clinico-pathological index and the morphological Grade 
assessed by a single expert-pathologist. For disease specific survival, a longer 
follow up may be needed and radical treatment (cystectomy) may give an 
additional bias. Nevertheless, the molecular Grade (FGFR3/MIB-1) again proved 
to be of independent significance. The data obtained from multivariate analyses 
indicated that the molecular variables were at least as predictive as clinico-
pathological indices and that combinations provided a more accurate prediction 
of prognosis than single variables. 
 A surprise to us was the finding that patients with aberrant expression of 
MIB-1, P53 or P27kip1 had a better prognosis when a coexisting FGFR3 mutation 
was present in their UCC, i.e. the presence of a FGFR3 mutation was 
“protective”. Our finding that these patients had a similar prognosis as patients 
with no FGFR3 mutation and normal expression of these proteins made it 
feasible to combine these groups and to propose a molecular grading model for 
UCC based on 3 molecular Grades (mG1-3). Because the combination of 
FGFR3 and MIB-1 proved, in contrast to other molecular combinations, of 
independent value for several of our study endpoints in multivariate analyses, we 
advocate this combination to be used for further validation of the molecular 
Grade in clinical settings.  
The poor reproducibility of pathological stage and grade is a recognized 
problem and a major concern for clinicians. Grade assessment may differ in 40-
50% of cases.9,10 Our study confirmed this high inter-observer variability. We also 
investigated the molecular markers and clearly demonstrated their superior 
reproducibility. To our knowledge, the present study is the first to compare the 
reproducibility of pathological grading and molecular variables on the same 
series of patients. McShane et al. performed an elaborate study, which 
addressed the reproducibility of P53 immuno-histochemistry.36 They found a 91% 
agreement, which is comparable with our result of 88%. Furthermore, inter-
observer variability seems not an issue for the FGFR3 mutation since this 
analysis appeared highly reproducible with 100% concordance. Moreover, the 
identification of FGFR3 mutations was a simple procedure and more 
sophisticated and faster ways for detection of single nucleotide changes have 
recently been developed.37 With our method, the molecular Grade may be 
provided in the same time frame that is needed for a routine pathological 
examination. The intermediate Grade 2 tumors are often bothersome for clinical 
decision making. Therefore, an additional advantage of molecular grade 
compared to morphological grade was the relative low number of Grade 2 tumors, 
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i.e. 24% mG2 vs. 44% G2 33. In conclusion, molecular grading composed of 3 
mGs is more reproducible than pathological assessment.   
FGFR3 mutations occur in 60% of primary UCC and their presence was 
generally linked to a favorable disease course. As expected from earlier studies, 
aberrant expression of MIB-1, P53 or P27kip1 pointed to unfavorable disease 
characteristics.11,16-20 By combining the “favorable” FGFR3 mutation with the 
“unfavorable” high MIB-1 expression, 87% of UCC could be characterized. Only 
12% of these UCC were positive for both markers. This supports a model in 
which the FGFR3 mutation and the MIB-1 marker define two pathways of UCC 
pathogenesis covering almost 90% of the patients (Figure 7). This model for two 
molecular pathways of UCC resembles the model originally proposed by Spruck 
et al.38 However, our model is the first to provide a selective molecular marker for 
patients with a favorable prognosis. Another important addition to the model of 
Spruck et al.38 is our observation that superficial UCCs with a FGFR3 mutation 
have a low recurrence rate (reference nr.28 and present study). We included this 
feature into our model to discern more accurately between the favorable 
superficial UCCs and the unfavorable ones as this is not evident from histo-
pathology alone (Table 3 and Figure 7). Genetic alterations affecting many 
different chromosomes have been observed in CIS and papillary high-grade 
UCC.13,39,40 However, besides FGFR3 mutations, deletions of chromosome 9 are 
the only other frequent (>35%) events in low grade and stage papillary UCC, 
indicating that loss of chromosome 9 occurs early in the development of UCC. 
Unfortunately however, chromosome 9 deletions are frequently found throughout 
all UCC stages and grades and, thus, can not be used for prognostic purposes.38-
43  
 
Figure 7 
 
 
 
 
 
 
 
 
 
 
 
 
Two-pathway model for disease pathogenesis of urothelial cell carcinoma. Arrow thickness is 
indicative for the percentage of tumors. Chromosomal alterations, not examined in this study 
have not been included in the interest of clarity but are represented by the bottom 
arrow.11,13,14,21,38-43 Abbreviations: FGFR3, fibroblast growth factor receptor 3 gene; mt, mutation; 
↑, elevated expression (MIB-1, P53); ↓, reduced expression (p27kip1); CIS, carcinoma in situ.  
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From the molecular point of view, the FGFR3 mutation and its apparent 
positive identification of low risk patients is also very intriguing. It has been 
shown that mutant FGFR3 can transform NIH 3T3 cells when targeted to the cell 
membrane and that these cells are tumorigenic in nude mice.44,45 Chesi et al. 
showed that, in multiple myeloma, FGFR3 and RAS mutations are mutually 
exclusive and both mutations lead to activation of the same downstream pathway 
(MAPK).45 Thus, it would be interesting to analyze RAS mutations and FGFR3 
mutations in the same UCCs. So far, the frequency of RAS mutations in UCC 
has been controversial.21 Assuming a link between favorable UCC and RAS 
mutations, some reported studies might have included too many patients with 
advanced disease.21 In addition to RAS mutations, it would be interesting to 
analyze other molecules of the FGFR3 signal-transduction pathway. 
 The identification of the FGFR3 mutation as the representative of the 
favorable pathway in this series of 286 primary UCCs is of major importance for 
patients, clinicians and scientists. Before this mutation and its apparent positive 
identification of low-risk patients were noted, only molecular indicators of worse 
prognosis were available in UCC. We proposed a simple, highly reproducible 
method to determine the molecular Grade of UCC which proved superior to 
traditional clinico-pathological indices. These results further underline the need 
for both worse and favorable molecular markers to accurately predict disease 
course and suggest that this approch will be of value for other types of 
malignancy as well. Our results warrant the need for future prospective trials and 
these may confirm the idea that the molecular Grade can be used in clinical 
decision making with regard to the frequency of cystoscopical follow up, adjuvant 
intravesical instillations or timing of radical treatments like cystectomy. In addition, 
the “favorable” FGFR3 mutation remains a major target for scientists to unravel 
its mechanisms of action. 
 
REFERENCES 
1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major 
cancers in 1985. Int J Cancer 1993;54:594-606 
2. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin 
2001;51:15–36 
3. Kurth KH, Denis L, Bouffioux Ch, et al. Factors affecting recurrence and progression in 
superficial bladder tumours. Eur J Cancer 1995;31A:1840-6 
4. Holmäng S, Hedelin H, Anderström C, et al. The relationship among multiple recurrences, 
progression and prognosis of patients with stages Ta and T1 transitional cell cancer of 
the bladder followed for at least 20 years. J Urol 1995;153:1823-7 
5. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of 
the prognostic factors of primary superficial bladder cancer. J Urol 2000;163:73-8  
6. Hall RR, Parmar MKB, Richards AB, et al. Proposal for changes in cystoscopic follow up 
of patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ 1994;308: 
257-60 
7. Kamat AM, Lamm DL. Intravesical therapy for bladder cancer. Urology 2000;55:161-8 
8. Allard P, Bernard P, Fradet Y, et al. The early clinical course of primary Ta and T1 
bladder cancer: a proposed prognostic index. Br J Urol 1998;81:692-8 
Molecular grading of UCC with FGFR3 
 - 127 -
9. Ooms EC, Anderson WA, Alons CL, et al. Analysis of the performance of pathologists in 
the grading of bladder tumors. Hum Pathol 1983;14:140-3 
10. Tosoni I, Wagner U, Sauter G, et al. Clinical significance of interobserver differences in 
the staging and grading of superficial bladder cancer. BJU Int 2000;85:48-53 
11. Barton Grossman H, Liebert M, Antelo M, et al. P53 and RB expression predict 
progression in T1 bladder cancer. Clin Cancer Res 1998;4:829-34 
12. Schmitz-Drager BJ, Goebell PJ, Ebert T, et al. p53 immunohistochemistry as a 
prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 2000;38: 
691-9 
13. Knowles MA. The genetics of transitional cell carcinoma: progress and potential clinical 
application. BJU Int 1999;84:412-27 
14. Stein JP, Grossfeld GD, Ginsberg DA, et al. Prognostic markers in bladder cancer: a 
contemporary review of the literature. J Urol 1998;160:645-59 
15. Pfister C, Moore L, Allard P, et al. Predictive value of cell cycle markers p53, MDM2, p21, 
and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 1999;5:4079-84 
16. Korkolopoulou P, Christodoulou P, Konstantinidou AE, et al. Cell cycle regulators in 
bladder cancer: a multivariate survival study with emphasis on p27Kip1. Hum Pathol 
2000;31:751-60 
17. Sgambato A, Migaldi M, Faraglia B, et al. Loss of P27Kip1 expression correlates with 
tumor grade and with reduced disease-free survival in primary superficial bladder cancers. 
Cancer Res 1999;59:3245-50 
18. Cote RJ, Dunn MD, Chatterjee SJ, et al. Elevated and absent pRb expression is 
associated with bladder cancer progression and has cooperative effects with p53. Cancer 
Res 1998;58:1090-4 
19. Popov Z, Hoznek A, Colombel M, et al. The prognostic value of p53 nuclear 
overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the 
bladder. Cancer 1997;80:1472-81 
20. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, et al. MIB-1 as a proliferative marker 
in transitional cell carcinoma of the bladder: clinical significance and comparison with 
other prognostic factors. Cancer 2000;88:2598-605 
21. Cordon-Cardo C, Cote RJ, Sauter G. Genetic and molecular markers of urothelial 
premalignancy and malignancy. Scand J Urol Nephrol 2000;34:82-93 
22. Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor 
multigene family. Adv Cancer Res 1993;60:1-41 
23. Vajo Z, Francomano CA, Wilkin DJ. The molecular and genetic basis of fibroblast growth 
factor receptor 3 disorders: The achondroplasia family of skeletal dysplasias, Muenke 
craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev 2000; 
21:23-39 
24. Bellus GA, Spector EB, Speiser PW, et al. Distinct missence mutations of the FGFR3 
Lys650 codon modulate receptor kinase activation and the severity of the skeletal 
dysplasia phenotype. Am J Hum Genet 2000;67:1411-21 
25. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in 
multiple myeloma is associated with increased expression and activating mutations of 
fibroblast growth factor receptor 3. Nat Genet 1997;16:260-4 
26. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in 
human bladder and cervix carcinomas. Nat Genet 1999;23:18-20  
27. Sibley K, Cuthbert-Heavens D, Knowles MA. Loss of heterozygosity at 4p16.3 and 
mutation of FGFR3 in transitional cell carcinoma. Oncogene 2001;20:686-91 
28. Van Rhijn BWG, Lurkin I, Radvanyi F, et al. The fibroblast growth factor receptor 3 
(FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence 
rate. Cancer Res 2001;61:1265-8 
29. Billerey C, Chopin D, Aubriot-Lorton M-H, et al. Frequent FGFR3 mutations in papillary 
non-invasive bladder (pTa) tumors. Am J Pathol 2001;158:1955-9 
Chapter 9 
 
 - 128 -
30. Fracchiolla NS, Luminari S, Baldini L, et al. FGFR3 gene mutations associated with 
human skeletal disorders occur rarely in multiple myeloma. Blood 1998;92:2987-9 
31. Wu R, Connolly D, Ngelangel C, et al. Somatic mutations of fibroblast growth factor 
receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix. Oncogene 2000; 
19:5543-6 
32. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union 
Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 
1997;80:1803-4  
33. Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. 
International classification of tumours, no. 10. World Health Organization, Geneva 1973; 
21-31 
34. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International 
Society of Urological Pathology consensus classification of urothelial (transitional cell) 
neoplasms of the urinary bladder. Am J Surg Pathol 1998;22:1435-48 
35. Vis AN, Noordzij MA, Fitoz K, et al. Prognostic value of cell cycle proteins p27(kip1) and 
MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate 
cancer. J Urol 2000;164:2156-61 
36. McShane LM, Aamodt R, Cordon-Cardo C, et al. Reproducibility of p53 
immunohistochemistry in bladder tumors. Clin Cancer Res 2000;6:1854-64 
37. Kwok PY. Methods for genotyping single nucleotide polymorphisms. Annu Rev Genomics 
Hum Genet 2001;2:235-58 
38. Spruck CH 3rd, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to 
transitional cell carcinoma of the bladder. Cancer Res 1994;54:784-8 
39. Rosin MP, Cairns P, Epstein JI, et al. Partial allelotype of carcinoma in situ of the human 
bladder. Cancer Res 1995;55:5213-6  
40. Zhao J, Richter J, Wagner U, et al. Chromosomal imbalances in noninvasive papillary 
bladder neoplasms (pTa). Cancer Res 1999;59:4658-61 
41. Knowles MA, Elder PA, Williamson M, et al. Allelotype of human bladder cancer. Cancer 
Res 1994;54:531-8 
42. Czerniak B, Chaturvedi V, Li L, et al. Superimposed histologic and genetic mapping of 
chromosome 9 in progression of human urinary bladder neoplasia: implications for a 
genetic model of multistep urothelial carcinogenesis and early detection of urinary 
bladder cancer. Oncogene 1999;18:1185-96 
43. van Tilborg AA, de Vries A, de Bont M, et al. Molecular evolution of multiple recurrent 
cancers of the bladder. Hum Mol Genet 2000;9:2973-80 
44. Webster MK, Donoghue DJ. Enhanced signaling and morphological transformation by a 
membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain. 
Mol Cell Biol 1997;17:5739-47 
45. Chesi M, Brents LA, Ely SA, et al. Activated fibroblast growth factor receptor 3 is an 
oncogene that contributes to tumor progression in multiple myeloma. Blood 2001;97: 
729-36 
  - 129 -
 
 
 
10 
 
 
 
Frequent FGFR3 Mutations in Urothelial Papilloma 
 
 
 
Bas W.G. van Rhijn, Rodolfo Montironi, Ellen C. Zwarthoff, Adriaan C. Jöbsis, 
Theo H. van der Kwast 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
J Pathol 2002;198:245-51 
 
 
 
Chapter 10 
 
 - 130 -
ABSTRACT 
Activating point mutations in the FGFR3 gene occur frequently in low 
grade and low stage bladder carcinomas whereas they are rare in high-grade 
carcinomas. This study investigates the incidence of FGFR3 mutations in 12 
urothelial papillomas and 79 pTaG1 tumors which were regraded according to 
the 1998 WHO/ISUP classification system resulting in 62 papillary urothelial 
neoplasms of low malignant potential (PUN-LMP) and 17 low grade papillary 
urothelial carcinomas (LG-PUC). We also performed FGFR3 mutation analysis of 
21 ovarian Brenner tumors. We detected 77 cases with a mutation in the FGFR3 
gene. The mutations were exclusively found in bladder neoplasms. In urothelial 
papilloma, generally considered a benign lesion, we found 9/12 (75%) mutations. 
This report is the first to describe a genetic defect in urothelial papilloma. A 
comparable percentage of mutations was found in PUN-LMP (85%) and LG-PUC 
(88%). No mutations were found in matched normal DNA from bladder tumor 
patients. The mean follow up was 5.78 years (range, 0.21-17.60 years). Five 
patients developed high-grade papillary urothelial carcinoma 2½ to 12 years after 
first diagnosis. Two patients died of bladder cancer. The mean number of 
recurrences (recurrence rate) per year was 0.03, 0.21 and 0.46, respectively, for 
papilloma, PUN-LMP and LG-PUC. Urothelial papilloma is a rare lesion with a 
benign natural behaviour compared to PUN-LMP and LG-PUC of the bladder. 
However, from a molecular perspective, papillomas should be classified together 
with all well differentiated urothelial neoplasms. 
 
INTRODUCTION 
The diagnostic criteria for urothelial papilloma are essentially identical in 
the 1973 WHO classification system and the 1998 WHO/International Society of 
Urological Pathology (WHO/ISUP) classification system for papillary urothelial 
neoplasms.1,2 Urothelial papilloma is generally considered a separate diagnostic 
entity with a benign natural behaviour by most researchers.3,4 This lesion 
accounts for less than 3% of papillary urothelial neoplasm.5 The majority of 
patients with a bladder tumor is diagnosed with superficial (i.e. pTa-pT1) disease 
at first presentation. High-grade carcinomas (G3), if still superficial, are 
associated with a poor prognosis and therefore these lesions require meticulous 
urological follow up and adjuvant treatment.6 Conversely, G1 and a large 
percentage of G2 tumors (1973 WHO classification) behave rather indolent. For 
this reason, the 1998 WHO/ISUP classification system introduced new 
categories for papillary, non-invasive lesions of low cytologic grade to distinguish 
by means of strict morphological criteria between papillary urothelial neoplasms 
of low malignant potential (PUN-LMP) and low-grade papillary urothelial 
carcinoma (LG–PUC).2 
The fibroblast growth factor receptor 3 (FGFR3) is part of a family of four 
highly conserved and structurally related tyrosine kinase receptors (FGFR1-4). 
The FGFRs are involved in cell signalling pathways regulating embryonic growth, 
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cell proliferation, angiogenesis, development and differentiation.7 The human 
FGFR3 gene, located on chromosome 4p16.3, consists of 19 exons and 18 
introns.8 Activating point mutations in the FGFR3 gene are well documented in 
several craniosynostoses and skeletal dysplasias associated with dwarfism, 
including thanatophoric dysplasia (TD) and severe achondroplasia with 
developmental delay and acanthosis nigricans (SADDAN).9,10 Next to the 
inhibitory role of FGFR3 mutations in skeletal anomalies, an oncogenic role for 
FGFR3 has been proposed in some malignancies. The same activating point 
mutations that accounted for the above mentioned skeletal anomalies were found 
in multiple myeloma 11 and the carcinomas of the bladder and the cervix.12 The 
frequency of mutations in multiple myeloma and cervix cancer is probably lower 
than initially reported.13-15 In addition, several malignancies and tumor cell lines 
were analysed for FGFR3 mutations, but no mutations were found in other 
epithelial or other tumor types of various organs.15,16 By contrast, in urothelial cell 
carcinoma (UCC), frequent mutations have been found in larger series.17,18 
Surprisingly, the presence of these mutations in UCC was related to favourable 
disease characteristics with up to 84% of cases with FGFR3 mutations in pTaG1 
tumors as compared to 7% in ≥pT2G3 tumors.18 
In the present study, we investigated the incidence of FGFR3 mutations in 
papilloma, PUN-LMP and LG-PUC of the bladder. We also performed FGFR3 
mutation analysis in ovarian Brenner tumors of borderline malignancy because of 
their morphological resemblance to urothelial neoplasms.  
 
MATERIAL AND METHODS 
This study comprised 12 cases of urothelial papilloma and 79 pTaG1 
tumors of 91 patients, graded according to the 1973 WHO classification for 
urothelial neoplasms1 and staged according to the 1997 TNM classification 
guidelines.19 Five papillomas were collected from the archives of the Department 
of Pathology of Erasmus University Rotterdam; four papillomas from the Institute 
of Pathological Anatomy and Histopathology, University of Ancona and three 
papillomas from the Department of Pathology of Sint Franciscus Gasthuis 
Rotterdam. The pTaG1 tumors were obtained from the two Departments of 
Pathology at Rotterdam. The histology slides of the urothelial papillomas and the 
pTaG1 tumors were reviewed (TvdK) according to the diagnostic criteria for 
urothelial papillary lesions of the 1998 WHO/ISUP classification system.2 
Histological examples of the different grades assessed are given in Figure 1. The 
bladder tumor cases were primary (first diagnosis) papillary bladder lesions. 
None had a coexistent or prior history of urothelial dysplasia, carcinoma in situ, 
invasive UCC, upper urinary tract UCC or, in case of multifocality, a tumor, which 
was >pTaG1. DNA extracted from venous blood for control purposes was 
available from 25 of 48 patients who were treated at the University hospital 
Rotterdam. Besides the bladder lesions, twenty-one ovarian Brenner tumors of 
borderline malignancy were obtained from the archives of the Department of 
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Pathology of Erasmus University Rotterdam. Standard H&E slides were made of 
the 112 paraffin-embedded tissue samples for pathological review. They also 
served as templates for the microdissection procedure to avoid contamination of 
the DNA sample with regions of normal mucosa, leukocytes or stroma. 
 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Morphological examples of urothelial papilloma, papillary urothelial neoplasm of low malignant 
potential and low grade papillary urothelial carcinoma in the studied patients graded according to 
the 1998 WHO/ISUP classification system.2 Examples A and B are urothelial papillomas 
characterised by a discrete papillary growth pattern with delicate fibrovascular cores lined by 
cytologically and architecturally normal urothelium. Examples C and D concern a papillary 
urothelial neoplasm of low malignant potential. This lesion shows an orderly proliferation of 
cohesive urothelial cells with normal polarity and without significant atypia. The papillae are lined 
by urothelium that is more than 7 cell layers in thickness. Examples E and F are low-grade 
papillary urothelial carcinoma. These are characterised by an overall orderly appearance but with 
easy recognisable variation of architectural and cytologic features, even at low power 
magnification. More detailed information on the 1998 WHO/ISUP classification system can be 
seen at: www.pathology.jhu.edu/bladder. 
A 
C 
E 
B
D
F
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The samples used for FGFR3 mutation analysis contained a minimum of 75% 
tumor cells, as assessed by histological examination. The DNA of the various 
tissues was extracted using DNeasy Tissue kit (Qiagen GmbH, Hilden, Germany) 
according to the protocol suggested by the manufacturer. The FGFR3 mutation 
analysis was performed by polymerase chain reaction (PCR) - single strand 
conformation polymorphism (SSCP) analysis on tumor- and, if available, control 
DNA of the patients as described.12,17,18  
In brief, four regions of interest encompassing all activating FGFR3 
mutations previously described in severe skeletal dysplasias and cancers were 
amplified by PCR. The Primer-sequences for PCR are shown in Table 1. 
Samples with an aberrant band at SSCP were sequenced with T7 Sequenase 
v2.0 (Amersham life Science, Inc., Cleveland, OH) to check the identity of the 
mutations. The laboratory analysis of the samples was carried out without the 
knowledge of clinical or histo-pathological status. Clinical information and follow 
up data were obtained by chart review. The statistical package for social 
sciences 9.0 (SPSS Inc., Chicago, IL) computer software was used for data 
documentation and analysis. The Chi-square test was used to analyse the 
FGFR3 mutation status in relation to pathological assessment. The Chi-square 
test and ANOVA (for comparison of means) were used for comparison clinical 
and pathological variables with urothelial papilloma, PUN-LMP and LG-PUC. 
Statistical significance was assumed if P<0.05. 
 
Table 1 
The primer sequences for FGFR3 mutation analysis. 
 
Exon Forward primer (5’-3’) Reverse primer (5’-3’) 
7 AGTGGCGGTGGTGGTGAGGGAG TGTGCGTCACTGTACACCTTGCAG 
10 CAACGCCCATGTCTTTGCAG CGGGAAGCGGGAGATCTTG 
15 GACCGAGGACAACGTGATG GTGTGGGAAGGCGGTGTTG 
19 TGTCGGCGCCTTTCGAGCAGTA AGCAGCAGGGTGGGCTGCTA 
 
RESULTS 
 The incidence of FGFR3 mutations was studied in 12 papillomas, 62 
PUNs-LMP and 17 LG-PUCs. We also analysed 21 Brenner tumors of borderline 
malignancy. The patient and tumor characteristics at diagnosis for the various 
types of papillary bladder tumors are reported in Table 2. These data show that 
papillomas are small, solitary papillary lesions. In addition, although significance 
was not reached because of the relative low number of papilloma patients, the 
papilloma patients were younger at diagnosis and the male-to-female ratio was 
1.4:1 for papilloma and 2.8:1 for the pTaG1 tumors. The mean patient’s age at 
diagnosis was 53.0 years (std. deviation, 9.5 years) for the Brenner tumor 
patients.  
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Table 2 
The patient and bladder tumor characteristics. The studied population consisted of 12 urothelial 
papillomas and 79 pTaG1 bladder carcinomas.1,19 **Between parentheses: The bladder 
carcinomas were re-graded by one pathologist according to the 1998 WHO/ISUP classification.2 
^ANOVA test. *Chi-square test.   
 
 Papilloma pTaG1 (PUN-LMP, LG-PUC)** P-value 
mean  59.5 64.7 (65.5, 61.9) Age (years) 
std. deviation  15.4 12.5 (12.8, 11.2) 
 
=0.194^ 
Male 7 58 (46, 12) Sex 
Female 5 21 (16, 5) 
 
=0.281* 
Solitary 12 67 (54, 13) Multiplicity 
Multiple 0 12 (8, 4) 
 
=0.147* 
bladder neck  3 3 (2,1) 
anterior wall 1 8 (6, 2) 
dome 0 8 (8, 0) 
posterior wall 2 9 (5, 4) 
trigone/ostia 2 13 (11, 2) 
Left lateral wall 2 14 (12, 2) 
right lateral wall 2 13 (11, 2) 
Localisation 
in bladder 
multiple 0 11 (7, 4) 
 
 
 
=0.174* 
< 1cm 9 12 (12, 0) 
1-3 cm 3 36 (31, 5) 
Tumor size 
(diameter) 
> 3 cm 0 31 (19, 12) 
 
<0.001* 
Total 12 79 (62, 17)  
 
 We detected five different shifts at SSCP analysis of the FGFR3 gene. In 
total, 77 shifts were found. All the shifts were found among the 91 bladder 
neoplasms and none in the Brenner tumors. Sequence analysis revealed six 
different mutations in bladder neoplasms. These mutations concerned 5 different 
codons of the FGFR3 gene (Table 3). The two different mutations in codon 652 
displayed identical shifts at SSCP. The mutations in the codons 248, 249, 372 
and 375 were reported before in TD and UCC.9,12,17,18,20 The Lys652Met mutation 
was reported before in multiple myeloma and the germinal activating mutation is 
responsible for SADDAN.9-11 The Lys652Thr was not previously reported in 
cancer or a syndrome associated with dwarfism. However, Bellus et al.10 showed 
that this particular mutation is capable of FGFR3 activation (relative activity 3.1x 
that of wild type FGFR3). The Ser249Cys was the most frequent FGFR3 
mutation in bladder neoplasms accounting for 49 of the 77 mutations (64%). An 
example of this mutation in a bladder tumor is shown in Figure 2. Table 4 shows 
the distribution of FGFR3 mutations among various bladder neoplasms. 
Interestingly, we found 9/12 (75%) FGFR3 mutations in urothelial papillomas. A 
similar high percentage of FGFR3 mutations was found in PUN-LMP and LG-
PUC (P=0.589). There were no differences in the types of FGFR3 mutations 
between the bladder neoplasms (not shown). No mutations were found in 
matched normal (blood) DNA samples from 25 bladder tumor patients confirming 
the somatic nature of FGFR3 mutations in neoplasms. 
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 C   T    A   G 
T 
 C  T   A   G
N
Codon
249
250
251
252
 
Table 3 
The FGFR3 mutations in bladder neoplasms. The codon and nucleotide numbering refers to the 
cDNA open reading frame of the FGFR3b isoform. This isoform is expressed in epithelia and 
contains two amino acids more than the FGFR3c isoform that is, in general, expressed in bone.12 
 
Exon Codon nt Position Mutation Predicted effect Number of tumors 
7 248 742 CGC → TGC Arg → Cys 7 
7 249 746 TCC → TGC Ser → Cys 49 
10 372 1114 GGC → TGC Gly → Cys 5 
10 375 1124 TAT → TGT Tyr → Cys 14 
15 652 1955 AAG → ACG Lys → Thr 1 
15 652 1955 AAG → ATG Lys → Met 1 
 
Figure 2  
 
 
 
 
 
 
 
 
An example of the most frequent FGFR3 gene mutation in bladder neoplasms. The G to C 
transition at nucleotide position 746 leading to the amino acid change Serine to Cysteine at codon 
249 was found in 64% of mutated bladder neoplasms. The FGFR3 mutation in tumor is indicated 
by a solid arrowhead. 
T = Sequence analysis of tumor DNA. 
N = Sequence analysis of matched normal (blood) DNA. 
 
Table 4  
The FGFR3 mutation status in papillomas and pTaG1 tumors (1973 WHO classification) that 
were reviewed with the histological criteria of the 1998 WHO/ISUP classification system. The 
percentage of FGFR3 mutations found in each histological entity is between parenthesis.  
*Chi-square test. 
PUN-LMP = Papillary Urothelial Neoplasm of Low Malignant Potential. 
LG-PUC = Low Grade Papillary Urothelial Carcinoma. 
 
FGFR3 mutation analysis  
Wild type Mutant % Mutant P value* 
Papilloma 3 9 75% 
PUN-LMP 9 53 85% 
LG-PUC 2 15 88% 
Total 14 77 85% 
 
= 0.589 
 
Follow up data were collected for the bladder tumor patients. Mean follow 
up was 4.84 years (range, 0.21-17.60 years) for the papilloma patients and 5.93 
years (range, 1.11-16.26 years) for the patients initially diagnosed with pTaG1 
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(1973 WHO classification). Nine of the 12 papilloma patients remained 
recurrence free. One patient had recurrent papilloma as highest grade, one 
patient developed PUN-LMP and another one high-grade papillary urothelial 
carcinoma (HG-PUC) after a 6 years recurrence free period. No patients 
progressed to invasive (i.e. ≥pT2) bladder carcinoma or died of bladder cancer. 
Of the 62 patients with primary PUN-LMP, 33 had no recurrence, 19 had 
recurrent PUN-LMP, eight developed LG-PUC and 2 HG-PUC after 5½ and 12 
years, respectively. One patient (1.6%) progressed to invasive disease and 
subsequently died of bladder cancer. Of the 17 patients with primary LG-PUC, 5 
had no recurrence, 1 recurrent PUN-LMP, 9 recurrent LG-PUC and 2 developed 
HG-PUC after 2½ and 6 years, respectively. One patient (5.9%) progressed to 
invasive disease and subsequently died of bladder cancer. Interestingly, three of 
the 5 patients who developed HG-PUC had no FGFR3 mutation (wild type) in 
their original tumor. Thus, 3/14 (21.4%) patients with wild type FGFR3 tumors 
progressed to HG-PUC as compared to 2/77 (2.6%) for mutant FGFR3 tumors 
(P=0.025). To further explore the long-term natural behaviour of urothelial 
papilloma, PUN-LMP and LG-PUC, we calculated the recurrence rate per year 
(number of recurrences divided by years of follow up) for each histological 
category. Minimum follow up was set at one year, so two papilloma patients were 
excluded from this analysis. The mean (95% confidence interval for mean) 
recurrence rate per year was 0.03 (-0.02 – 0.09) for the papilloma patients, 0.21 
(0.11 – 0.30) for the PUN-LMP patients and 0.46 (0.21 – 0.71) for the LG-PUC 
patients (Figure 3). 
 
Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The recurrence rate per year 
(number of recurrences / years of 
follow up) was calculated for each 
histological category. The bars 
represent the 95% confidence 
intervals for the mean. The figure 
shows a different natural clinical 
behaviour using the 1998 
WHO/ISUP classification system 
for the 3 histological tumor types (P 
value for comparison of means 
(ANOVA) = 0.01). PUN-LMP = 
Papillary Urothelial Neoplasm of 
Low Malignant Potential. LG-PUC 
= Low Grade Papillary Urothelial 
Carcinoma. 
 
 
Taken together, these follow up data point to a spectrum of disease outcome for 
cases classified according to the 1998 WHO classification system from a relative 
P (ANOVA) = 0.01 
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indolent natural behaviour of papilloma towards a more aggressive behaviour of 
LG-PUC. 
 
DISCUSSION 
Urothelial papillomas of the bladder are rare and generally considered 
benign lesions since these patients seldomly experience recurrence or 
development of UCC [4,5]. Furthermore, papillomas usually are small (< 2 cm), 
solitary lesions which are generally diagnosed at a somewhat lower age and 
occur relatively more often than UCC in women compared to men.2-4,21 Apart 
from one papilloma patient who developed high-grade disease, our series of 12 
papillomas closely resembled the above mentioned papilloma characteristics. 
These favourable characteristics justify that papillomas are a distinct entity in the 
classification systems used by pathologists.1,2 However, the high frequency (75%) 
of oncogenic FGFR3 mutations in papillomas reported in this paper suggests that 
papillomas should be grouped together with the well differentiated papillary 
urothelial neoplasms which now range from PUN-LMP to LG-PUC. 
The oncogenic role of FGFR3 mutations in urothelium was recently 
studied.12,17,18,20 The highest frequency of FGFR3 mutations was detected in 
pTaG1 carcinomas, comparable with the incidence of mutations reported in the 
present study.17,18 In addition, we found that the presence of a FGFR3 mutation 
was associated with a low recurrence rate of superficial bladder cancer.17 This 
prompted us to analyse the FGFR3 mutation status in papillomas. Three studies 
analysed the expression patterns of immuno-histochemical markers (CK20, 
CD44, TP53, Ki-67/MIB-1) in small series of in total 18 papillomas.22-24 
Essentially, it was not possible with these markers to discriminate normal from 
papilloma urothelium. In addition, Chow et al.25 investigated 4 papillomas and 15 
papillary hyperplasias (PH) for loss of heterozygosity (LOH) at 17 microsatellite 
markers on 9 chromosomal arms. LOH was found in 8/15 PHs but no genetic 
changes were found in the papillomas examined. Thus, to our knowledge, the 
present report is the first to describe a genetic defect (i.e. FGFR3 mutation) in 
urothelial papilloma. Most LOHs in PH were detected on chromosome 9, 
confirming that LOH on chromosome 9 is an early event in human bladder 
tumorigenesis.25-27 Chow et al.25 concluded that PH was the clonal precursor to 
papillary UCC. As we now have identified a high percentage of FGFR3 mutations 
in papillomas and low-grade UCC, this indicates that papilloma may also be 
regarded as a precursor of (low-grade) UCC. Moreover, papilloma and PH might 
represent two separate precursor pathways with distinct molecular features (i.e. 
FGFR3 mutation in papilloma and LOH in PH). However, this should be 
interpreted with caution as Chow et al.25 only investigated 4 papillomas and we 
did not analyse our papillomas for LOH. Next to genetics, clinical and 
pathological parameters of papilloma such as tumor size, solitary lesion, lower 
mean age at diagnosis also advocate its potential as precursor lesion for UCC. 
Furthermore, the rare association with development of UCC and the notion that 
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papillomas are usually successfully treated with a single surgical intervention4 
may indicate that papilloma is still a local neoplasm which is not capable of 
spread throughout the bladder as UCC. 
Some studies have recently investigated the 1998 WHO/ISUP 
classification system for its ability to predict the natural course of bladder 
neoplasms and its relationship with the expression patterns of certain immuno-
histochemical markers.21,22,28,29 In these and the present study, the patients had a 
risk of recurrence ranging from 25% to 47% for PUN-LMP and from 48% to 71% 
for LG-PUC. The risk of progression to invasive (i.e. ≥pT2) UCC ranged 0% to 
1.8% for PUN-LMP and from 4.0% to 6.8% for LG-PUC. These reports indicate 
that 1998 WHO/ISUP classification system more or less parallels the one of 1973 
for the group of tumors analysed in this study (i.e. PUN-LMP ≈ Grade 1 
carcinoma and LG-PUC ≈ Grade 2 carcinoma). Anyhow, the adherence to the 
strict morphological criteria defined in 1998 may lead to a better prediction of the 
natural course of bladder tumors because patients with an original diagnosis of 
pTaG1 who were "upgraded" by the 1998 WHO/ISUP classification system to 
LG-PUC had a worse natural course than the patients with PUN-LMP in our 
study (Figure 3). However, we have to take into account that the original 
diagnosis (pTaG1) was provided by many different pathologists in a routine 
setting and, of course, grading is subject to inter- and intra-observer variability.30 
A criticism to the 1998 WHO/ISUP classification and previous classification 
systems was that the morphological approach was not complemented with the 
use of molecular markers.31 If molecular markers prove to be of independent 
significance, the elimination of subjective elements in grading by adding these 
markers holds considerable promise. A normal CK-20 staining pattern was 
related to tumors, which were less likely to recur.22,29,32 The FGFR3 mutation also 
identified patients with tumors, which were less likely to recur.17 However, 
identification of FGFR3 mutations has two additional advantages. As it is not 
determined by immuno-histochemistry, interobsever variability is not possible and 
secondly, the FGFR3 mutation is not present in normal-looking random urothelial 
biopsies from patients known to have a FGFR3 mutation in their papillary UCC.18 
Therefore, the FGFR3 mutation and its apparent positive identification of low risk 
patients represent a major target for future UCC research. 
Having found frequent (75%) FGFR3 mutations in urothelial papillomas, 
we chose to further analyse the FGFR3 mutation status in another epithelial 
tumor. Our choice for Brenner tumors of the ovary was supported by the 
resemblance of this tumor to low grade UCC from a cytological point of view. 
Moreover, expression of uroplakins, CK13 and CK20 was detected in Brenner 
tumors as well as in normal and neoplastic urothelium.33,34 Nevertheless, we 
found no FGFR3 mutations in this form of borderline malignancy. Therefore, 
FGFR3 mutations seem to be very specific for urothelial neoplasms as 
reported.15,16 
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The FGFR3 mutation is found at a high frequency in “favourable” urothelial 
neoplasms and carcinomas. In addition, this mutation is also present in the 
majority of urothelial papillomas. The strict morphological criteria defined in the 
1998 WHO/ISUP classification system for papillary neoplasms of the bladder 
encomprise a spectrum of disease outcome from favourable (papilloma) towards 
a more aggressive behaviour of LG-PUC. From a molecular perspective, 
urothelial papillomas should subsume the spectrum of well-differentiated 
urothelial neoplasms.  
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ABSTRACT 
 Fibroblast growth factor receptor 3 (FGFR3) and P53 mutations are 
frequently observed in urothelial cell carcinoma (UCC). We here describe the 
distribution of FGFR3 and P53 over-expression in 260 primary bladder cancers. 
FGFR3 mutations were observed in 59% and P53 over-expression in 25%. 
Interestingly, FGFR3 and P53 alterations were mutually exclusive as they 
coincided in only 5.7% of tumors. Consequently, we propose that they 
characterize two alternative genetic pathways in UCC pathogenesis. The genetic 
alterations were reflected in the pathology and the clinical outcome, i.e. FGFR3 
mutations were found in low stage/grade tumors and were associated with a 
favorable prognosis, whereas P53 alterations were tied to adverse disease 
parameters. 
 
INTRODUCTION 
 Urothelial cell carcinoma (UCC), of which bladder cancer is the major 
representative, is the fifth most common malignancy in the western society.1 
Because of its frequent recurrence and the relatively long life span of patients, 
UCC is the most expensive cancer in health care.2 Approximately 70% of the 
patients with UCC initially present with superficial tumors (stages: pTa, pT1 or 
pTis). UCCs fall into two major groups with a substantially different natural 
behavior, i.e. superficial and invasive UCC. More than 80% of superficial UCCs 
remain confined to the (sub)mucosa throughout their clinical course, whereas 
most invasive UCCs exhibit their invasive property at first presentation and these 
tumors are associated with a high propensity to metastasize.3 In the last decade, 
many efforts were undertaken to find a molecular basis for this divergent disease 
pathogenesis of UCC. Mutations in the P53 gene were frequently found in 
invasive UCC as well as high-grade superficial UCC including carcinoma in situ 
(CIS), the putative precursor of invasive UCC, whereas these mutations were 
rare in well-differentiated superficial UCC.4,5 On the other hand, loss of 
heterozygosity (LOH) on the chromosomal arms 9p and 9q was the most 
frequent genetic alteration in the low-grade papillary lesions.4,5 However, 
subsequent studies showed that LOH on 9p/q was also a very common finding in 
high grade superficial and invasive UCC.6-9 Consequently, LOH on 9p/q did not 
provide a sufficient molecular explanation for the clinically divergent disease 
pathogenesis of UCC. Recently, fibroblast growth factor receptor 3 (FGFR3) 
mutations, identical to the mutations responsible for several skeletal anomalies 
associated with dwarfism in most cases, were reported at a high frequency in 
UCC and at a low frequency in multiple myeloma and cervical cancer.10-12 
Surprisingly, the oncogenic FGFR3 mutations were particularly related to 
favorable UCCs in three pilot studies.13-15 The FGFR3 mutations occur 
predominantly in UCC 11,12, while P53 mutations are found in over 50% of human 
cancers. In the present study, we investigated the distribution of FGFR3 and P53 
alterations in 260 primary (first diagnosis) UCCs. We here report that FGFR3 and 
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P53 characterize almost 80% of UCCs and that these mutations seem to exclude 
each other. These distinct molecular features were also reflected in the different 
pathological parameters and the clinical follow-up of the patients. We therefore 
propose that FGFR3 and P53 characterize different pathogenesis pathways for 
UCC. 
 
MATERIAL AND METHODS 
 Patients & Tumor Samples. We analyzed the tumors of 260 patients 
(196 males) with papillary, first diagnosis, UCC. The median patient's age was 
67.2 years. No patient had a hereditary skeletal anomaly. A paraffin-embedded, 
formalin fixed tissue block was obtained from the archives of two pathology 
departments (Erasmus MC and SFG) and classified according to the TNM and 
WHO guidelines. A single pathologist (TvdK) reviewed the slides using the 1998 
WHO/ISUP classification system for grading. In case of multifocality (N=67), the 
lesion with the highest grade/stage was taken. The largest tumor was taken if 
grade/stage were the same for multiple UCCs. 
 P53 analysis: Four µm thick sections were freshly cut from each tumor-
tissue block. These were mounted on amino alkylsilane coated glass slides. 
Incubation with primary antibody P53 (clone DO-7, DAKO, Denmark, dilution 
1:200) was 30 min in PBS/BSA 5%. Positive and negative controls were included. 
The conventional avidin-biotin complex method was applied for all immuno-
stainings. Two persons (BvR, AV) independently assessed the slides without 
knowledge of clinical data. In case of heterogeneity, the parts within the tumor 
that showed highest positive to total ratio were particularly assessed. This was 
performed if these regions comprised at least 10% of the tumor load in the 
examined tissue section. P53 over-expression was scored if >10% stained 
positive. In case of discrepancy between the observers, the slides were 
reassessed in a combined session without the information of the previous scores. 
FGFR3 analysis: Standard H&E slides served as templates for manual 
micro-dissection. The dissected samples contained a minimum of 70% tumor 
cells, as assessed by histological examination. The DNA was extracted using the 
DNeasy Tissue kit (Qiagen GmbH, Hilden, Germany). The FGFR3 mutation 
analysis was performed by polymerase chain reaction (PCR) - single strand 
conformation polymorphism (SSCP) analysis.14 Samples with a shift were 
sequenced with T7 Sequenase v2.0 (Amersham life Science, Inc., Cleveland, 
OH). In addition, DNA extracted from venous blood was available from the 139 
patients who attended the Urology department of the Erasmus MC. These 
laboratory analyses were also performed without knowledge of clinical data. 
 Clinical Follow-up & Statistical analysis. The follow-up data were 
collected by chart review. Disease specific survival was determined. The patients 
were censored at their last clinical visit or the time of their death. The statistical 
package for social sciences 9.0 (SPSS Inc., Chicago, IL) computer software was 
used for the data documentation and analysis. The two-sided Fisher's exact test 
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was used to analyze the relations between the molecular variables and their 
correlation with pathological stage and grade. The clinical outcome was analyzed 
by applying the Kaplan-Meier method. Statistical Significance was assumed if 
P<0.05. 
 
RESULTS 
 Mutations in the P53 and FGFR3 genes were studied in 260 primary 
UCCs. Activating FGFR3 mutations were found in 153 (59%) of these tumors. 
We found 117, 32 and 4 mutations in the exons 7 (R248C & S249C), 10 (G372C, 
Y375C & A393E) and 15 (K652T, K652E & K652M), respectively. No mutations 
were detected in exon 19. No activating FGFR3 mutations were seen in the 
matched blood samples. P53 over-expression, presumably reflecting missense 
mutations in the P53 gene, was noted in 66 (25%) cases. Table 1 shows a highly 
significant inverse relation between the presence of a FGFR3 mutation and P53 
over-expression (P < 0.0001). Only 5.7% of the 260 primary UCCs were positive 
for both molecular features whereas 72.7% UCCs were either positive for FGFR3 
or positive for P53.  
 
Table 1 
Inverse relationship between FGFR3 mutations and P53 over-expression in Urothelial Cell 
Carcinoma (P-value < 0.0001). A P53 mutation was assumed if >10% of the cells stained positive. 
 
 FGFR3 wt FGFR3 mt 
P53 wt 56 138 
P53 mt 51 15 
Total 107 153 
Abbreviations: wt, wild type; mt, mutated type; FGFR3, fibroblast growth factor receptor 3. 
 
 We subsequently determined the correlation of FGFR3 and P53 with 
pathological Stage and Grade for the 260 UCCs. FGFR3 mutations were found in 
77% of pTa, 31% pT1 and 15% ≥pT2 tumors. Conversely, P53 over-expression 
was found in 11% pTa, 51% pT1 and 56% ≥pT2 tumors, respectively (P-values < 
0.0001). The numbers for pathological Grade showed the same trend. FGFR3 
mutations were found in 85% of urothelial neoplasia of low malignant potential 
(LMP), in 71% of low grade papillary urothelial carcinoma (LG) and in 26% of 
high grade papillary urothelial carcinoma (HG) cases. On the other hand, P53 
over-expression was found in only 1% of LMP, in 15% of LG and in 54% of HG 
cases, respectively (P-values < 0.0001). The distributions of the various 
pathological Stages and Grades for the FGFR3/P53 subgroups are given in 
Figure 1. In general, the FGFR3 mutation related to favorable, i.e. pTa and 
LMP/LG disease, whereas P53 over-expression indicated unfavorable, i.e. 
invasive and HG disease. 
 The UCCs, which were wild type for both genes, the so-called double 
negatives, were a substantial subgroup encompassing 21% of the 260 UCCs 
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(Table 1). When compared to Stage and Grade, these UCCs apparently 
comprised tumors of all grades and stages, with a higher percentage pTa tumors 
than the P53-positive subgroup, i.e. 51% vs. 22%, but also a higher percentage 
high Grade tumors than the FGFR3-mutation subgroup, i.e. 48% vs. 12% 
(Figure1). 
 
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Relation for FGFR3/P53 subgroups with pathological Stage (upper panel) and Grade (lower 
panel). The Stage distribution was 171 pTa, 55 pT1 and 27 pT2 and 5 pT3 and 2 pT4 lesions. 
Note the correlation between mutations in the FGFR3 gene with pTa and low grade (LMP & LG) 
tumors. Conversely, P53 over-expression, presumably caused by missense mutations, was 
associated with invasive (≥ pT1) and high-grade (HG) disease. The tumors that were wild type for 
both genes represent a group, in which all stages and grades are found. 
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 Besides histopathological parameters, the clinical outcome of the 260 
patients was also determined. The mean follow-up was 5.6 years (standard 
deviation: 3.7 years). Twenty-one patients died of UCC. The Kaplan-Meier 
analyses in Figure 2 clearly show that patients with a FGFR3 mutation in their 
UCC have a favorable prognosis, whereas patients with P53 over-expression 
have a worse prognosis than patients with a normal P53 expression pattern. 
 
Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kaplan-Meier analyses for disease specific survival. The survival plots (log-rank) for FGFR3 
(P=0.0001) and P53 (P=0.0011) are shown. The dashed lines display the follow-up of patients 
with a FGFR3 mutation and P53 over-expression, respectively.   
 
DISCUSSION  
UCCs are genetically characterized by frequent losses of heterozygosity 
(LOH), mutations and deletions in the P53, RB and p16 tumor suppressor genes 
and activating point mutations in the gene for the FGFR3. LOH of chromosomal 
arms 9p and 9q is observed in over 50% of UCC. Homozygous deletions of the 
p16 cyclin dependent kinase inhibitor are found in 20-30% of high grade and 
stage tumors.16 Bladder tumors with pRB alterations are significantly more prone 
to metastasize (ref. 17 and references therein). Mutations in the P53 gene are 
observed in poorly differentiated carcinomas and mutations in this gene 
apparently characterize tumors with a worse prognosis. Based on these 
observations Spruck et al.5, proposed a two-pathway model for UCC 
pathogenesis, in which P53 mutations delineated one arm of the pathway. LOH 
on chromosome 9 was supposed to characterize the other arm. However, later 
work revealed that chromosome 9 loss is found in all grades and stages and 
therefore can no longer serve as a marker for the non-invasive pathway.6-9 A 
recent update of the UCC pathogenesis model, including more markers, was 
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published by Cote and Datar.17 However, although many genes may play a role 
in UCC pathogenesis, most of them are only mutated in a limited percentage of 
tumors and, at present, their mutual dependencies, when present, are not 
entirely clear. 
 We have recently shown that FGFR3 mutations are generally associated 
with favorable disease characteristics such as low stage and grade, low 
recurrence rate and a better prognosis.13,18 In the present study, we intended to 
place this new genetic marker in the genetic pathogenesis model for UCC. To 
this end, we determined the FGFR3 and P53 status in 260 primary tumors. To 
our surprise, we observed that alterations in FGFR3 and P53 were almost always 
mutually exclusive. Together these two markers described 79% of the primary 
UCC. However, they concurred in only 5.7%. This suggested that FGFR3 and 
P53 characterize two distinct genetic pathways in UCC pathogenesis. While this 
paper was being reviewed, Bakkar et al. reported similar findings based on a 
study of 81 patients.19 The FGFR3 mutation resulted in pTa and LMP/LG tumors, 
whereas the P53 pathway led to invasive and HG carcinomas. In addition, the 
clinical outcome of the two investigated molecular markers confirmed this 
suggestion of two genetic pathways. A model for UCC pathogenesis based on 
our observations is given in Figure 3.  
 
Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model for UCC pathogenesis. FGFR3 and P53 indicate two different pathways for UCC 
pathogenesis and together they classify 79% of primary UCCs. These mutations clearly result in 
distinct pathological parameters. The small group of tumors with mutations in both genes is 
presumably derived from the FGFR3 group (see also text). The 21% tumors that lack alterations 
in P53 or FGFR3 are not included in the figure. The arrow on the right signifies increasing LOH 
and mutations in other genes. 
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This model resembles Spruck’s original model, but clearly designates two distinct 
pathways with genetic markers for a non-invasive and papillary, FGFR3-
associated pathway and an invasive P53-associated pathway. Together, these 
two markers provided a genetic framework for the majority of UCCs. The addition 
of the FGFR3 marker significantly expands Spruck’s original model (most 
recently reviewed in Cote and Datar17). We feel that, at the moment, it is not 
completely clear where to put LOH, especially of chromosome 9q, in this 
pathway. In P53-positive tumors, this event may have occurred before the P53 
mutation. However, in a considerable percentage of FGFR3-mutant tumors, LOH 
may occur after the FGFR3 mutation, since FGFR3 mutations are more frequent 
than LOH of 9q. On the other hand, we previously showed in evolutionary tree 
models of multiple UCC recurrences that tumors with LOH of 9q can precede 
recurrences with a mutation in the FGFR3 gene.7 Thus, the FGFR3 mutation is 
not necessarily the first genetic event in superficial tumor formation. In the model 
displayed here, we also suggest that UCC with alterations in both FGFR3 and 
P53 derive from FGFR3-mutant tumors. We argued that it would be more difficult 
for a P53 positive, invasive, HG carcinoma to become a lower grade superficial 
tumor than that a pTa, LMP/LG tumor transforms into a more invasive, higher 
grade descendant. This small group of UCCs apparently displays an intermediate 
phenotype when compared to the tumors with single alterations (ref. 18 and 
present study). Thus, it appears that the effect of the FGFR3 mutation mitigates 
the effect of the P53 mutation. The remainder of UCCs, 21% in our series, 
lacking P53 or FGFR3 alterations forms an interesting subset. The fact these 
tumors comprise all possible grades and stages suggests that they may also 
harbor different genotypes. Some of these tumors may in the future perhaps be 
placed in an FGFR3-like group or a P53-like group. However, it is also possible 
that yet a third genetic pathway is responsible for a portion of these tumors. 
Previous work reviewed by Cote and Datar 17 suggests that RB and p16 and/or 
pARF alterations are mostly associated with the P53-mutant UCCs and, thereby, 
are expected to be part of this pathway. However, it is not yet clear whether 
these mutations occur before or after the P53 event. The same holds true for 
other less frequently occurring alterations. So far, no mutations, besides LOH for 
9p/9q and other chromosomes have been described to concur with FGFR3 
mutations.  Therefore, additional investigations are required in order to place all 
markers in the pathway model. Consequently, the arrow on the right in Figure 3 
signifies an increasing frequency of LOH and other genetic aberrations from the 
top to the bottom. 
 The colorectal cancer model proposed by Fearon and Vogelstein is the 
prototype for the molecular evolution of cancer.20 The model is presented as a 
linear model, in which inactivation of APC, mutation of KRAS, inactivation of a 
gene on 18q and inactivation of P53 occur as subsequent steps in the 
development from low-grade adenomas to carcinoma. However, Smith et al. 21 
recently showed that co-occurrence of mutations in both KRAS and P53 in 
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colorectal cancers is extremely rare and they suggest that these mutations in fact 
lie on alternate pathways of colorectal tumor development. Thus, the route to 
colorectal cancer seems to bifurcate after the initial APC step into at least two 
alternative genetic pathways. This situation is similar to the one we describe for 
UCC in Figure 3. In colorectal cancer, K-RAS mutations are over-represented in 
Dukes C tumors and, thereby, it may be a marker for tumor progression. The 
added value of the model for UCC pathogenesis is that FGFR3 and P53 
represent makers for favorable and unfavorable disease, respectively. Together, 
these markers characterize almost 80% of all primary tumors. The search for 
mutations in other genes of both pathways may increase the percentage of 
molecularly characterized tumors further and may facilitate a more complete 
molecular description of UCC as a possible alternative for classical pathology.18 
Moreover, the favorable FGFR3 marker is a potential candidate to identify 
patients for whom a less frequent follow-up is required and this may help reduce 
the costs of management for patients with UCC. 
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ABSTRACT 
 Activating mutations in the fibroblast growth factor receptor 3 (FGFR3) 
gene are responsible for several autosomal dominant craniosynostosis 
syndromes and chondrodysplasias i.e. hypochondroplasia, achondroplasia, 
SADDAN and thanatophoric dysplasia - a neonatal lethal dwarfism syndrome. 
Recently, activating FGFR3 mutations have also been found to be present in 
cancer, i.e. at high frequency in carcinoma of the bladder and rarely in multiple 
myeloma and carcinoma of the cervix. Almost all reported mutations in 
carcinomas corresponded to the mutations identified in thanatophoric dysplasia. 
We here screened a series of 297 bladder tumors and found three FGFR3 
somatic mutations (G380/382R; K650/652M and K650/652T) that were not 
previously identified in carcinomas or thanatophoric dysplasia. Another novel 
finding was the occurrence of two simultaneous FGFR3 mutations in 4 tumors. 
Two of the three new mutations in bladder cancer, the G380/382R and the 
K650/652M mutations, were previously reported in achondroplasia and SADDAN, 
respectively. These syndromes entail a longer life span than thanatophoric 
dysplasia. The K650/652T mutation has not previously been detected in patients 
with skeletal disorders, but affects a codon that has been shown to be affected in 
some cases of thanatophoric dysplasia, SADDAN and hypochondroplasia. From 
a clinical perspective, the patients with FGFR3-related, non-lethal skeletal 
disorders might be at a higher risk for development of bladder tumors than the 
general population. 
 
INTRODUCTION 
The fibroblast growth factor receptor 3 (FGFR3) belongs to a family of 
structurally related tyrosine kinase receptors encoded by four different genes 
(FGFR1-4). These receptors consist of three glycosylated extracellular 
immunoglobulin-like domains (Ig-like), a transmembrane domain and a split 
intracellular tyrosine-kinase domain. Ligand binding induces FGFR dimerization, 
resulting in autophosphorylation of the kinase domain and interaction with and 
phosphorylation of effector signaling proteins.1,2 Alternative mRNA splicing 
mechanisms generate many different receptor isoforms, which differ in ligand 
specificity. The isoforms FGFR3b and FGFR3c result from a mutually exclusive 
splicing event, in which the second half of the third Ig-like domain is encoded by 
either the 151 nucleotides of exon 8 or the 145 nucleotides of exon 9.3 These two 
isoforms have different tissue distributions: for example, FGFR3b is the main 
form in epithelial cells whereas FGFR3c is the predominant form in 
chondrocytes.3-5 
Point mutations in specific domains of FGFR3 are associated with 
autosomal dominant dwarfism and craniosynostosis syndromes such as 
hypochondroplasia, achondroplasia (the most common form of skeletal 
dysplasia), severe achondroplasia with developmental delay and acanthosis 
nigricans (SADDAN), thanatophoric dysplasia (a lethal form of dwarfism), 
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Crouzon syndrome with acanthosis nigricans and Muenke coronal 
craniosynostosis.3,6,7 Several reports have demonstrated that these mutations 
lead to constitutive activation of the receptor.8-11 
In contrast with the inhibitory role on bone growth, an oncogenic role for 
FGFR3 in human cancer has emerged. Indeed, somatic activating mutations in 
FGFR3 have been reported in multiple myeloma and, more recently, in two 
epithelial malignancies, i.e. bladder- and cervix carcinomas.5,12,13 FGFR3 
mutations are rare in multiple myeloma and cervix carcinomas,14,15 whereas their 
high incidence in bladder carcinomas (74% of non-invasive papillary tumors) 
suggests that the constitutive activation of FGFR3 is an important event for 
bladder tumorigenesis.16,17 Nearly all mutations identified in bladder tumors are 
identical to the activating mutations responsible for thanatophoric dysplasia, a 
lethal form of dwarfism.5,16-18 Only two of the 117 FGFR3 mutations identified by 
these groups, the A393E and K652Q mutations, do not correspond to 
thanatophoric dysplasia mutations.17,18 The A393E mutation is identical to a 
mutation associated with a craniosynostosis syndrome (Crouzon syndrome with 
acanthosis nigricans) and the K652Q mutation is identical to a mutation 
associated with hypochondroplasia.11,19 
In this report, we describe three new somatic FGFR3 mutations in bladder 
tumors (G380/382R, K650/652M and K650/652T) (FGFR3c isoform 
numbering/FGFR3b isoform numbering). The G380/382R and the K650/652M 
mutations have previously been reported in achondroplasia and SADDAN, 
respectively. The K650/652T mutation has not been reported before in a skeletal 
disorder. In addition, among the 177 mutated tumors, we observed the 
occurrence of two concurrent FGFR3 mutations in 4 cases. 
 
MATERIALS AND METHODS 
FGFR3 mutation analysis was performed in a series of 297 bladder 
tumors as described.16 T7 Sequenase v2.0 (Amersham life Science, Inc., 
Cleveland, OH) was used for sequencing to analyze the four regions of FGFR3, 
located in exons 7, 10, 15 and 19, known to harbor the point mutations previously 
described in multiple myeloma, bladder- and cervix carcinomas, thanatophoric 
dysplasia and SADDAN. None of the 297 patients had a hereditary skeletal 
disorder documented. The mean patient’s age at diagnosis was 65.9 years 
(range, 23–90). Seventy (24%) of the 297 patients were female. The three new 
mutations of FGFR3 and all the "double" mutations were confirmed on a second 
PCR product. 
 
RESULTS 
In this series of 297 bladder carcinomas, we detected 181 FGFR3 
mutations. Consistent with previous studies,5,16-18 most of the mutations (173/181, 
96%), were identical to the germinal activating mutations responsible for 
thanatophoric dysplasia, with the S249C mutation, found in 125 (69%) of the 181 
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mutations as the most frequent point mutation. The A391/393E mutation, 
identical to the germinal mutation that causes Crouzon syndrome with acanthosis 
nigricans and already identified in bladder cancer,17 was found in four tumors. 
We detected three mutations in this series of 297 bladder carcinomas, 
which were not previously identified in carcinomas or in thanatophoric dysplasia 
patients (Figure 1A and 1B).  
 
Figure 1A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identification of novel FGFR3 mutations in bladder cancer. 
Figure 1A. Novel somatic FGFR3 mutations were identified by PCR-SSCP followed by direct 
DNA sequencing. The tumor shown on the left side has a G to A transition in exon 10, which 
changes the sequence of codon 380/382 from GGG (Gly) to AGG (Arg). The tumor in the middle 
has an A to T transversion in exon 15, which changes the sequence of codon 650/652 from AAG 
(Lys) to ATG (Met). The tumor on the right side has an A to C transversion in exon 15, which 
alters the sequence of codon 650/652 from AAG (Lys) to ACG (Thr). Arrowheads indicate the 
positions of the mutations. The FGFR3b isoform, which is expressed in epithelial cells, contains 
two amino acids more than the FGFR3c isoform expressed in bone. Therefore, the G380R, 
K650M and K650T mutations in FGFR3c are equivalent to the G382R, K652M and K652T 
mutations in FGFR3b. Note in addition: while the present study was under evaluation, the 
K650/652M mutation in bladder cancer was reported by Kimura et al.26 N, sequence of normal 
DNA; T, sequence of tumor DNA. 
Figure 1B. Schematic diagram of the FGFR3 protein. The areas within the two exons, in which 
the new missense mutations occurred, are shown in greater detail. The nucleotide substitutions 
are shown above, the amino acid substitutions are shown at the bottom of the Figure. 
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These mutations affected the codons 380/382 and 650/652 (FGFR3c isoform 
numbering/FGFR3b isoform numbering). The G380/382R mutation affected the 
transmembrane domain and resulted in the replacement of a glycine by an 
arginine residue. This mutation is identical to a germinal activating mutation 
associated with the most common form of genetic dwarfism, i.e. 
achondroplasia.20-22 The other two mutations (K650/652M and K650/652T), 
affecting the tyrosine kinase domain, resulted in the replacement of a lysine by a 
methionine or a threonine. The K650/652M mutation is identical to the germinal 
activating mutation that causes SADDAN.23 This novel mutation was found twice 
in this series of tumors. The matched constitutional DNA contained the wild-type 
sequence in every case, demonstrating the somatic nature of these mutations in 
(bladder) cancer. The tumor with the G380/382R mutation also displayed a 
S249C mutation in FGFR3. This patient suffered a recurrence five years later 
and the recurrent tumor was found to contain the same two FGFR3 mutations. 
In addition to the above-mentioned case, three other bladder tumors also 
contained two distinct FGFR3 mutations. In each case, the S249C mutation was 
present. S249C was accompanied by the R248C, G370/372C and A391/393E 
mutations. The clinico-pathological data of the bladder-carcinoma patients 
carrying the new and the "double" mutations are depicted together with the type 
of FGFR3 mutations in Table 1. We found no significant differences in the 
pathological status or the clinical data for the various FGFR3 mutations in 
bladder cancer (not shown). 
 
Table 1 
The patient characteristics and the histopathological data corresponding to the novel and the 
concurrent FGFR3 mutations in bladder carcinomas. The cases with the numbers 143, 172, 287 
and 265 contained two concurrent FGFR3 mutations in one tumor. The cases 287, 213, 17 and 
55 presented with the novel mutations reported here for the first time. 
 
Case # Age/sex Stage/grade* Exon nt Position** Mutation Predicted effect** 
143 77 / M pTa/G2 7 7 
nt742 
nt746 
CÆT 
CÆG 
R248C 
S249C 
172 65 / M pT3/G3 7 10 
nt746 
nt1114 
CÆG 
GÆT 
S249C 
G372C 
287 68 / M pTa/G1 7 10 
nt746 
nt1144 
CÆG 
GÆA 
S249C 
G382R 
265 74 / M pTa/G2 7 10 
nt746 
nt1178 
CÆG 
CÆA 
S249C 
A393E 
213 74 / M pTa/G2 15 nt1955 AÆT K652M 
17 66 / M pTa/G1 15 nt1955 AÆT K652M 
55 63 / M pTa/G1 15 nt1955 AÆC K652T 
* Pathological status according to the TNM97 and the WHO classification guidelines. 
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Figure 2 indicates the locations and the nature of the missense mutations 
associated with skeletal disorders and bladder carcinomas. The frequencies of 
the various FGFR3 mutations in bladder cancer are also indicated. These 
numbers are based on the previously published series by Cappellen et al.5, 
Billerey et al.16, van Rhijn et al.17 and Sibley et al.18 (n=273 patients) and the 
series described in this paper (n=297 patients). 
 
 Figure 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FGFR3 mutations associated with skeletal disorders and bladder carcinomas. A schematic 
diagram of the structure of FGFR3 is shown (IgG I-III, immunoglobulin-like domains; TM, 
transmembrane domain; TK-1 and -2, tyrosine kinase domains). The locations of the missense 
mutations associated with skeletal dysplasias (TDI, thanatophoric dysplasia type I; TDII, 
thanatophoric dysplasia type II; MC, Muenke craniosynostosis; HCH, hypochondroplasia; ACH, 
achondroplasia; C+AN, Crouzon syndrome with acanthosis nigricans; SADDAN, severe 
achondroplasia with developmental defect and acanthosis nigricans) and bladder carcinomas are 
indicated. The positions are numbered according to the FGFR3c/FGFR3b numbering. The 
number of occurrences and the percentage of each FGFR3 mutation in mutated bladder tumors 
are given. These data were obtained from 570 bladder tumors of which 273 were reported 
before5,16-18 and 297 were reported here. The different mutations found in skeletal dysplasias 
have been obtained from the review of Passos-Bueno et al.6 and the work of Bellus et al.11 and 
Winterpacht et al.27. 
*This region of FGFR3b corresponding to a region of FGFR3c where a mutation associated with 
hypochondroplasia (N328I) was previously found was only examined in 26 of the 570 bladder 
tumors studied so far.5 
**This region containing mutations associated with hypochondroplasia was only examined in 89 
of the 570 bladder tumors studied so far.5,18 
 FGFR3 MUTATION SKELETAL BLADDER  
  DYSPLASIAS CANCER 
  (GERMLINE) (SOMATIC) 
Ig I 
Ig II 
Ig III 
TM 
TK-1 
TK-2 
R248C TD I 24 (8.1%) 
S249C TD I 214 (71.8%) 
P250R MC 0 (0%) 
G370/372C TD I 16 (5.4%) 
S371/373C TD I 0 (0%) 
Y373/375C TD I 30 (10.1%) 
G375/377C ACH 0 (0%) 
G380/382R ACH 1 (0.3%)  
A391/393E C+AN 5 (1.7%) 
K650/652E TD II 4 (1.3%) 
K650/652M SADDAN 2 (0.7%) 
K650/652Q HCH 1 (0.3%) 
K650/652N HCH 0 (0%) 
K650/652T ? 1 (0.3%) 
n = 298 (100%) 
I538/540V** HCH 0 (0%)  
N540/542K,T,S** HCH 0 (0%) 
X807/809C,G,L,R,W TD I 0 (0%) 
N328I* HCH 0 (0%) 
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DISCUSSION  
FGFR3 mutations occur frequently in bladder carcinoma.5,16-18 The vast 
majority of somatic FGFR3 mutations identified in bladder cancer are identical to 
those found in thanatophoric dysplasia.7,9 In the previous published series, only 
two FGFR3 mutations (A391/393E and K650/652Q) did not correspond to 
thanatophoric dysplasia mutations.17,18 However, both mutations have been 
found to be associated with milder types of skeletal dysplasia: the A391/393E 
mutation with the Crouzon syndrome with acanthosis nigricans and the 
K650/652Q mutation with hypochondroplasia. In this new series of 297 bladder 
carcinomas reported here, we identified 181 FGFR3 mutations. Ninety-six 
percent (173/181) of these somatic mutations have been previously reported to 
be associated with thanatophoric dysplasia. However, other activating FGFR3 
mutations including the three described here for the first time in bladder cancer 
(G380/382R, K650/652M and K650/652T), have never been reported to be 
associated with thanatophoric dysplasia. 
The activating G380/382R mutation, which affects the transmembrane 
domain, is responsible for almost all (~97%) cases of achondroplasia.20,22 
Achondroplasia is the most common form of non-lethal skeletal dysplasia, 
affecting approximately  1 in 15,000 to 1 in 40,000 live births.7 This mutation is 
here reported in cancer for the first time. 
The activating K650/652M mutation, located in the kinase domain, has 
already been found in SADDAN (severe achondroplasia with developmental 
delay and acanthosis nigricans)23 and in a primary multiple myeloma12. Transient 
transfection studies have demonstrated that the K650/652M mutation results in 
stronger constitutive activation of FGFR3 than does the K650/652E mutation 
responsible for thanatophoric dysplasia.23 Nevertheless, despite multiple physical 
and neurological impairments, most SADDAN patients survive past infancy 
without the need for prolonged ventilator support.7,23 
The K650/652T mutation has never been reported before in either skeletal 
dysplasia or cancer. However, other mutations of the same codon are associated 
with either thanatophoric dysplasia (K650/652E), SADDAN (K650/652M) or 
hypochondroplasia (K650/652N and K650/652Q).10,11,23 Bellus et al.11 
investigated all the possible amino acid substitutions resulting from single 
nucleotide changes in the 650/652 codon and showed that the K650/652T 
mutation leads to constitutive activation of the FGFR3 tyrosine kinase. This 
activation was equivalent to that observed with the K650/652N and K650/652Q 
(hypochondroplasia) mutations but was considerably weaker than observed with 
the K650/652E and K650/652M mutations associated with thanatophoric 
dysplasia and SADDAN, respectively. 
The identification of mutations in bladder cancers identical (K650/652Q)18 
or similar (K650/652T) (this study) to mutations found in hypochondroplasia 
suggests that other hypochondroplasia mutations, such as the I538/540V and 
N540/542K,T,S mutations in exon 13 may also occur in this carcinoma.6,24 In 
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other words, possible hypochondroplasia mutations in other exons than 15 may 
have escaped their detection in bladder cancer. Among the 570 bladder tumors 
studied so far, only 89 have been studied for the hypochondroplasia mutations 
located in exon 13.5,18 No activating mutations were detected in this exon for the 
89 cases. Nevertheless, the percentage of mutations not corresponding to 
thanatophoric dysplasia in bladder cancer might be slightly higher than 
suggested. 
Another novel finding presented here was the occurrence of two 
simultaneous FGFR3 mutations in 4 tumors (case-numbers: 143, 172, 265 and 
287, Table 1). The PCR-SSCP analysis of exon 7 in the case with number 404 
provided a strong indication that the two concurrent mutations (R248C and 
S249C), are carried by the two different alleles (not shown). For the remaining 3 
cases, this remains to be determined because these tumors had no loss of 
heterozygosity at the FGFR3 locus (not shown) and RNA was not available. 
From a clinical perspective, the presence of FGFR3 mutations in bladder 
carcinomas, identical to the mutations found in patients with non-lethal skeletal 
disorders (hypochondroplasia, achondroplasia, SADDAN and Crouzon syndrome) 
suggests that the patients with these FGFR3-related syndromes might have a 
higher risk to develop bladder cancer than the general population. However, to 
our knowledge, there are no reports on a higher incidence of cancer in these 
patients, so it is possible that the non-lethal FGFR3 mutations do not sufficiently 
activate the protein to an extent that is needed for tumor formation or other genes 
must be affected for bladder tumor formation. On the other hand, the 
predisposition may have gone unnoticed to clinicians, especially if we consider 
the relative low prevalence of non-lethal skeletal syndromes (~10.000 cases in 
the USA). For example, the retinoblastoma gene, cloned 18 years ago, has been 
demonstrated to play a role in many carcinomas, including bladder carcinomas. 
Yet, it was only recently proven that hereditary retinoblastoma patients have a 
higher risk to develop lung cancer than unaffected individuals.25 
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SUMMARY 
 Urothelial cell carcinoma (UCC) of the urinary bladder is a serious health 
problem. The disease accounts for 3.2% of all new cancer cases worldwide. 
UCC of the bladder is the 5th most common cancer and the 9th leading cause of 
cancer death. In most patients (± 75%), UCC is superficial (i.e. pTa-pT1) at first 
presentation. There are two problems in the management of these patients. First, 
superficial UCC of the bladder is characterized by a high risk of recurrence (55-
85%), with most recurrences in the first year after trans-urethral resection (TUR). 
These recurrences are detected by urethro-cystoscopy (UCS), the gold standard, 
which is performed every 3-4 months, often in combination with urine cytology 
(UC) as an adjunct. After a two-year recurrence free period, the intensity of follow 
up may be lowered. UCS and UC are routinely used in the daily clinical practice. 
However, UCS is invasive, bothersome for the patients and costly. Unfortunately, 
UC is characterized by a low sensitivity, especially for low grade UCC. Hence, 
there is room for improvement, i.e. a need for development of techniques to 
diagnose superficial bladder cancer recurrences in urine and/or to identify a 
subset of patients who require a less frequent follow up. The second concern in 
managing patients with UCC is to prevent progression (10-15%) to muscle 
invasive, potentially lethal UCC. The ability to distinguish superficial tumors with 
invasive capabilities from those unlikely to become invasive would be of great 
clinical benefit. Carcinoma in situ (CIS), a flat and high grade (G3) manifestation 
of superficial UCC is especially associated with an unfavorable disease course. 
However, individual prediction of prognosis by clinical and pathological features 
is still very difficult. Superficial UCC that maintains a more malignant phenotype 
might be better treated with radical cystectomy in an early stage of the disease. 
This explains the need for more accurate predictors of UCC-progression. With 
the recent advances in molecular biology, research is more and more focusing 
on understanding the molecular mechanisms associated with bladder 
carcinogenesis. Therefore, molecular markers may aid in solving the two UCC 
management problems outlined above. If molecular markers prove to have 
additional value over the established clinico-pathological variables, they could 
become part of the clinical practice. This thesis deals with these two problems 
concerning the management of patients with UCC. Molecular markers for 
diagnosis in urine and prognosis of UCC were analyzed in various clinical 
settings. 
 Part one gives a short introduction on UCC in general perspective and 
contains the scope of this thesis (chapter 1). 
In the second part of the thesis, we evaluated Microsatellite analysis (MA); 
a test based on PCR reactions with DNA of the urine sediment, in different 
clinical settings. Chapter 2 provides an overview of the accuracy of the current 
urine markers to diagnose recurrent UCC. The sensitivity (patients with a 
recurrent lesion and positive urine test divided by all patients with recurrent UCC) 
and specificity (patients without recurrence and a negative test divided by all 
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patients without recurrent UCC) were determined for 18 urine markers. All the 
urine markers reviewed had a higher sensitivity, but a lower specificity than 
conventional cytology for recurrent UCC. The sensitivities increased with tumor 
grade. In this meta-analysis confined to studies on recurrent disease, MA had a 
sensitivity of 82% and a specificity of 89% for detection of UCC recurrences. We 
found a considerably lower sensitivity to detect recurrent UCC for 13/18 urine 
markers in comparison with earlier review articles where no distinction between 
primary and recurrent UCC was made. The reason for this reduced sensitivity is 
most likely a higher percentage of small, pTa and low grade UCC among 
recurrent lesions compared to primary tumors. At this time, sufficient clinical 
evidence to change the cystoscopic follow-up scheme with the use of a urine 
marker is not available. Chapter 3 describes a phase II study on urinary MA, 
which we performed in a cross-section of 109 patients who visited the outpatient 
department for a follow-up UCS. Earlier investigations in other clinical settings 
and with a limited number of patients showed that MA had a high potential to 
diagnose UCC in urine. Our study was conducted to investigate whether MA was 
also capable of diagnosing UCC in patients who were under surveillance after 
TUR. MA detected 18/24 recurrent tumors. The undetected UCCs were small 
pTaG1 lesions. In 5 of 9 cases where no tumor was seen at UCS but MA was 
positive, an UCC was found within 6 months after MA. In the same group of 
patients, MA was more sensitive (74%) than the BTAstat test (56%) or 
conventional urine cytology (22%). A drawback of MA was the exclusion of 7 
patients due to an insufficient amount of DNA in the urine sediment and another 
9 patients with leukocyte abundance. Nevertheless, MA appeared a reliable 
molecular test in urine for detection of recurrent UCC, sometimes even before 
cystoscopical evidence of the disease. Chapter 4 describes MA in conjunction 
with the Fibroblast Growth Factor Receptor 3 (FGFR3) mutation, a genetic 
marker for favorable UCC. This study was initiated to explore the possibility to 
improve the sensitivity of MA by adding FGFR3 mutation analysis to the 
molecular marker panel. The tests were carried out on tumor- and urine samples 
of 59 UCC patients allowing a direct comparison of molecular changes in tumor 
and urine. Conventional cytology was used as a reference and a full clinical 
record of each patient was obtained. UCCs with a higher stage or grade had 
more microsatellite alterations per tumor. Conversely, FGFR3 mutations were 
only found in pTaG1-2 lesions. The sensitivity of MA in FGFR3 positive and 
negative UCC was 71% and 91%, respectively. When a Microsatellite alteration 
was detected in tumor tissue, the chance to find the same alteration in the urine 
was 35% regardless of FGFR3 status. The chance to find the same FGFR3 
mutation in the urine was 52%. Additional alterations in the urine that were not 
present in the UCC were only seldom reported (1.8%).  By combining the FGFR3 
mutation with MA, the sensitivity of molecular cytology could be enhanced to 
89% without compromising specificity. The similarity of the molecular profiles in 
urine and tumor corroborate the clonal relation of tumor cells in the urine and the 
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original tumor(s). In chapter 5, the value of MA for patients under surveillance 
after radiotherapy was investigated. The follow up of these patients is more or 
less the same as for the patients with superficial UCC. However, UCS and UC 
are often difficult to interpret in case of previous radiotherapy. Therefore, MA was 
tested in this particular patient group. Although only 6 recurrences were found in 
the 49 patients, MA detected 5 of them. The specificity values for routine urine 
cytology, MA and expert urine cytology were 85%, 93% and 97%, respectively. In 
addition, the negative predictive value of MA (true negative MA / all negative MA) 
was 99% (70/71 urine samples) for this group. The latter is especially interesting 
because the positive predictive value of UCS (40% in this series) is much lower 
for irradiated patients. The results of this study indicate that MA may also be a 
useful tool for surveillance of patients who were previously treated by 
radiotherapy. 
 Part three of this thesis focuses on the prognostic value of the Fibroblast 
Growth Factor Receptor 3 (FGFR3) mutation in UCC. Its relation to favorable 
disease will be discussed as well as its relation to clinical variables and other 
molecular markers. Chapter 6 gives an overview of the clinico-pathological and 
molecular prognostic features in (superficial) UCC. The last part of this chapter 
gives a short introduction of the FGFR3 gene. The chapters 7 & 8 contain the 
first two papers published on the favorable nature of the FGFR3 mutation in UCC. 
The FGFR3 mutation was detected in 70/98 (71%) of pTaG1-2 UCC. Conversely, 
invasive G3 lesions had a mutation in only 7% of tumors. Moreover, the mutation 
was absent in 20 cases of CIS, again pointing to the favorable nature of the 
FGFR3 mutation in UCC. White blood cells and normal-looking urothelial 
biopsies of patients with a FGFR3 mutation in their bladder tumor lacked FGFR3 
mutations. This emphasized the somatic nature and the tumor specificity of these 
mutations in UCC. The FGFR3 mutation was also associated with a low 
recurrence rate of superficial UCC in the fist year after a TUR. In 57 patients with 
superficial UCC, only 6% of UCS was positive for patients with a FGFR3 
mutation. This was 28% for patients who had no FGFR3 mutation in their tumor. 
These two preliminary studies showed that FGFR3 is the first gene to be mutated 
at a high frequency in favorable (pTa G1-2) UCC. This mutation is the first 
genetic marker to selectively identify a large group of patients with favorable 
disease characteristics. Furthermore, the results presented in these two chapters 
suggest that the frequency of UCS can be reduced considerably for patients with 
FGFR3 positive tumors. In chapter 9 the results of a large, retrospective multi-
center study are displayed. The purpose of this study was to compare the 
FGFR3 mutations to other molecular markers and to obtain long term clinical 
follow up. In addition, the reproducibility of pathological grade and molecular 
variables was determined. In this study of 286 patients with primary UCC, the 
FGFR3 mutation was related to the expression of three immunohistochemical 
markers (MIB-1, P53 and P27kip1) known to be associated with prognosis. 
FGFR3
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FGFR3 mutation in 88% of cases, G3-tumors in 16%. Conversely, aberrant 
expression patterns of MIB-1, P53 and P27kip1 were seen in 5%, 2% and 3% of 
G1-tumors and in 85%, 60% and 56% of G3-tumors, respectively. In multivariate 
analysis with recurrence rate, progression and disease specific survival as 
endpoints, the combination of FGFR3 and MIB-1 proved of independent 
significance for all 3 disease parameters. With regard to disease progression of 
superficial UCC, the difference in the clinical course between UCC combining 
FGFR3 mutation / MIB-1 normal (N=138) and those combining FGFR3 wild type / 
MIB-1 high (N=47) was evident. Interestingly, the 61 remaining patients with 
tumors characterized by absence of FGFR3 mutation and normal MIB-1 
expression or by a FGFR3 mutation and high MIB-1 expression behaved more or 
less the same representing an intermediate prognosis. These results led to the 
proposal of a molecular grading model for UCC distinguishing three molecular 
grades (mG1-3): mG1 (favorable prognosis), mG2 (intermediate prognosis) and 
mG3 (poor prognosis). Moreover, the molecular Grade was more reproducible 
than pathological grade (91% vs. 47–61%). Based on the observations in the 
chapters 7, 8 and 9, it was concluded that the FGFR3 mutation represents the 
favorable molecular pathway of papillary UCC. Furthermore, molecular Grading 
provides a new, simple and highly reproducible tool to determine UCC prognosis. 
Chapter 10 shows that FGFR3 mutations are also common in urothelial 
papilloma, a rare urothelial neoplasm. Papillomas are generally considered as a 
separate diagnostic entity because of their benign natural behavior. Therefore, 
they are currently classified apart from papillary lesions of low malignant potential 
(PUN-LMP, G1) and low grade papillary urothelial carcinomas (LG-PUC, G1-2) 
by the 1998 World Health Organization / International Society of Urological 
Pathology consensus classification. In our study, FGFR3 mutations were found in 
9/12 papillomas and in 68/79 pTaG1 lesions (reclassified as PUN-LMP and LG-
PUC in 62 and 17 cases, respectively). Besides urothelial papillomas, the FGFR3 
mutation analysis was also performed for 21 ovarian Brenner tumors. This tumor 
was chosen for its resemblance to low grade UCC from a cytological point of 
view. However, no FGFR3 mutations were found in Brenner tumors. This report 
was the first to describe a genetic defect in urothelial papilloma and we 
suggested from a molecular perspective, that urothelial papillomas should be 
classified together with all well differentiated urothelial neoplasms. Chapter 11 
describes the distribution of FGFR3 mutations and P53 over-expression 
(assumed if expression level >10%) for 260 patients in UCC. As described in the 
chapters 7 and 8, the FGFR3 gene is mutated in a high percentage of low grade 
UCCs. Therefore, the purpose of this study was to evaluate the relationship 
between FGFR3 mutations and over-expression of the P53 tumor suppressor 
protein as a manifestation of a mutation in the P53 gene. The over-expression of 
P53 and/or the mutant P53 gene have been reported in earlier studies as an 
unfavorable marker in UCC. FGFR3 mutations and P53 over-expression were 
observed in 59% and 25% of tumors, respectively. Together, the FGFR3 and 
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P53 over-expression described 79% of UCC. However, alterations in FGFR3 and 
P53 coincided in only 5.7% of UCC. Because each of these alterations was also 
associated with opposite clinico-pathological parameters, it was proposed that 
mutations in FGFR3 and P53 mark two alternative genetic pathways in papillary 
UCC pathogenesis. Chapter 12 gives an overview of the distribution of FGFR3 
mutations detected in UCC and the corresponding germline mutations, which are 
responsible for a wide variety of skeletal anomalies. Almost all FGFR3 mutations 
in earlier studies corresponded to the mutations that lead to thanatophoric 
dysplasia, a congenital disorder that is generally lethal shortly after birth. This 
study reported a few new FGFR3 mutations in UCC that matched non-lethal 
skeletal syndromes. Therefore, patients with skeletal syndromes associated with 
FGFR3 mutations and a relative normal life span (for example: achondroplasia) 
might be at a higher risk for development of bladder tumors than the general 
population provided that the FGFR3 mutation on its own is capable of bladder 
tumor formation. 
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FUTURE PERSPECTIVES 
 The focus of this thesis was twofold. Nowadays, UCC recurrences are 
detected by urethro-cystoscopy (UCS) with urine cytology (UC) as an adjunct. 
These techniques are used routinely but they are not ideal. UCS is invasive, 
bothersome and costly and UC lacks sensitivity. Hence, there is room for 
improvement to detect superficial bladder cancer recurrences in urine. In the 
studies that were performed with Microsatellite analysis (MA) of urine as a non-
invasive diagnostic tool, we found that MA was highly sensitive and equal in 
specificity to urine cytology and capable of competing with UCS for recurrent 
UCC diagnosis. In a recent review (chapter 2), MA was highly sensitive and 
specific for patients under surveillance in comparison with other urine markers. 
Since MA is still a time consuming and labor intensive technique, future studies 
should address the automation and upscaling of the assay. Moreover, multi-
center studies, in which the results have to be delivered in a certain time frame, 
will be essential if this assay is to become a commonly enjoyed clinical tool. 
Furthermore, one of the next steps for MA may include a randomized study, in 
which half of the patients will receive a less stringent cystoscopical follow up 
scheme in combination with MA. Such a study, which is coordinated by the 
Erasmus MC, is ongoing at this time. Only via this way the question whether MA 
is the urine test that can be used to reschedule UCS can be answered. The 
patients with G3-UCC should be excluded from such a protocol since the 
possible drawbacks of MA have not been fully investigated yet and delay in the 
diagnosis of recurrent disease of these patients with a high risk of progression 
may not occur. Additionally, it should be anticipated that the sensitivity of MA 
might decrease if the G3 patients will be excluded. So far, much attention has 
been paid to the performance (sensitivity and specificity) of urine markers. 
Studies on the opinion of the patients have received little attention. Vriesema et 
al. found that 89% of the patients will prefer UCS if the sensitivity of the urine 
marker is less than 90%.1 This prerequisite can not be satisfied by any of the 
currently available tests in urine. Probably, these patients did not realize that a 
sensitivity of >90% will also be a problem for UCS, as this gold standard is at 
best 90% sensitive and specific.2 On the other hand, Schrag et al. analyzed the 
adherence to surveillance among patients with superficial UCC in a 3 year follow 
up period and they reported that only 40% of patients had all the cystoscopical 
examinations, which were recommended by the clinical guidelines.3 The opinion 
of patients should ideally be addressed with the use of validated questionnaires 
in a randomized study that may be performed simultaneously with a urine marker 
study (see above for example). Cost-effectiveness is becoming more important in 
the daily clinical practice. The current follow-up schemes largely contribute to the 
fact that the total costs per patient are the highest for UCC compared to other 
malignancies.4 Lotan and Roehrborn found that a modified care protocol, in 
which UCS was alternated by a urine marker was cost-effective at a cost of less 
than $264 per test.5 They also concluded that such a protocol warrants a 
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prospective, randomized evaluation to determine whether the benefits outweigh 
any potential drawbacks. Close monitoring of patients is essential for the 
detection of recurrent disease, which in turn requires repeated resection to rule 
out progression to invasive cancer. However, how close our surveillance should 
be, whether a urine marker may be of use to plan UCS and other aspects like 
patient opinion and costs are all issues that will have to be addressed in future 
prospective randomized evaluations. The high sensitivity and specificity of MA 
highlight its potential application in these studies. On the other hand, UCS is also 
a subject of study. Fluorescence cystoscopy with the intravesical application of 
photodynamic agents proved more sensitive than the conventional white light 
cystoscopy for the detection of UCC.6 Moreover, a single fluorescent trans-
urethral resection (TUR) was superior to white light TUR with respect to both 
residual tumor rate and recurrence free survival.7 As MA of urine was highly 
sensitive and specific in studies with white light UCS as a reference, it would be 
interesting to analyze MA in combination with fluorescent UCS. Furthermore, the 
application of MA in other settings, like in screening protocols or as adjunct to 
UCS in high grade UCC, may be studied. 
The second focus of this thesis was the prognostically favorable FGFR3 
mutation in UCC. The association of this mutation with low stage and low grade 
UCC is evident and confirmed by other groups.8,9 The suggestion made in this 
thesis that patients with a FGFR3 mutation in their UCC require a less stringent 
follow up has to be confirmed in a prospective multi-center study. Perhaps, this 
can be performed in conjunction with the randomized study on MA. Progression 
to invasive UCC occurs in 10-15% of patients with superficial UCC. To identify 
those patients who will progress is a major challenge, especially because 
patients with progressive disease seem to have a worse prognosis than patients 
with primary invasive disease.10 Unfortunately, predictability of progressive 
disease with the conventional clinical and pathological parameters is not 
sufficiently accurate in individual patients and it may only be used to identify (risk) 
groups of patients with UCC.11,12 Because molecular grade, which depends on 
FGFR3 and MIB-1 status was a significant predictor for recurrence rate, 
progression and disease specific survival and because molecular grade was 
more reproducible than pathological grade, there is a need for a prospective 
evaluation of this molecular grading system (see chapter 9). If such trials would 
come out positive and if FGFR3 mutation analysis has additional value over the 
classical clinical and pathological parameters, then implementation of a FGFR3 
mutation assay for clinical purpose may happen. However, such studies take 
many years to perform. Other techniques like cDNA expression microarrays and 
proteomics might be especially useful for the individual prediction of prognosis as 
they analyze many molecular variables at the same time, thereby providing a 
more tailor-made risk profile. Dyrskjot et al. developed a 32-gene molecular 
classifier in an independent test set of 68 UCCs.13 The classifier provided new 
predictive information in pTa tumors with regard to progression and recurrence 
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rate.13 The authors are currently evaluating the classifier in a three-year 
prospective clinical study.13 With the help of protein profiles, Vlahou et al. were 
able to detect 7 differentially expressed protein cluster regions that demonstrated 
differences between UCC and controls.14 Here again, it is important that the initial 
results of the cDNA expression microarray and proteomics investigations are 
confirmed by other research groups and that prospective trials are required 
before considering implementation of these techniques. 
The bladder is an easy accessible organ for instillation therapy. 
Intravesical treatments with immunotherapeutic (BCG) and chemotherapeutic 
agents have been developed, tested extensively in many study-protocols and 
they are widely used in the daily clinical practice to reduce recurrences and 
prevent progression. Two promising clinical studies showed that a combination of 
mitomycin-C and local hyperthermia was more effective than standard 
endovesical chemotherapy and that this combination had promising value in 
intermediate and high risk superficial bladder cancer compared to the literature 
data on BCG and intravesical chemotherapy.15,16 Hanel et al. found in an 
experimental orthotopic rat model that the intravesical application of reovirus (an 
oncolytic virus that selectively destroys cancer cells with an activated Ras 
pathway) was safe and more effective with regard to tumor-free survival than 
BCG or normal saline.17 FGFR3 is part of a family of 4 tyrosine kinase receptors. 
In the physiological situation, various signal transduction pathways are initiated 
via FGF binding to the receptor. A mutation in FGFR3 causes constitutive 
activation of the receptor. Considering the results of Hanel et al.,17 it is of interest 
that FGFR3 and RAS mutations in multiple myeloma both lead to the activation 
of the same downstream pathway.18 Because the involvement of FGFR3 in UCC 
is a recent discovery, an attempt to develop drugs to target this receptor has not 
yet been undertaken. The incidence of superficial UCC and the high percentage 
of FGFR3 mutations in these tumors together with the high percentage of over-
expression of FGFR3 in UCC19 justify further study in this direction. The clinical 
success of kinase inhibitors in other types of cancer underlines this.20 For 
superficial UCC, a possible intravesical application for FGFR3 inhibition would be 
preferable and such a study would be of great interest. 
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SAMENVATTING (DUTCH) 
Het urotheelcelcarcinoom (UCC) van de urineblaas is een serieus 
gezondheidsprobleem. Wereldwijd is 3.2% van alle nieuwe kankerdiagnosen aan 
deze ziekte toe te schrijven. UCC is de 5e meest voorkomende vorm van kanker 
en de 9e meest voorkomende vorm van kanker gerelateerde sterfte. De meeste 
patiënten (± 75%) presenteren zich met oppervlakkig UCC (pTa-pT1). Er zijn 
twee dilemma's bij het begeleiden van deze patiënten. Als eerste kenmerkt het 
oppervlakkig UCC zich door een hoge kans op één of meerdere recidieven (55-
85%), waarbij de meeste recidieven gevonden worden in het eerste jaar na een 
transurethrale resectie (TUR). Deze recidieven worden gedetecteerd door middel 
van urethro-cystoscopie (UCS), de gouden standaard, die elke 3-4 maanden na 
een TUR wordt verricht, vaak in combinatie met urine cytologie (UC) als 
hulpmiddel. Na een recidief vrije periode van twee jaar kan de frequentie van de 
controles verlaagd worden. UCS en UC worden in de dagelijkse praktijk 
routinematig toegepast. UCS is echter invasief, vervelend voor de patiënten en 
duur. UC wordt helaas gekenmerkt door een lage sensitiviteit, met name voor 
laaggradig UCC. Er is derhalve ruimte voor verbetering, dat wil zeggen de 
ontwikkeling van methoden om oppervlakkige blaaskanker recidieven in urine te 
diagnosticeren en/of een subgroep van patiënten aan te wijzen die minder vaak 
gecontroleerd zouden kunnen worden. Een tweede punt van zorg bij het 
begeleiden van patiënten met UCC is het voorkomen van progressie (10-15%) 
naar spier-invasief carcinoom waaraan de patiënt mogelijk kan overlijden. De 
mogelijkheid om onderscheid te maken tussen oppervlakkige tumoren met en 
zonder invasieve capaciteiten zou klinisch van grote importantie zijn. Carcinoma 
in situ (CIS), een vlakke, hooggradige (G3) variant van oppervlakkig UCC is met 
name geassocieerd met een slecht ziekteverloop. Ondanks alles is het 
voorspellen van prognose voor een individuele patiënt met behulp van klinische 
en pathologische variabelen zeer moeilijk. Oppervlakkig UCC van een meer 
kwaadaardig phenotype kan wellicht in een vroeg stadium van de ziekte beter 
behandeld worden door middel van een radicale cystectomie. Dit verklaart 
waarom betere voorspellers voor UCC progressie nodig zijn. Met de recente 
vooruitgang in de moleculaire biologie, is ook de research steeds meer gericht op 
het begrijpen van de moleculaire mechanismen die ten grondslag liggen aan 
blaascarcinogenese. Moleculaire markers zouden kunnen helpen bij het 
oplossen van de hierboven beschreven dilemma's. Als deze markers additionele 
waarde blijken te hebben ten opzichte van de huidige klinische en pathologische 
parameters, dan zouden ze onderdeel kunnen worden van de dagelijkse 
klinische praktijk. Dit proefschrift gaat over deze twee dilemma's t.a.v. de zorg 
voor patiënten met UCC. Moleculaire markers voor diagnose in urine en 
prognose van UCC werden geanalyseerd in verschillende klinische kaders. 
 Deel één bevat een korte introductie over UCC in het algemeen en 
beschrijft de opzet van dit proefschrift (hoofdstuk 1). 
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 In het tweede gedeelte van het proefschrift evalueerden we in 
verschillende klinische kaders de Microsatelliet analyse (MA); een test 
gebaseerd op PCR reacties met DNA uit het urinesediment. Hoofdstuk 2 geeft 
een overzicht van de waarde van de huidige urine markers voor de diagnose van 
een recidief UCC. De sensitiviteit (patiënten met een recidief en een positieve 
urine test gedeeld door alle patiënten met een recidief UCC) en specificiteit 
(patiënten zonder recidief en een negatieve test gedeeld door alle patiënten 
zonder recidief UCC) werden bepaald voor 18 urine markers. Alle urine markers 
in het overzicht hadden een hogere sensitiviteit maar een lagere specificiteit voor 
recidief UCC dan de conventionele cytologie. De sensitiviteit nam toe met 
tumorgraad. In deze meta-analyse die alleen studies over recidief ziekte bevatte, 
was de sensitiviteit van de MA 82% en de specificiteit 89%. We vonden een 
behoorlijk lagere sensitiviteit t.a.v. recidief UCC voor 13/18 urine markers in 
vergelijk met eerdere overzichtsartikelen waarbij geen onderscheid gemaakt is 
tussen primair en recidief UCC. De reden voor deze lagere sensitiviteit is 
waarschijnlijk een hoger percentage klein, pTa en laaggradig UCC bij recidief 
laesies t.o.v. primaire tumoren. Vooralsnog ontbreekt voldoende klinisch bewijs 
om het cystoscopische controle schema te wijzigen m.b.v. een urine marker. 
Hoofdstuk 3 bevat een fase II studie over MA van urine die uitgevoerd werd in 
een dwarsdoorsnede van 109 patiënten die de polikliniek bezochten voor een 
controle UCS. Eerdere studies uitgevoerd in andere klinische kaders en met een 
lager aantal patiënten hadden reeds laten zien dat MA veelbelovend was om 
UCC in urine te diagnosticeren. Deze studie werd uitgevoerd om te onderzoeken 
of MA ook in staat was UCC te diagnosticeren bij patiënten die onder controle 
waren na een TUR. MA detecteerde 18/24 recidieven. De niet gevonden 
recidieven waren kleine pTaG1 laesies. In 5 van de 9 gevallen waarbij geen 
tumor werd gezien bij UCS maar waarbij MA wel positief was, werd toch nog een 
UCC gevonden binnen 6 maanden na MA. Bij dezelfde patiënten bleek MA 
sensitiever (74%) dan de BTAstat test (56%) en conventionele UC (22%). 
Nadelen van de MA waren de exclusie van 7 patiënten vanwege een 
onvoldoende hoeveelheid DNA in het urinesediment en 9 patiënten vanwege 
teveel leukocyten in de urine. Desondanks bleek MA een betrouwbare 
moleculaire test in urine om een recidief UCC te vinden, soms zelfs voordat er bij 
cystoscopie een recidief gezien werd. Hoofdstuk 4 gaat over MA in combinatie 
met de Fibroblast Groei Factor Receptor 3 (FGFR3) mutatie, een genetische 
marker voor gunstig UCC. Deze studie werd uitgevoerd om te onderzoeken of 
het mogelijk was de sensitiviteit van de MA te verhogen door de FGFR3 mutatie 
analyse eraan toe te voegen. De tests werden uitgevoerd op tumor- en urine 
monsters van 59 UCC patiënten waardoor er een directe vergelijking van de 
moleculaire veranderingen in tumor en urine mogelijk was. Conventionele 
cytologie werd gebruikt als referentie en een volledig klinisch rapport was 
beschikbaar van iedere patiënt. De UCCs met een hoger stadium en graad 
hadden meer microsatelliet veranderingen per tumor. Daarentegen werden 
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FGFR3 mutaties alleen gevonden bij pTaG1-2 laesies. De sensitiviteit van de MA 
alleen was voor FGFR3 positief en negatief UCC respectievelijk 71% en 91%. 
Wanneer een microsatelliet verandering in tumor werd aangetoond, dan was de 
kans om dezelfde verandering ook in urine te vinden 35%. Dit was onafhankelijk 
van de FGFR3 status. De kans om dezelfde FGFR3 mutatie in urine te vinden 
was 52%. Veranderingen in de urine die niet in de corresponderende tumor 
gevonden werden, waren zeldzaam (1.8%). Door het combineren van de FGFR3 
mutatie met de MA kon de sensitiviteit van moleculaire cytologie verbeterd 
worden tot 89% zonder daling van de specificiteit. De overeenkomst tussen de 
moleculaire profielen van urine en tumor in deze studie onderstrepen de clonale 
relatie van tumor cellen in de urine en de originele tumor(en). De waarde van de 
MA voor patiënten die gecontroleerd worden na bestraald te zijn op hun blaas is 
onderzocht in hoofdstuk 5. De controle van deze patiënten verloopt min of meer 
op dezelfde wijze als bij patiënten met oppervlakkig UCC. UCS en UC zijn echter 
vaak moeilijk te interpreteren na radiotherapie. Om die reden werd deze 
bijzondere groep patiënten getest m.b.v. MA. Hoewel er slechts 6 recidieven 
gevonden werden bij 49 patiënten, ontdekte de MA er 5 van. De specificiteit van 
routine UC, MA en expert UC was respectievelijk 85%, 93% en 97%. Daarnaast 
was de negatief voorspellende waarde van MA (echt negatieve MA / alle 
negatieve MA uitslagen) 99% (70/71 urine monsters) bij deze groep. Dit laatste is 
met name interessant omdat de positief voorspellende waarde van de UCS (40% 
in deze serie) veel lager is na bestraling. De resultaten van deze studie laten zien 
dat de MA ook van waarde kan zijn bij patiënten die gecontroleerd worden na 
bestraling. 
 Het derde deel van dit proefschrift gaat over de prognostische waarde van 
de FGFR3 mutatie bij UCC. De relatie van deze mutatie met een gunstig 
ziektebeloop en de relatie tot andere klinische variabelen en moleculaire markers 
werd bediscussieerd. Hoofdstuk 6 bevat een overzicht van de klinische, 
pathologische en moleculaire kenmerken van het (oppervlakkig) UCC. Het 
laatste gedeelte van dit hoofdstuk geeft een korte inleiding over het FGFR3 gen. 
De hoofdstukken 7 & 8 bevatten de eerste twee publicaties over het gunstige 
karakter van de FGFR3 mutatie bij het UCC. Een FGFR3 mutatie werd gevonden 
bij 70/98 (71%) van de pTaG1-2 UCC. Aan de andere kant had slechts 7% van 
de invasieve G3 tumoren zo'n mutatie. Verder was de mutatie afwezig in 20 
gevallen van CIS wat ook weer wijst op het gunstige karakter van de FGFR3 
mutatie bij het UCC. Witte bloedcellen en biopten van normaal urotheel bij 
patiënten met een FGFR3 mutatie in hun tumor lieten geen FGFR3 mutaties zien. 
Dit benadrukte het somatische karakter en de tumorspecificiteit van deze 
mutaties voor UCC. De FGFR3 mutatie was tevens geassocieerd met een lage 
recidief-frequentie van oppervlakkig UCC in het eerste jaar na een TUR. Bij 57 
patiënten met oppervlakkig UCC, was slechts 6% van de UCS positief voor de 
patiënten met een FGFR3 mutatie. Dit was 28% voor de patiënten die geen 
FGFR3 mutatie in hun tumor hadden. Deze twee preliminaire studies maakten 
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duidelijk dat FGFR3 het eerste gen is dat vaak gemuteerd is bij gunstig (pTaG1-2) 
UCC. Daarnaast suggereren de resultaten uit deze twee hoofdstukken dat de 
frequentie van UCS behoorlijk verlaagd zou kunnen worden voor de patiënten 
met FGFR3 positieve tumoren. In hoofdstuk 9 worden de resultaten van een 
grote, retrospectieve, multicentrische studie getoond. Het doel van deze studie 
was het vergelijken van de FGFR3 mutatie met andere moleculaire markers en 
het verkrijgen van een lange klinische follow-up. Tevens werd de 
reproduceerbaarheid van de pathologische graad en de moleculaire variabelen 
bepaald. De FGFR3 mutatie werd in deze studie van 286 patiënten met primair 
UCC vergeleken met de expressie van drie immunohistochemische markers 
(MIB-1, P53 en P27kip1) waarvan het bekend is dat ze correleren met prognose. 
Een FGFR3 mutatie werd gevonden bij 172/286 (60%) van de UCCs. G1 
tumoren hadden een mutatie in 88% van de gevallen, G3 tumoren in 16%. 
Daarentegen werden aberrante expressie niveaus van MIB-1, P53 en P27kip1 
gevonden bij respectievelijk 5%, 2% en 3% van de G1 tumoren en 85%, 60% en 
56% van de G3 tumoren. De combinatie van FGFR3 en MIB-1 was significant in 
de multivariaat analyse met als eindpunten recidief frequentie, progressie en 
ziekte vrije overleving. Het verschil in klinisch beloop met betrekking tot 
progressie van oppervlakkig UCC was evident t.a.v. de combinaties FGFR3 
mutatie / MIB-1 normaal (N=138) en FGFR3 wild type / MIB-1 verhoogd (N=47). 
Het was interessant dat de overige 61 patiënten met tumoren zonder FGFR3 
mutatie en normale MIB-1 expressie of tumoren met een FGFR3 mutatie en 
tevens een hoge MIB-1 expressie, een nagenoeg identiek klinisch beloop 
hadden dat tussen de twee eerdere groepen lag en zich kenmerkte door een 
redelijke prognose. Dit resultaat stelde ons in staat een moleculair 
graderingsmodel voor UCC te propageren waarin 3 moleculaire graden te 
onderscheiden zijn (mG1-3): mG1 (goede prognose), mG2 (redelijke prognose) 
en mG3 (slechte prognose). Daarnaast was de moleculaire Graad 
reproduceerbaarder dan de pathologische graad (91% vs. 47-61%). Op basis 
van de hoofdstukken 7, 8 en 9 was het de conclusie dat de FGFR3 mutatie 
selectief de gunstige moleculaire “pathway” van papillair UCC karakteriseert. 
Verder is moleculair graderen een nieuw, eenvoudig en zeer reproduceerbaar 
instrument om de prognose van UCC te bepalen. Hoofdstuk 10 laat zien dat 
FGFR3 mutaties ook frequent voorkomen bij het papilloom wat een zeldzame 
afwijking van het urotheel is. Papillomen worden in het algemeen beschouwd als 
een aparte diagnostische entiteit vanwege hun benigne natuurlijk beloop. 
Daarom zijn ze ook in de 1998 World Health Organization / International Society 
of Urological Pathology consensus classificatie als zodanig geclassificeerd naast 
de papillaire urotheel-laesies met lage maligniteits potentie (PUN-LMP, G1) en 
de laaggradige papillaire urotheel carcinomen (LG-PUC, G1-2). In onze studie 
werden FGFR3 mutaties gevonden bij 9/12 papillomen en bij 68/79 pTaG1 
laesies (na review geclassificeerd als PUN-LMP en LG-PUC in respectievelijk 62 
en 17 gevallen). Naast papillomen van het urotheel werd de FGFR3 mutatie 
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analyse ook verricht op 21 Brenner tumoren van het ovarium. Deze tumor werd 
gekozen vanwege de gelijkenis met laaggradig UCC vanuit cytologisch oogpunt. 
Desalniettemin werden er geen FGFR3 mutaties gevonden bij Brenner tumoren. 
Deze studie beschreef als eerste een genetisch defect bij papillomen van het 
urotheel. Verder suggereerden we dat vanuit een moleculair perspectief, de 
papillomen van het urotheel samen in één groep met alle andere goed 
gedifferentieerde tumoren van het urotheel geclassificeerd zouden moeten 
worden. Hoofdstuk 11 beschrijft de verdeling van FGFR3 mutaties en P53 over-
expressie (als expressie niveau >10%) voor 260 patiënten met UCC. Zoals 
beschreven in de hoofdstukken 7 en 8, is het FGFR3 gen gemuteerd bij een 
hoog percentage van laaggradige UCCs. Het doel van deze studie was derhalve 
om de relatie tussen FGFR3 mutaties en over-expressie van het P53 tumor 
suppressor eiwit als uiting van een mutatie in het P53 gen te evalueren. De over-
expressie van P53 en/of het mutant P53 gen zijn in eerdere studies beschreven 
als ongunstige markers m.b.t. het UCC. FGFR3 mutaties en P53 over-expressie 
zijn bij respectievelijk 59% en 25% van de tumoren gevonden. Samen 
beschrijven de FGFR3 mutatie en de P53 over-expressie 79% van de UCCs. 
Echter, veranderingen in FGFR3 en P53 kwamen slechts bij 5.7% van de UCCs 
tegelijkertijd voor. Omdat deze genetische veranderingen ook nog eens 
geassocieerd waren met tegenovergestelde klinische en pathologische 
parameters, opperden wij dat mutaties in FGFR3 en P53 twee verschillende 
genetische “pathways” in de pathogenese van UCC markeren. Hoofdstuk 12 
geeft een overzicht van de verdeling van de FGFR3 mutaties die gevonden zijn 
in UCC en dezelfde mutaties in de kiembaan die verantwoordelijk zijn voor een 
grote verscheidenheid aan skelet afwijkingen. Bijna alle FGFR3 mutaties in 
eerdere studies m.b.t. UCC kwamen overeen met de mutaties die thanatophore 
dysplasie veroorzaken, een aangeboren afwijking die in het algemeen snel na de 
geboorte tot de dood leidt. Deze studie rapporteert enkele nieuwe FGFR3 
mutaties bij UCC die gevonden zijn bij niet-lethale syndromen met 
skeletafwijkingen. Onder de voorwaarde dat de FGFR3 mutatie op zich 
voldoende is voor het aanmaken van een blaastumor, zou het dus wel eens zo 
kunnen zijn dat patiënten met een FGFR3 geassocieerde skeletafwijking en een 
relatief normale levensverwachting (bijvoorbeeld: Achondroplasie) een hogere 
kans hebben op het krijgen van blaastumoren in vergelijk met de algehele 
populatie. 
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SOMMAIRE (FRENCH) 
Le carcinome cellulaire de l’épithélium (CCU) vésical est un problème de 
santé grave. Au niveau mondial 3,2% de tous les nouveaux diagnostics de 
cancer sont imputés à cette maladie. Le CCU est le cancer qui représente en 
fréquence le cinquième des plus répandus et le neuvième des formes mortelles. 
Le plus grand nombre des patients (75%) se présentent avec un carcinome 
superficiel (pTa-pT1). Le suivi de ces patients pose deux dilemmes. 
Premièrement, il y a un grand risque que ce CCU superficiel récidive dans 55 à 
85% des cas. La plupart de ces récidives sont retrouvées dans la première 
année après une résection trans-uréthrale (RTU). Les récidives sont détectées 
au moyen d’uréthro-cystoscopie (UCS), l’étalon or, qui est appliquée tous les 
trois à quatre mois après une RTU, souvent en combinaison avec la cytologie 
urinaire (CU) comme moyen de support. Après une période de non-récidives de 
deux ans la fréquence des contrôles pourra être diminuée. UCS et CU font partie 
de la pratique journalière. Cependant, la UCS est invasive, désagréable pour le 
patient et coûteuse. Malheureusement le désavantage de la CU est la faible 
sensibilité notamment à un CCU de basse gradation. Une amélioration est donc 
possible i.e. le développement de méthodes pour identifier des récidives de 
tumeurs de vessie superficielles dans l’urine et/ou indiquer un sous-groupe de 
malades qui pourraient être contrôles moins souvent. Un deuxième point de 
souci dans le suivi des malades de CCU est de prévenir la progression, 10 à 
15%, vers un carcinome invasif musculaire dont le malade pourrait mourir. La 
possibilité de distinguer les tumeurs superficielles avec et sans capacités 
invasives serait d’une grande importance au niveau de la clinique. Carcinome in 
situ (CIS), une variante plane de haut grade(G3) du CCU superficiel est 
notamment associé à une mauvaise progression de la maladie. Faire des 
pronostics pour le malade individuel à l’aide de variables cliniques et 
pathologiques est malgré tout très difficile. Dans in stade précoce de la maladie 
le CCU superficiel d’un phénotype plus malin pourra probablement être mieux 
traité par une systectomie radicale. Cela explique pourquoi il faut de meilleurs 
pronostics de la progression du CCU. Par l’évolution récente dans la biologie 
moléculaire les recherches sont de plus en plus orientées vers les 
compréhensions des mécanismes moléculaires qui sont à la base de la genèse 
du cancer de la vessie. Des marqueurs moléculaires pourraient aider à résoudre 
les deux dilemmes décrits ci-dessus. Si ces marqueurs se trouvent avoir des 
valeurs additionnelles vis-à-vis les paramètres cliniques et pathologiques actuels 
ils pourraient faire partie de la pratique clinique quotidienne. Cette thèse traite 
ces deux dilemmes concernant le suivi des malades de CCU. Des marqueurs 
moléculaires pour le diagnostic dans l’urine et le pronostic du CCU ont été 
analysés dans des cadres cliniques différents. 
La première partie contient une courte introduction sur le CCU en général 
et décrit le plan de cette thèse (chapitre 1). 
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Dans la deuxième partie de cette thèse nous avons évalué l’analyse 
Microsatellite (AM) dans des cadres cliniques différents. L'AM est un test basé 
sur PCR avec ADN pris du sédiment urinaire. Chapitre 2 donne un aperçu de la 
valeur des marqueurs d’urine actuels pour le diagnostic d’un CCU récidivant. La 
sensibilité (des patients avec une récidive et un test d’urine positif divisés par 
tous les patients avec un CCU récidivant) et la spécificité (des patients sans 
récidive et un test négatif divisés par tous les patients sans récidive de CCU) 
était définie pour 18 marqueurs d’urine. Tous les marqueurs d’urine dans 
l’aperçu avaient, en ce qui concerne la récidive du CCU un degré de sensibilité 
plus haut, mais une spécificité plus basse que la cytologie conventionnelle. La 
sensibilité augmentait avec le degré de la tumeur. Dans cette méta-analyse qui 
ne contenait que des études de récidives la sensibilité de l’AM était de 82% et la 
spécificité de 89%. Nous avons trouvé une sensibilité nettement plus basse par 
rapport à la récidive du CCU. Pour 13 des 18 marqueurs d’urine en comparaison 
avec des aperçus précédents où la distinction entre un CCU primaire et une 
récidive n’était pas faite. La raison de cette faible sensibilité est probablement un 
plus élevé pourcentage de petit pTa et un CCU de bas grade dans des lésions 
récidives par rapport à des tumeurs primitives. Pour le moment nous n’avons pas 
encore suffisamment de preuves cliniques pour changer le schéma de contrôle 
cystoscopique à l’aide d’un marqueur d’urine. Chapitre 3 contient une étude 
phase II sur l’AM d’urine réalisée sur une coupe transversale de 109 patients 
venus à la policlinique pour un contrôle de UCS. Des études antérieures faites 
dans d’autres cadres cliniques et avec un nombre plus restreint de patients 
avaient montré que l’AM était très prometteuse pour diagnostiquer le CCU dans 
l’urine. Cette étude était faite pour examiner si avec l’AM il était possible de 
diagnostiquer le CCU chez des patients qui avaient subi un RTU. L’AM a détecté 
18 sur 24 récidives. Les récidives non-trouvées étaient de petites lésions pTaG1. 
Dans 5 cas sur 9 où l’on n’a pas vu de tumeur dans la UCS mais où par contre 
l’AM était positive, on a quand-même trouvé un CCU avant 6 mois après l’AM. 
Chez ces mêmes patients l’AM s’est avérée plus sensitive (74%) que le test 
BTAstat (56%) et la conventionnelle CU (22%). Les désavantages de l’AM était 
l’exclusion de 7 patients à cause d’une quantité insuffisante de ADN dans le 
sédiment de l’urine et 9 patients à cause de trop de leucocytes dans l’urine. 
Pourtant, l’AM s’est avérée un test moléculaire dans l’urine fiable pour trouver un 
CCU récidivant, parfois même avant qu’on ait vu une récidive par cystoscopie. 
Chapitre 4 traite l’AM en combinaison avec la mutation de FGFR3 («Fibroblast 
Growth Factor Receptor 3»), un marqueur génétique pour un CCU positif. Cette 
étude a été entreprise pour voir s’il était possible de hausser la sensibilité de 
l’AM en y ajoutant l’analyse de la mutation de FGFR3. Les tests étaient effectués 
sur des prises de tumeurs te d’urine de 59 patients de CCU ce qui a permis une 
comparaison directe des mutations moléculaires dans la tumeur et l’urine. La 
cytologie conventionnelle était utilisée comme système de référence. On pouvait 
disposer d’un dossier clinique complet de chaque patient. Les CCUs plus 
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avancés avaient plus de mutations microsatellites par tumeur. Les mutations de 
FGFR3 par contre n’étaient trouvées qu’avec les lésions pTaG1-2. La sensibilité 
de l’AM seule était pour FGFR3 positive et négative CCU, 71% et 91% 
respectivement. Quand une mutation microsatellite était détectée dans la tumeur, 
la chance de trouver la même mutation dans l’urine était de 35%, ceci 
indépendamment du dossier médical de FGFR3. La chance de trouver la même 
mutation de FGFR3 dans l’urine était de 52%. Rares étaient les mutations dans 
l’urine qui n’étaient pas trouvées dans les tumeurs correspondantes (1,8%). En 
combinant la mutation de FGFR3 avec l’AM on a pu améliorer la sensibilité de la 
cytologie moléculaire jusqu`à 89% sans que la spécificité diminue. La similitude 
des profiles moléculaires de l'urine et de la tumeur soulignent dans cette étude la 
relation clonale de cellules carcinogènes dans l’urine et les tumeurs primitives. 
Chapitre 5 évalue la valeur de l’AM pour les patients dont la vessie a été traités 
aux rayons et qui sont examinés après par UCS. Le protocole du suivi de ces 
patients est plus ou moins pareil à celui des patients d'un CCU superficiel. 
Pourtant le UCS et la CU sont souvent difficiles à interpréter après radiothérapie. 
C’est pour cette raison que ce groupe de patients exceptionnel a été testé à 
l’aide de l’AM. Quoique 6 récidives seulement soient trouvées chez 49 patients, 
l’AM en a détecté 5. Les spécificités de routine de CU, d’AM et de CU expert 
étaient de 85%, 93% et 97% respectivement. En plus, la valeur prédicative 
négative de l’AM (AM vraiment négative / tous les résultats négatifs de l’AM) était 
de 99% (70/71 prises d’urine) chez ce groupe. Ceci est d’autant plus intéressant 
que la valeur prédicative positive du UCS (40% dans cette série) est beaucoup 
plus basse après radiothérapie. Les résultats de cette étude montrent que l’AM 
prend de la valeur aussi pour les patients qui sont examinés après un traitement 
par rayons. 
La troisième partie de cette thèse traite la valeur prognostique de la 
mutation de FGFR3 dans le CCU. La relation entre cette mutation et un bon 
pronostic et la relation de celle-là avec d’autres variables et marqueurs 
moléculaires ont été discutées. Chapitre 6 présente un aperçu de tous les 
caractères cliniques, pathologiques et moléculaires du CCU superficiel. La 
dernière partie de ce chapitre donne une courte introduction au gène FGFR3. 
Les chapitres 7 et 8 contiennent les deux premières publications sur le 
caractère positif de la mutation de FGFR3 dans le CCU. Une mutation de FGFR3 
était trouvée dans 70/98 (71%) des CCU de pTaG1-2. De l’autre côté, il n’y avait 
que 7% des tumeurs invasives et G3 qui montraient une telle mutation. La 
mutation était absente dans 20 cas des CIS ce qui indique aussi le caractère 
positif de la mutation de FGFR3 dans la CCU. Des leucocytes et des biopsies 
urothéliques normales des patients avec une mutation de FGFR3 dans leur 
tumeur ne montraient pas de mutations de FGFR3. Ceci souligne le caractère 
somatique et la spécificité tumorale de ces mutations dans le CCU. La mutation 
de FGFR3 était en même temps associée à une faible fréquence de récidive de 
CCU superficiel dans la première année après une RTU. Chez 57 patients avec 
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un CCU superficiel seulement 6% des UCS étaient positives pour les patients 
avec une mutation de FGFR3. Cela constituait 28% pour les patients qui 
n’avaient pas de mutation de FGFR3 dans leur tumeur. Ces deux études 
préliminaires montraient que le FGFR3 est le premier gène qui a souvent muté 
dans un CCU favorable (pTaG1-2). Les résultats de ces deux chapitres 
suggèrent en plus que la fréquence des UCS pourrait être considérablement 
réduite pour des patients avec des tumeurs positives pour FGFR3. Chapitre 9 
montre les résultats d’une grande étude rétrospective et multicentrée. Par cette 
étude nous avons voulu comparer la mutation de FGFR3 avec d’autres 
marqueurs moléculaires et obtenir un long «follow-up» clinique. Nous avons 
déterminé en même temps la reproductibilité du grade pathologique et les 
variables moléculaires. Dans cette étude de 286 patients avec un CCU primaire, 
la mutation de FGFR3 a été comparée avec l’expression de trois marqueurs 
immunohistochimiques (MIB-1, P53 et P27kip1) dont il est connu qu’ ils corrèlent 
avec le pronostic. Une mutation était trouvée dans 172/286 (60%) des CCU. Les 
tumeurs de G1 avaient une mutation dans 88% des cas, les tumeurs de G3 en 
avaient dans 16%. Par contre, des niveaux d’expression aberrants de MIB-1, 
P53 et P27kip1 étaient trouvés dans respectivement 5%, 2% et 3% des tumeurs 
de G1 et dans 85%, 60% et 56% des tumeurs de G3. La combinaison de FGFR3 
et MIB-1 était significatif dans l’analyse multivariate avec comme point finals la 
fréquence de récidives, la progression et la survie par guérison totale. La 
différence du cours clinique entre la progression du CCU superficiel et la 
combinaison de la mutation de FGFR3 / MIB-1 normal (N=138) et FGFR3 «wild 
type» / MIB-1 élevé (N= 47) était évidente. Il était intéressant que les autres 61 
patients avec des tumeurs sans mutation de FGFR3 et une expression normale 
de MIB-1 ou des tumeurs avec une mutation de FGFR3 et une expression de 
MIB-1 élevée avaient un cours clinique identique, situé entre les deux groupes ci-
devant et caractérisé par un pronostic raisonnable. Ce résultat nous a permis de 
propager un modèle moléculaire de gradation pour le CCU où trois grades 
moléculaires sont à distinguer (mG1-3): mG1 (pronostic favorable), mG2 
(pronostic raisonnable) et mG3 (pronostic défavorable). En plus, le grade 
moléculaire était plus reproductible que le grade pathologique (91% vs. 47-61%). 
Les chapitres 7,8 et 9 ont mené à la conclusion que la mutation de FGFR3 
caractérise d’une façon sélective le «pathway» moléculaire favorable du CCU 
papillaire. En plus, la gradation moléculaire est un nouvel outil, simple et très 
reproductible pour déterminer le pronostic de CCU. Chapitre 10 montre que les 
mutations de FGFR3 se produisent aussi fréquemment dans le papillome, une 
malformation rare de l’urothélium. Les papillomes sont généralement considérés 
comme une entité diagnostique à part à cause de leurs cours naturels bénins. 
C’est pourquoi qu'ils ont été classifiés comme tels dans le consensus de 1998 de 
l’Organisation Mondiale de la Santé / «International Society of Urological 
Pathology», à côté des lésions de l’urothélium papillaire avec un bas potentiel de 
malignité (PUN-LMP, G1) et les carcinomes papillaires de l’urothéliun grade bas 
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(LG-PUC, G1-2). Dans notre étude des mutations de FGFR3 étaient trouvées 
dans 9/12 papillomes et dans 68/79 lésions pTaG1 (après une révision 
classifiées comme PUN-LMP et LG-PUC dans 62 et 17 cas respectivement). À 
côté des papillomes de l’urothélium l’analyse de la mutation de FGFR3 a été faite 
aussi sur 21 tumeurs Brenner de l’ovaire. Cette tumeur était choisie à cause de 
la ressemblance avec le CCU de bas grade du point de vue cytologique. 
Pourtant, aucune mutation de FGFR3 n’était trouvée dans les tumeurs Brenner. 
Cette étude était la première à décrire un défaut génétique dans des papillomes 
de l’urothélium. Nous avons aussi suggéré que du point de vue moléculaire les 
papillomes devraient être classifiés dans un seul groupe avec toutes les autres 
tumeurs bien différenciées de l’urothélium. Chapitre 11 décrit la répartition des 
mutations de FGFR3 et la sur-expression P53 (niveau d’expression >10%) pour 
260 patients avec un CCU. Comme c’est décrit dans les chapitres 7 et 8 le gène 
FGFR3 a muté dans un pourcentage élevé des CCUs de bas grade. Le but de 
cette étude était par conséquent d’évaluer la relation entre les mutations de 
FGFR3 et la sur-expression de la protéine P53, comme manifestation d’une 
mutation dans le gène P53. La sur-expression de P53 et/ou le gène mutant ont 
été décrits dans des études antérieures comme des marqueurs défavorables par 
rapport au CCU. Des mutations de FGFR3 et des sur-expressions P53 ont été 
trouvées dans respectivement 59% et 25% des tumeurs. Les mutations et les 
sur-expressions ensemble répertorient 79% des CCUs. Cependant, ce n’était 
que dans 5,7% des CCUs qu’il y avait simultanément les deux changements. 
Comme ces mutations génétiques étaient en plus associées à des paramètres 
cliniques et pathologiques contraires nous avons suggéré que des mutations 
dans FGFR3 et P53 marquent deux «pathways» génétiques différents dans la 
pathogenèse du CCU. Chapitre 12 fait passer en revue la division des mutations 
de FGFR3 trouvées dans les CCUs et les mêmes mutations germinales qui sont 
responsables d’une grande variété de malformations du squelette. Presque 
toutes les mutations de FGFR3 dans des études antérieures concernant le CCU 
correspondaient avec les mutations responsable de nanisme thanatophore, une 
anomalie congénitale qui conduit généralement à la mort tout de suite après la 
naissance. Cette étude signale quelques nouvelles mutations de FGFR3 dans le 
CCU trouvées dans des syndromes avec des anomalies du squelette non-létales. 
À condition que la mutation de FGFR3 en soi suffise pour développer une tumeur 
de vessie, il pourrait bien être possible que les patients avec une anomalie du 
squelette associée au FGFR3 et une espérance de vie relativement normale 
(p.ex. achondroplasie) courent un plus grand risque que des tumeurs de vessie 
soient détectées chez eux en comparaison avec l’ensemble de la population.       
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